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Abstract 
When 90% or more of native kidney function is lost, renal replacement therapy 
must be initiated to sustain life. Renal transplantation is the preferred method, but 
availability is limited. The ideal dialysis prescription remains elusive. Small 
molecular weight molecules (such as urea and creatinine) have been used as 
markers of both kidney (native and transplant) and dialysis toxin clearance 
(function), but there are pitfalls in using these markers to assess total ‘renal’ dose 
(kidney plus dialysis). Body weight, gender and other factors also affect the 
concentrations of these small molecules, but not cystatin C. Furthermore, 
cystatin C has been shown to be a better marker for estimating kidney function 
than creatinine, and is associated with cardiovascular morbidity and mortality. 
Studies have shown that it is removed by dialysis. Therefore, we investigated the 
use of cystatin C, a naturally occurring endogenous protein, as a marker for 
estimating dialysis adequacy and renal clearance. This investigation was 
comprised of four studies to understand the kinetics of cystatin C in patients with 
advanced kidney disease with or without dialysis.  We found that the amount of 
cystatin C reduction was influenced positively by hemodialysis blood flow rate 
and treatment time, and negatively by ultrafiltration rate. We further 
demonstrated that renal hyperfiltration significantly influenced the error of 
creatinine-based glomerular filtrate rate equation, but not for the cystatin C 
equation. Therefore, cystatin C appears to be a useful marker for the assessment 
of kidney function in patients with advanced kidney disease but not yet on 
dialysis. This was taken further in our third study where we developed an 
equation, which gave a better estimate of residual renal function than previously 
published equations in patients on dialysis but who have some remaining kidney 
function. Finally, we confirmed our hypothesis that cystatin C is cleared during 
dialysis by both diffusion and convection. It is distributed mainly in the 
extracellular space but equilibrates slowly between the extravascular and 
intravascular spaces. Furthermore, we have shown that cystatin C while cleared 
by dialysis is stable between dialysis treatments rather than being influenced by 
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a single dialysis treatment. It is a marker for both dialysis and renal clearances 
and, thus, gives a stable index of total renal clearance.  
 
The long term goal will be to define the cystatin C threshold level that influences 
patient morbidity and mortality and to allow better dialysis prescriptions for 
patients with varying (and changing) residual renal function.  
Keywords 
Cystatin C, Dialysis, Dialysis Adequacy, Hemodialysis, Nuclear Glomerular 
Filtration Rate, Residual Renal Function 
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1. CHAPTER 1. GENERAL INTRODUCTION 
1.1. INTRODUCTION TO RENAL CLEARANCE 
1.1.1. Renal and Urinary Collecting System 
Most humans have two kidneys, which are located in the retroperitoneal space 
on each side of the abdominal aorta. An adult kidney weighs about 115-170 g (11 
cm x 6 cm x 3 cm).1 It is bean-shaped and contains approximately 400,000 to 
800,000 nephrons in the renal cortex.2 Each functional unit of the kidney is called 
a nephron, which consists of a glomerulus and a tubule. Blood is filtered through 
the glomeruli (each one approximately 6.0 M microns in size) into the Bowman’s 
capsule. This filtered fluid (approximately 180 L in an adult) is then processed 
during its transit through the tubule. The tubule can be separated into four parts 
(proximal tubule, loop of Hénle, distal tubule and collecting duct) and each part 
has different transporters and channels to maintain water, electrolytes and the 
acid-base balance. The final waste products and fluid from the collecting duct are 
drained into the renal pelvis. This is further emptied into the ureter through 
peristalsis initiated by special pacemaker cells and squirted into the bladder as 
urine. Once a certain bladder pressure is reached, the urine is voided through the 
urethra. 
The major blood supply to each kidney comes through a renal artery. Because of 
the important function for maintaining electrolytes, and excreting toxins and fluid, 
kidneys need to have exceptionally high blood flow to tissue ratio. In fact, it has 
the highest ratio of any organ. The total blood flow to both kidneys is 
approximately 25% of the total cardiac output (1.25 L/min, or 350 mL/min/100 g 
of tissue).1 This renal circulation is separated into two capillary networks where 
the glomerular vascular bed serves the purpose of filtration and the peri-tubular 
capillary bed serves as metabolic support.2 In addition to excreting metabolic 
waste products, the kidneys have multiple additional functions: They regulate 
water and electrolyte balance, contribute to the control blood pressure, maintain 
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acid-base balance, produce erythropoietin, and convert vitamin D to its active 
form 1,25-dihydroxy-vitamin D.3 
 
1.1.2. Glomerular Filtration, Filtration Fraction and Chronic 
Kidney Disease 
Although a kidney has multiple tasks, kidney function is typically assessed by the 
glomerular filtration rate and, to a lesser extent, renal blood flow.4 It is important 
to measure accurately or estimate the glomerular filtration rate for early detection 
and monitoring of kidney function impairment, determining drug dosages based 
on renal clearance and assessing eligibility for kidney donation.  
A glomerulus contains a network of many capillaries and it has unique structural 
support to hold the capillaries, the endothelium with numerous fenestrations, the 
glomerular basement membrane and cells such as podocytes and mesangial 
cells. The diameter of a endothelial fenestration is approximately 70–100 nm.5 
The glomerular basement membrane forms both a size and charge barrier to 
filtration. The podocytes probably form the most important filtration barrier for 
plasma proteins.6 In normal conditions, urine formation starts when the blood 
from the afferent arterioles filtrates through the glomerular capillaries that consist 
of a filtrate with small plasma proteins and electrolytes. The amount of the filtered 
blood per time interval normalized to an idealized body surface area (1.73m2) is 
called the glomerular filtration rate (GFR, mL/min/1.73m2), which is determined 
by the hydrostatic pressure and colloid osmotic (oncotic) pressure across the 
capillary membrane, and the capillary filtration coefficient in the glomerulus.3 
Filtration occurs by means of the transcapillary pressure difference: 𝑺𝒊𝒏𝒈𝒍𝒆  𝑵𝒆𝒑𝒉𝒓𝒐𝒏  𝑮𝑭𝑹 =   𝑲𝒇    (∆𝑷𝒉 −   ∆𝝅)                Equation 1-1 
where Kf is a coefficient determined by hydraulic conductivity and the surface 
area, ΔPh and Δπ are the hydrostatic pressure and the oncotic pressure 
differences between the capillary and the Bowman’s space (the beginning of the 
tubular component of a nephron), respectively. If the hydraulic pressure 
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difference is smaller than the oncotic pressure, there is no filtration. The hydraulic 
pressure differences (ΔPh) between the capillary and the Bowman’s space do not 
alter much at the beginning and the end of the glomerular capillary. However, the 
oncotic pressure difference (Δπ) rises from 18 to 34 mmHg along the glomerular 
capillary.5 This is due to plasma filtration into the Bowman’s space, a fluid which 
has no protein passes. The oncotic pressure increases within the capillary and 
thus is reduced in the Bowman’s space. Therefore, the amount of filtration 
reduces along the capillary pathway.  
𝑺𝒊𝒏𝒈𝒍𝒆  𝑵𝒆𝒑𝒉𝒓𝒐𝒏  𝑮𝑭𝑹 = 𝑸𝒂𝒇𝒇𝒆𝒓𝒆𝒏𝒕 𝟏−    𝝅𝑨∆𝑷𝒉           Equation 1-2 
where πA is the initial capillary oncotic pressure, and Qafferent is the afferent blood 
flow rate. Assuming πA and ΔPh are unchanged constant, then the single nephron 
GFR varies, according to the Qafferent.5 In general, the single nephron GFR, 
afferent and efferent blood flow rate, oncotic and hydraulic pressure are stable: 
this renal aurtoregulation is controlled by changes in afferent and efferent 
arteriolar resistance.7 
It is impractical, or even impossible, to measure GFR at the glomerular level. The 
GFR measurement is the overall glomerular filtration rate in one or both kidneys 
in a subject. A normal GFR in an adult is approximately 125 mL/min.1 Therefore, 
an average adult has a glomerular filtration rate of 180 L per day. If this filtered 
fluid is not reabsorbed, the patient will lose a significant number of electrolytes. 
As a result, the majority of the filtered electrolytes (such as sodium and 
potassium) and plasma fluid are reabsorbed.  Currently, kidney function is 
reported based on GFR, either measured or estimated. The ideal markers for 
assessing GFR should be freely filtered by glomeruli without tubular secretion 
and reabsorption.3 This will be discussed in the next section.  
Another variable that is closely linked to GFR is the renal filtration fraction (FF). 
FF is the amount of renal plasma flow that is filtered. It is calculated by the 
following equation:1 
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𝑭𝒊𝒍𝒕𝒓𝒂𝒕𝒊𝒐𝒏  𝑭𝒓𝒂𝒄𝒕𝒊𝒐𝒏 𝑭𝑭 =    𝑮𝑭𝑹𝑹𝒆𝒏𝒂𝒍  𝑷𝒍𝒂𝒔𝒎𝒂  𝑭𝒍𝒐𝒘             Equation 1-3 
A normal FF is approximately 18.7 ± 3.2% in healthy young adults between the 
ages of 20 and 30 years.8 When the FF is above the reference interval of 18-
22%, it is considered hyperfiltration.9 Hyperfiltration can occur at the individual 
glomerular level in a situation where GFR is decreased. Early development of 
diabetic nephropathy is commonly associated with hyperfiltration and is a 
maladaption process.10 This can lead to poor renal outcome.11 Reducing 
hyperfiltration through medications, such as angiotensin receptor blockers or 
angiotensin converting enzyme inhibitors, may prevent or reduce the rate of renal 
function decline.  
As kidney function is commonly measured by GFR, the National Kidney 
Foundation has proposed five stages of Chronic Kidney Diseases (CKD).12 
Measurements of urinary sediments, markers of renal damage, renal imaging 
and renal pathologic abnormalities can help identify kidney diseases where the 
GFR is not significantly altered. Therefore, the CKD Stages 1 and 2 are defined 
as kidney damage, which are measured by using urinary, imaging or pathologic 
methods, with normal or increased GFR (≥ 90 mL/min/1.73m2) and with mildly 
decreased GFR (60-89 mL/min/1.73m2). The CKD Stages 3-5 are defined mainly 
by GFR measurements: 30-59 mL/min/1.73m2, 15-29 mL/min/1.73m2, and <15 
mL/min/1.73m2, respectively.  
The CKD staging system has some issues and it has received some major 
criticisms.13 It does not consider the underlying pathophysiology of renal failure. 
Furthermore, proteinuria (protein in the urine) is an important renal prognostic 
indicator: the current CKD staging system does not take it into account. 
Therefore, Tonelli et al. have proposed a new classification system based on 
both the GFR and the proteinuria level.14 This classification has not yet been 
widely adapted. For physicians and health care providers, it is important to know 
that the management of CKD patients should be individualized and should not be 
based solely on the CKD stages.  
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1.1.3. Methods of Measuring Glomerular Filtration Rate 
Over the last 80 years, several methods have been developed to assess GFR. 
Each of these methods has its pros and cons - some are more invasive and time-
consuming, while others may not be sufficiently sensitive or specific. Here, we 
will discuss the methods for assessing GFR.    
(1) The Inulin Study 
Inulin is a fructose polymer made from the Jerusalem artichoke that does not 
have non-renal elimination, no plasma protein binding, and is neither absorbed or 
excreted by the tubule. It has the characteristics of an ideal renal marker for GFR 
measurements.15 Therefore, inulin clearance is considered the gold standard for 
measuring GFR.16,17 This method was initially developed in 1935 by Homer 
Smith.17 In the traditional method, an intravenous infusion of inulin is given after a 
bolus injection until a steady state is reached. Urinary inulin clearance is then 
measured. Because it is time consuming, modified versions of the traditional 
inulin clearance were developed. Several hours of inulin infusion is the ideal 
method for measuring clearance, and to minimize error, catheterization is best for 
accurate urine collection. Despite the use of these methods, there is a 10% inter-
assay variability with inulin measurements due to analytical challenges and the 
inhomogeneity of the biomarker, especially when older biochemical methods are 
employed, rather than mass spectrometry.16 Because of its invasiveness 
(catheterization) and difficulties with the availability of inulin, an inulin study is 
rarely performed and is limited to a research setting.18 
(2) The Nuclear GFR Study 
In the 1970’s, nuclear medicine techniques replaced the inulin clearance method. 
The techniques, which use radio-labeled markers that have similar properties to 
inulin, have produced findings comparable to inulin GFR clearance studies of 
patients with GFRs above 20 mL/min/1.73m2.19,20 A bolus of clearly measured 
and suitable compound, which was injected through a venipuncture, is commonly 
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utilized. The rate of decreasing plasma concentration of the compound, after 
adjusting for its inherited decay rate, is measured and is used to calculate renal 
GFR. In Europe, chromium 51-labeled ethylenediaminetetraacetate (51Cr-EDTA) 
is the most widely used radio-labeled isotope. Technetium 99m-labeled 
diethylenetriaminepentaacetic acid (99mTc-DTPA) is the most commonly used 
GFR marker in North America.21-23 Although some studies have observed 
systematic differences between 51Cr-EDTA and 99mTc-DTPA, these differences 
are small and 99mTc-DTPA is recommended as an acceptable alternative to 51Cr-
EDTA.20,21,24-27 Other exogenous markers that have been utilized are 125Iodine 
iothalamate, iothalamate and iohexol. The latter two have been used without 
being radiolabeled. All markers except iothalamate have a small amount of 
plasma protein binding.  
For calculating GFR clearance using radioactive isotopes, some centers utilized 
a single-compartmental model.16 An example of the one-compartmental linear 
approach used log-transformation of the counts in each of the three samples:28 
 
Equation 1-4 
where Ti is the time of the sampling, BSA is the body surface area, and Pi is the 
plasma concentration of the isotope adjusted for the isotopic decay. This method 
can lead to overestimation of the GFR. Although this issue may be overcome by 
delay sampling, it is time-consuming.29-32 The lack of assessment of isotope 
extravasation, and the lack of information to demonstrate equilibration between 
intravascular and extracellular compartments, could explain the inaccuracy of the 
plasma isotopic GFR method.  In patients with expanded extracellular volume 
(ECV), it will over-estimate GFR. Finally, not taking into account the extra-renal 
metabolism and/or excretion of the isotopic markers, i.e. hepatobiliary, can also 
over-estimate GFR.  Since plasma isotopic GFR techniques commonly utilize a 
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single bolus-injection technique, it is important that the entire quantity of 
radioisotope enters the intravascular space, since extravasation can lead to the 
overestimation of GFR.  
There are certain compartmental methods where the timing of the blood 
sampling can result in different values. It has been considered that the slope-
intercept method, restricting the blood samples to the second of the two 
exponential components, provides the best compromise between accuracy and 
reliability, in addition to its simplicity.33 The Brochner-Mortensen technique has 
been developed to correct the systematic error of the slope-intercept 
technique.34,35 Appropriate pharmacokinetic approaches using the actual time 
point of sampling and Bayesian estimation for the calculation of the GFR from the 
isotope counts are important.36 The frequency and timing of collected samples 
matter, and are significant for accurate plasma isotopic GFR determination.21,22 It 
is generally recognized that at least 3 sampling points are required. 
The accuracy of plasma isotopic GFR measurement when the GFR is below 20-
30 mL/min/1.73m2 is limited.37,38 Therefore, the plasma isotopic GFR method can 
over-estimate GFR unless sampling time is extended; this may not be practical, 
especially for the dialysis population. To overcome this limitation, trials assessing 
GFR-estimation equations have used the urinary clearance isotopic GFR 
method.39 The urinary clearance can be calculated using the following method: 
 
Equation 1-5 
where Ti is the time of the sampling, Ui is the urinary concentration of the isotope 
adjusted for isotopic decay, BSA is the body surface area, Vi is the urinary 
volume, and Pi is the plasma concentration of the isotope adjusted for the 
isotopic decay. However, few studies have been performed to resolve the 
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Ui ×Vi
Ti −Ti−1( )× exp 0.5× ln Pi + ln Pi−1( )#$ %&
   where i =1,2,3 (sample)
GFRUrine =median GFR1,GFR2 ,GFR3( )×
1.73
BSA
'
(
)
*
+
,    where BSA= 0.007184× height0.725 ×weight0.425( )
 8 
question as to whether urinary isotopic GFR could serve as a suitable 
replacement method. 
(3) Endogenous Biomarkers to Estimate GFR 
Although using exogenous markers, such as inulin and nuclear isotopes, to 
measure GFR is considered more accurate; the method is invasive and time-
consuming, and not practical for day-to-day use. Therefore, endogenous 
biomarkers are commonly used to estimate.  The ideal biomarkers in patients 
with chronic kidney diseases should confirm the level of renal function, measure 
the total “renal clearance” and predict the outcomes of “renal health”. Once the 
potential biomarkers are identified, they need to go through vigorous 
development and testing. In stage 1, pre-clinical research identifies promising 
markers that require further exploration. In stage 2, the potential biomarker is 
tested in human beings to determine if it can distinguish individuals severely 
affected with the disease from those who are healthy. In stage 3, retrospective 
studies establish whether the biomarker detects disease before the clinical 
diagnosis becomes evident. In stage 4, the biomarker undergoes prospective 
evaluation to determine the performance characteristics of the test in a setting in 
which it will be clinically applied. Finally, in stage 5, the focus is on the use of 
biomarkers to assess in the natural course of illness. When biomarkers are used 
for screening, it should be shown in randomized controlled trials that the 
application of interventions earlier in the process is indeed beneficial. Several 
biomarkers have been used to estimate glomerular filtration rate and have gone 
through at least stage 3 or 4; they include small plasma solutes such as 
creatinine, and endogenous small molecular weight proteins such as cystatin C, 
beta-trace protein and B2 microglobulin.  
1.1.4. Methods of Estimating Glomerular Filtration Rate: 
Biomarkers 
(1) Creatinine  
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Creatinine is a small molecular weight solute (113 Dalton).40,41 It is the product of 
creatine and phosphocreatine, and is filtered by glomeruli. Proper and Mandel in 
1937 proposed that it could be used for assessing kidney function.42 There are 
various methods and reference ranges for serum creatinine measurements.43,44 
Recently, the isotope dilution-mass spectrometry (IDMS) reference method has 
improved and standardized the accuracy of creatinine measurements by 
eliminating some of the analytical problems.45 Measuring the creatinine clearance 
(mL/min/1.73m2) using 24-hour urinary creatinine measurements approximate 
GFR. However, it is not a true measure of GFR because there is some tubular 
secretion of creatinine. The equation for calculating 24-hour urinary creatinine 
clearance (CrCl) is as follows: 
𝑪𝒓𝑪𝒍 =   𝑼𝑪𝒓×𝟏𝟎𝟎𝟎  ×  𝑽𝒖𝒓𝒊𝒏𝒆𝟏𝟒𝟒𝟎𝑷𝑪𝒓 × 𝟏.𝟕𝟑𝑩𝑺𝑨                                                Equation 1-6 
where UCr (mmol/L) is the urinary creatinine concentration, Vurine is the urinary 
volume (L/24 hours), PCr (mmol/L) is the plasma creatinine concentration and 
BSA is the body surface area. This method is not routinely used because 
collecting 24-hour urinary creatinine clearance is cumbersome for patients. 
Timed urine collections are also notoriously inaccurate. Furthermore, creatinine 
is secreted by tubule. Therefore, creatinine clearance overestimates GFR by 
approximately 10% of the total excretion.1 A method called cimetidine creatinine 
clearance, where cimetidine treatment is used to block tubular secretion of 
creatinine, is impractical. To adjust for the problems, an equation to estimate 
CrCl was developed by Cockcroft and Gault (CG CrCl) and was published in 
1976.46  
𝐂𝐆  𝐂𝐫𝐂𝐥   = 𝟏𝟒𝟎!𝑨𝒈𝒆 ×   𝒘𝒆𝒊𝒈𝒉𝒕  𝒊𝒏  𝑲𝒈 ×   𝟎.𝟖𝟓  𝒊𝒇  𝑭𝒆𝒎𝒂𝒍𝒆   𝟕𝟐  ×  𝑺𝒆𝒓𝒖𝒎  𝒄𝒓𝒆𝒂𝒕𝒊𝒏𝒊𝒏𝒆                   Equation 1-7 
The Cockcroft-Gault equation requires the weight of the patients, whereas some 
of the estimated GFR equations do not. Therefore, it is much easier to generate 
laboratory GFR results using the Modification of Diet in Renal Disease (MDRD) 
study equation along with the creatinine values. There have been more published 
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studies on using other creatinine-based estimating GFR (eGFR) equations than 
the Cockcroft-Gault equation. As a result, the Cockcroft-Gault equation is not as 
commonly used. There are several different eGFR equations.  In the pediatric 
population, the most commonly used equation is the Schwartz equation.47 In the 
adult population, there are a few commonly used eGFR equations. See Table 1-1 
for a summary.  
Table 1-1. Commonly Used Creatinine-Based eGFR Equations 
  Equations (GFR mL/min/1.73m2) 
Original 
MDRD39 eGFR =  170 𝑆𝑐𝑟 !!.!!!𝐴𝑔𝑒!!.!"#𝐵𝑈𝑁!!.!"#𝐴𝑙𝑏!.!"# 0.762  𝑖𝑓  𝐹 1.180  𝑖𝑓  𝐴.𝐴.  
Abbreviated 
MDRD39 eGFR = 175 𝑆𝑐𝑟 !!.!"#𝐴𝑔𝑒!!.!"# 0.742  𝑖𝑓  𝐹 1.212  𝑖𝑓  𝐴.𝐴 * 
CKD-EPI48 eGFR = 141  (𝑚𝑖𝑛 !!"!,! !𝑚𝑎𝑥 !!"!,! !!.!"#)0.993!"# 1.018  𝑖𝑓  𝐹 1.159  𝑖𝑓  𝐴.𝐴. ** 
Schwartz47 eGFR = (𝑘  ×  𝐻𝑒𝑖𝑔ℎ𝑡)/𝑆𝑐𝑟*** 
Scr: serum creatinine (mg/dL); BUN: blood urea nitrogen concentrations (mg/dL); 
albumin (g/dL); F: female; A.A.: African-American. *This equation should be used 
when creatinine measurements have been calibrated to be traceable to IDMS. 
**K is 0.7 for females and 0.9 for males; a is -0.329 for females and -0.411 for 
males; min: minimum of Scr/K or 1; and max: maximum of Scr/K or 1. ***k is 0.33 
for pre-term infant, 0.45 for full term infant and 0.55 for children of age 1-12.  
 
However, creatinine is not a perfect GFR marker. Its production is affected by 
age, gender, ethnicity, and nutritional status.12 Because creatinine reflects 
individual body muscle mass, there is a large variability of its blood level among 
patients, independent of renal function.40,41,49 For example, disease such as 
spina bifida and neuromuscular disease can lead to unusually low creatinine 
levels.50 The estimated creatinine-based GFR, especially when the true GFR is 
greater than 60 mL/min/1.73m2, can lead to the over diagnosis of chronic kidney 
disease. Over the last few years, almost all of the laboratories in Canada widely 
implemented the reporting of eGFR, rather than just creatinine values. Studies 
have shown that there was an increase in referral rate to nephrologists.51,52 
Despite these issues, it is still the most commonly used biomarker to assess 
GFR.53 However, there is a need for better GFR biomarkers.  
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 (2) Cystatin C  
Serum cystatin C is a mid sized molecule with molecular weight of 13 kDalton.54 
It is positively charged with an isoelectric point of 9.3 and is an inhibitor of 
cysteine proteases.55-57 This protein is produced at a very constant rate by all 
nucleated cells.58,59 The secretion of cystatin C is affected only by a few states, 
such as inflammation, uncontrolled hyperthyroidism and large doses of 
glucocorticoids.60-62 Furthermore, age-dependency reference intervals have been 
suggested.63,64 Currently, cystatin C levels are measured by automated and rapid 
particle-enhanced immunoturbidimetric (PETIA) and immunonephelometric 
(PENIA) methods rather than the original radioimuno- or enzyme-linked 
immunosorbant assays. This allows rapid and more precise measurements.65 
Approximately 94% of cystatin C is freely filtered in the glomeruli, and 99% of this 
filtered cystatin C is degraded in the tubular cells.56 In a thorough meta-analysis, 
Dharnidharka et al.66 demonstrated that cystatin C is an excellent marker for 
kidney function assessment in patients with chronic kidney disease. Similar 
observations about the superiority of cystatin C-based eGFR measurements 
have been noted by Stevens et al. in chronic kidney disease.67 White et al. 
further showed that cystatin C is also superior to creatinine in assessing kidney 
function in adult patients after renal transplantation.68,69 Several cystatin C 
estimating equations are summarized in Table 1-2.70-77 We recently published the 
results of a study, which compared all cystatin C-based estimating equations to 
the creatinine-based estimating equations (the abbreviated 4-variable 
Modification of Diet in Renal Disease and the Chronic Kidney Disease 
Epidemiology Collaboration Equations).78 We found that in this heterogeneous 
sample, the cystatin C-based Hoek equation performed the best overall. Stevens 
et al. also showed the superiority of cystatin-C-based GFR measurement.67 
Furthermore, White et al. demonstrated that cystatin C-based equations, in 
particular the Filler equation, performed better than the creatinine-based GFR 
equation in renal transplant patients.69 
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Table 1-2. Commonly Used Cystatin C-Based eGFR Equations 
 Cystatin C-based GFR estimating equation (mg/L) 
Filler70 Log eGFR = 1.962 + [1.123 log (1 / cystatin C)] 
Grubb71 eGFR = 84.69 cystatin C-1.680 (1.384 if < 14 years) 
Hoek77 eGFR = -4.32 + (80.35/cystatin C) 
Larsson72 eGFR* = 77.239 cystatin C-1.2623 
Le Bricon73 eGFR = 78/cystatin C + 4 
Rule74 eGFR = 66.8 cystatin C-1.30 
Boekenkamp75 eGFR = 137/cystatin C -20.4 
Zappitelli76 eGFR = 75.94/cystatin C1.17 x (1.2 if renal transplant) 
eGFR: estimating Glomerular filtration Rate 
Recently, the CKD-EPI investigators and the Chronic Kidney Disease in Children 
investigators developed equations that used both creatinine and cystatin C. They 
showed that the combined creatinine–cystatin C equation performed even better 
than either cystatin C- or creatinine-based equations.79,80 However, it has not 
been commonly used in clinical practice. 
(3) Other Potential Markers  
There are other potential GFR biomarkers; however, they have not been studied 
as extensively as creatinine and cystatin C. One example is beta-2 microglobulin, 
which has been used to estimate GFR. However, its use as a GFR marker has 
been limited because of its strong association with inflammation.16 Another 
example is Beta Trace Protein (BTP), which was mentioned briefly above. It has 
a molecular weight of 23-29 kDalton and has been studied to estimate GFR.21 It 
is expressed in all tissues except the ovaries.81 Some studies have demonstrated 
a good correlation between BTP levels and the inulin clearance.82 However, its 
use in estimating GFR is still preliminary and more studies are needed. 
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1.2. INTRODUCTION TO RENAL REPLACEMENT THERAPY  
1.2.1. History and Development of Renal Replacement 
Therapy 
When 90% or more of usual kidney function is lost, either kidney transplantation 
or dialysis is required to sustain life. As of December 31, 2012, there were 
41,252 Canadians living with end-stage kidney disease and 23,814 persons in 
Canada (58%) were receiving dialysis; the remaining 42% had a functioning 
transplanted kidney.83 Hemodialysis is the most common form of dialysis, which 
is typically delivered three times a week with a machine connected to a patient’s 
vascular system. Mortality remains high (approximately 18 to 20% per year) 
despite improvements in technology for dialysis, development of new 
pharmaceutical agents, and nearly 50 years of experience. Although dialysis can 
sustain life, it rarely restores health. Patients undergoing dialysis have 
considerable complications often requiring hospitalization, and relatively poor 
functional status and health-related quality of life. The “renal health” of the 
dialysis patient relates to that component of health directly or indirectly impaired 
by loss of kidney function and, hence, possibly restored by effective (“adequate”) 
dialysis therapy.  
1.2.2. History and Development of Hemodialysis 
Dialysis uses very basic concepts, such as osmosis and diffusion, to clear extra 
fluid and substances from the body. The first person to describe this process was 
Thomas Graham84, known as the ‘Father of Dialysis’. He first studied diffusion in 
gases and later performed a series of experiments in liquids. He predicted that 
‘dialysis’ would be an important treatment for renal failure. Subsequently, Fick85 
published a quantitative description of diffusion.  
Hemodialysis is a procedure that circulates blood from the body over an external 
circuit, exchanges substances between blood and dialysate through a semi-
permeable membrane, and returns the ‘purified’ blood to the patient. The process 
is done outside of the body. Abel86 and colleagues created the first artificial 
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kidney in 1913. They dialyzed anesthetized animals using vividiffusion machines, 
which consisted of tubes with semipermeable membranes. He was also the first 
person to use an anticoagulant, Hirudin, to prevent clotting in the dialyzer. 
Subsequently, Haas87 documented the first human hemodialysis treatment in 
1924. Although none of their patients survived, they started the use of the 
Collodion dialyzer membrane and was the first person to use heparin to prevent 
dialyzer clotting. Heparin is still the most commonly used method of 
anticoagulation in hemodialysis therapies.  
Kolff88 in 1943 developed a more practical rotating drum hemodialysis machine 
and working dialyzer, and performed the first hemodialysis treatment where the 
patient survived. Although the basic concept of dialysis has not changed, the 
technical improvement in this rotating drum became the first major breakthrough 
in clinical hemodialysis. Kolff used a new material called cellophane, where the 
blood travelled through the inside the cellophane membrane tube and rotated 
through the dialysate fluid. The substances were removed and/or exchanged 
through the cellophane membrane. At this point, dialysis was to provide life 
support while waiting for recovery from acute renal failure. Kolff89 developed the 
next-generation dialysis machine, known as the Kolff-Brigham Kidney. These 
machines were used in the Korean War and significantly improved the survival 
rate of the soldiers. Kolff’s dialysis machine did not allow for excess fluid 
removal. It was Alwall90,91 who modified the machine and allowed a negative 
pressure to be applied for fluid removal. He also invented the arteriovenous 
shunt for hemodialysis in a rabbit in 1948. He later collaborated with a 
businessman and founded one of the major dialysis companies, Grambro, Inc. 
Improvements in equipment design and dialyzer occurred over the next few 
decades, but the basic concepts of dialysis, based on diffusion, have not 
changed.  
Before the 1960’s, chronic hemodialysis was believed to be impossible. This is 
because when hemodialysis started, each hemodialysis session required 
physicians to cut down to the vessels to create vascular access.  The damaged 
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veins and arteries made it difficult to find access to a patient’s blood after several 
sessions of treatment. The challenge of creating a reusable vascular access in 
humans was solved by Scribner. He worked with Quinton92 in the 1960’s who 
designed a U-Shaped Teflon tube that connected between artery and vein. 
Quinton later started a business called Quinton Instruments, which sold his 
inventions, including treadmills for cardiac stress tests. However, the Scribner’s 
shunt has problems, especially with clotting. Appell, Cimino, and Brescia93 
pioneered the arterial-venous fistula for chronic vascular access that is used for 
hemodialysis patients today. An arterial-venous fistula is created by arterializing 
a vein by connecting it to an artery. These major improvements and advances in 
technology have helped the development of our current hemodialysis machines 
and equipment. 
1.2.3. History and Development of Peritoneal Dialysis 
Peritoneal dialysis was the first renal replacement therapy to be applied clinically. 
In 1877,94 Wegner documented osmotic ultrafiltration in Germany and infused a 
concentrated glucose solution into the peritoneal cavity of animals to increase 
fluid removal. During a peritoneal dialysis treatment, the peritoneal solution 
(dialysate) is infused into the peritoneal cavity, which is the space between the 
parietal peritoneum (the part that lines the abdominal wall) and the visceral 
peritoneum (the part that lines the visceral gastrointestinal tracts). The peritoneal 
membrane serves as the ‘membrane’ that separates the dialysate from the 
mesenteric blood flow. The surface area of the peritoneum membrane, which is 
covered by mesothelial cells, is approximately 1.00-2.07 m2 in adults.95 The 
interstitial layers are embedded with microvessels, or peritoneal blood supplies. 
As a result, both diffusion and convection clearance can be achieved between 
the peritoneal blood and dialysate fluid.  
In 1923, Ganter96 applied this therapy clinically and treated a woman with 
obstructive uremia by infusing 1.5 L of saline into her abdominal cavity. She 
showed some temporary improvement, but died later. Like hemodialysis, 
intermittent peritoneal dialysis treatments prior to the 1960’s were used as short-
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term renal replacement therapies due to a lack of permanent peritoneal dialysis 
catheters.97-99 It was Tenckhoff100 who designed a permanent and safe catheter, 
which allowed the development of chronic peritoneal dialysis. Later, Popovich 
and Moncrief101 using glass containers had the first clinical application of 
continuous ambulatory peritoneal dialysis (CAPD). They also developed a 
comprehensive calculation for dialysis clearance using the volume and the dwell 
time of dialysate solutions.102 The major comorbidity of these patients was 
peritonitis (infection of the peritoneum). It was known that the risks were related 
to the patients’ peritoneal dialysis technique and the connecting system.  The 
peritonitis rate has significantly improved since Oreopoulos introduced peritoneal 
dialysate into plastic bags and used the Y connecting system, introduced by 
Buoncristiani,103,104 with the flush-before-fill technique. These simple concepts 
have dramatically reduced the peritoneal dialysis peritonitis complication rate. 
Although the automated cycler system was developed in 1962 by Boen, it has 
only become a common peritoneal dialysis technique over the last 10-20 
years.105 Today, the common peritoneal dialysis prescription uses an automated 
cycler machine at night, which allows approximately 4 exchanges in 8-10 hours 
overnight, and up to two exchanges over 4-14 hours during daytime.  
1.3. COMPONENTS OF HEMODIALYSIS 
Both peritoneal dialysis and hemodialysis use the concepts of diffusion and 
convection clearance. Peritoneal dialysis uses the peritoneal blood flow, which 
allows molecules and fluid exchange to occur between the blood and dialysate in 
the peritoneal cavity. The dialysate fluid is drained and then the new dialysate 
fluid is infused. It is considered a continuous dialysis therapy. Similarly, 
hemodialysis uses the diffusion and convection clearance mechanisms. 
However, the blood is first removed from the body. As a result, fluid and 
molecules are exchanged outside of the body through a hemodialysis machine 
and a dialyzer. Dialysate runs in the counter-current direction in the dialyzer to 
maximize the concentration gradient. The ‘clean’ blood is then returned back to 
the patients. The therapy is usually performed three times per week, with four 
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hours each session.  However, prolonged and/or frequent hemodialysis is 
performed only in a small population of patients, usually in the home setting. The 
focus of this chapter will be on hemodialysis, including its components and 
mechanisms, dialysis and patient physiology, and the concepts of dialysis 
adequacy and kinetics.  The five major components of hemodialysis are: a 
vascular access, a dialysate circuit, a blood circuit, a dialyzer and a hemodialysis 
machine.    
1.3.1. Vascular Access 
A vascular access for a patient allows a gate for the blood to pass into the 
hemodialysis circuit. It is considered the Achilles’ heel of hemodialysis. Without a 
permanent vascular access, chronic hemodialysis cannot occur. However, the 
access can fail due to infection, stenosis, thrombosis or fibrin sheath formation. 
The commonly used vascular accesses currently are: arterial-venous fistulae 
(created by connecting a patient’s artery to a vein), arterial-venous graft (created 
by connecting patient’s artery to a vein, through a synthetic hollow tube), and 
central venous catheter (inserted into an internal jugular vein, a femoral vein, or a 
sub-clavian vein). To lower the infection rate, the central venous catheter usually 
tunnels under the skin for chronic use.  
1.3.2. Dialysate Circuit 
Another component of hemodialysis is a dialysate circuit. It is the circuit where 
the dialysate leaves its source/supply and passes through the dialyzer.  Dialysate 
is the clean fluid that exchanges the electrolytes, toxins and fluid with the blood. 
Dialysate is generated from a water supply (i.e. from the city) after meeting 
certain universal standards. Because of the large water exposure, it is important 
that the water goes through a vigorous detoxing process, using a combination of 
water softener, activated carbon filter, reverse osmosis, and/or distillation. The 
clean water can be delivered to the dialysis machine, mixing with the 
concentrated electrolytes (such as sodium, potassium and bicarbonate) to form 
dialysate, which allows hemodialysis to occur.  Its composition of sodium, 
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potassium and bicarbonate can be adjusted. To ensure the patient is not 
exposed to a hyper- or hypo-osmolar dialysis solution, which can be fatal, the 
dialysate conductivity (usually 12-16 mS/cm) is monitored in modern 
hemodialysis machines. During a 4-hour hemodialysis treatment, the patient is 
exposed to ~100 L of water.  
1.3.3. Blood Circuit 
The third component is a blood circuit. This is a circuit where the blood leaves 
the patient from the vascular access, passes through the dialyzer, and returns 
back to the patient. To allow for an efficient hemodialysis treatment with the 
current hemodialysis regime (four-hours thrice weekly), the blood flow rate needs 
to be at least 250 mL/min in adults, and is usually between 300-400 mL/min. In 
children, 5-8 mL/kg/min are targeted. The inflow bloodline (arterial) connects 
from the patient’s vascular access to the dialyzer. The outflow bloodline (venous) 
returns the blood from the dialyzer back to the patient. Before the roller pump 
was used in modern hemodialysis machines, the inflow bloodline would need to 
connect to an artery and the outflow bloodline was connected to a vein. The 
blood flow rate depended on the blood pressure difference between the artery 
and the vein. This pressure difference also allowed ultrafiltration to occur. With 
modern technology, the roller pump is placed in the arterial line to generate 
‘negative’ pressure. Therefore, both the arterial and venous lines can be placed 
in the venous system of a hemodialysis patient. Blood flow rate is a function of 
the roller pump rotation rate and the bloodline pump segment volume. However, 
because of the negative pressure generated by the roller pump, air can get into 
the bloodline if there is a breakage in the bloodline system. An air detector is 
placed in the venous line as a safety measure before the blood is returned back 
to the patients, in order to avoid an air embolism. 
1.3.4. Dialyzer 
A dialyzer is where dialysis occurs. It contains many thin semi-permeable 
membrane hollow fibers with many small pores. It allows the molecules and fluid 
 19 
to be exchanged between the blood and the dialysate. The blood flows within the 
hollow fibers in one direction and the dialysate flows outside the hollow fibers in 
the opposite direction. This counter-current flow maintains some concentration 
gradient between the blood and the dialysate. As the dialyzer membrane acts as 
a separator between the blood and the dialysate, there are two liquid phases: the 
transport (solute transport due to diffusion and convection) and the contact 
phases (blood material interaction with the dialyzer material). There is also 
adsorption of proteins on the membrane, which more commonly occurs for the 
hydrophobic molecules. One of the issues with dialyzer membranes is activation 
of the coagulation system leading to dialyzer thrombosis. As the dialyzer 
membrane is a foreign body, the blood coagulation system may be activated 
when blood comes into contact with the membrane. Dialyzer membrane 
thrombosis can lead to significant reduction in blood flow and diffusion capacity. 
The use of heparin has significantly reduced clot formation on the dialyzer 
membrane. 
Dialyzer membranes have undergone significant development in the last century. 
The first human dialysis was performed using cellulose membranes. Cellulose is 
a polysaccharide polymer that consists of repeating units of cellobiose monomer. 
Each cellobiose monomer constitutes two glucose molecules, which contains 
three hydroxyl groups (-OH) that can lead to chemical reactions forming esters or 
ethers. Kolff began to use cellophane materials for dialysis. In the 1960s, 
cuprophane had become popular.106,107 Both cellophane and cuprophane are 
types of cellulosic membranes.48 Cuprophan is a low flux membrane with a wall 
thickness of 5-20 µm. Although it is good for small solute clearance, it has very 
low sieving capacity for large solute. It is also considered bio-incompatible. 
Bioflux, on the other hand, has a similar structure to cuprophan, but has larger 
pore diameters. Therefore, it has higher flux and has better clearance for medium 
solutes.  Cuprammonium rayon was introduced to increase the removal of higher 
molecular weight molecules. It replaced the hydroxyl groups with hydrogen 
bonds. The bio-incompatibility of these membranes is because of the hydroxyl 
groups (-OH), which can activate the complement system and lead to 
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inflammatory reactions (interleukin-1, 6, and 8, and TNF-α) with activation of 
complement factors. Some patients develop anaphylactoid reaction (C3a and 
C5a) and leukopenia during dialysis. Therefore, there was a big movement to 
develop more biocompatible membranes.  
The modified cellulosic dialyzers were developed and acetate or hemophane was 
used to replace the hydroxyl groups on the cellulosic backbone. Hemophan has 
5% of the hydroxyl groups substituted to diethyl-amino-ethyl groups. It has 
reduced complement activation to some degree, but it is also considered a low 
flux membrane.  Synthetically modified cellulose has 20-25% of the hydroxyl 
groups substituted by benzyl groups. It is approximately 8-9 µm in thickness. It is 
considered more biocompatible as compared to hemophane and cuprophan.  
Celluose acetate (and di- and tri-acetate) substitutes the hydroxyl group with 
CH3CO radicals. The cuprammonium-rayon polyethylene glycol substitutes the 
hydroxyl groups with polyethylene glycol chains.  
There was a significant increased in the use of synthetic membrane dialyzers 
over the last 10-20 years.108 Now, the more commonly used dialyzers in North 
America contain synthetic membranes (based on synthetic polymers).109 These 
materials are more biocompatible and heat resistant with endotoxin retention. 
They are more permeable. The natural stiffness of the material provides 
membrane strength and overall the structural support.110 Cellulose membranes 
have the thinnest membrane and the synthetic membranes are much thicker.111 
By contrast, the membrane inner diameters are relative similar between cellulosic 
and synthetic membrane (170-230 µm). The common synthetic membranes are 
polyacrylonitrile, polysulfone and polyamide. One of the major issue that needs to 
be addressed for cellulose dialyzer membranes is complement activation. 
Synthetic dialyzer membranes are less likely to bind to complement-regulating 
protein and are considered more biocompatible. The development of synthetic 
membranes was started in 1970 using polyacrylnitrile materials, with the desire to 
increase higher molecular weight solutes clearance.111 Subsequently, 
polysulfone membrane has become the most widely used synthetic dialyzer. 
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Some of the polysulfone membrane was developed using a steam sterilization 
technique with another safety feature, endotoxin retention. The various 
proportion of hydrophilic and hydrophobic composition different between different 
polysulfone dialyzers. The advantages and disadvantages of the different types 
of membrane are summarized in Table 1-3 and the different types of 
hemodialysis membranes are summarized in Table 1-4.  
Table 1-3. Advantages and Disadvantages of Unmodified Cellulosic, 
Modified Cellulosic and Synthetic Hemodialysis Membranes 
 Advantages Disadvantages 
Unmodified 
Cellulosic 
High diffusive membrane transport 
for small molecular solutes  
Higher complement 
activation 
Lower clearance of 
middle and large 
molecular solutes  
Modified 
Cellulosic 
Increased removal of middle 
molecular solutes 
 
Higher complement 
activation 
 
Synthetic High water permeability for 
ultrafiltration; 
Better middle molecular solute 
removal 
Thick membrane wall 
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Table 1-4. Different Types of Hemodialysis Membranes 
 Unmodified 
Cellulosic 
Modified 
Cellulosic 
Synthetic 
Low-Flux Cuprophan Cellulose (di) 
acetate 
Polysulfone 
 
 Saponified 
cellulose ester 
Hemophan Polyamide 
 Cuprammonium-
rayon 
Cuprammnonium-
rayon 
polyethylene 
glycol 
Polyethersulfone 
  Synthetic 
modified cellulose 
Polyester polymer alloy 
High-Flux Bioflux Cellulose tri 
acetate 
Poly-acrylonitrile 
 
  Vitamin E Polymethylmethacrylate 
   Polyarylethersulfone 
   Ethylene vinyl-alcohol 
copolymer 
   Polycarbonate 
polyether copolymer 
 
1.3.5. Hemodialysis Machines 
Finally, the hemodialysis machine is the controlling center for all these 
components. It has a computer system and a monitor, pressure sensors, flow 
sensors, and an air detector. More modern hemodialysis machines also include 
other devices, such as online ionic effective dialysance methodology, blood 
pressure monitoring, and relative blood volume measurements. Figure 1-1, 
summarizes all the necessary components of the hemodialysis therapy.  
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Figure 1-1. A Simple Schematic Diagram of Hemodialysis Circuit 
 
1.4. HEMODIALYSIS MODALITIES 
Hemodialysis can be performed at home, in hospitals (in-center), or in satellite 
units (hemodialysis units associate with major dialysis centers but not inside 
hospitals). The duration and the timing of hemodialysis treatments can vary 
between 2-24 hours per day and it can be performed during daytime and 
nighttime. Below are some of the common hemodialysis settings and 
techniques/modalities: 
• Intermittent hemodialysis therapies (3-4 days per week) 
• Conventional hemodialysis (3-4 hours per session): in-center, satellite 
units, or home 
• Extended-hours hemodialysis (6-8 hours per session): in-center or home 
• Quotidian hemodialysis therapies (5-7 days per week) 
• Short-hours daily (2-2.5 hours per session) – in-center or home 
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• Nocturnal (8-10 hours per night) – home  
• Slow continuous dialysis therapies (24 hours per day) 
• Continuous renal replacement therapy, usually with venous to venous 
access and less commonly with arterial to venous access  
o Hemodialysis only: Continuous venovenous hemodialysis – intensive 
care units 
o Hemofiltration only: Continuous venovenous hemofiltration – intensive 
care units 
o Both hemodialysis and hemofiltration: Continuous venovenous 
hemodiafiltration – intensive care units 
• Slow continuous ultrafiltration (SCUF) with no dialysis or replacement fluid 
- in-center 
1.5. THE PHYSIOLOGY OF HEMODIALYSIS CLEARANCE 
1.5.1. Basic Concepts of Diffusion and Convection 
Diffusional clearance occurs when solutes from solution A (blood) move to 
solution B (dialysate) and are driven by concentration differences through a 
semipermeable membrane (Figure 1-2). Molecules and ions dissolved in the 
solutions are in constant motion. More of the molecules on average moves from 
high concentration solution to low concentration solution. Only molecules that are 
smaller than the pore size can pass through the membrane. Water molecules 
can also ‘diffuse’ through a semi-permeable membrane. The term ultrafiltration 
refers to the situation where water molecules move from solution A (blood) to 
solution B (dialysate). This process is driven by either a hydrostatic or an osmotic 
gradient through a semipermeable membrane. The hydrostatic pressure 
difference between the two sides of the semi-permeable membrane is opposed 
by osmotic pressure. As a result, convectional clearance can occur when water 
moves from one solution to another solution through the semipermeable 
membrane (i.e. blood to dialysate), and the water is accompanied by other 
solutes. This process is called convection or solvent drag. 
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Dialysis clearance is defined as the volume of blood from which all solutes in 
question are reduced during a specified time period. The total amount of solute 
removal depends on the duration of the therapy. This is similar to renal clearance 
in the healthy kidney (discussed earlier). Conventional hemodialysis (3 times per 
week and 4 hours per session) is highly efficient in removing small solutes, and it 
has a high clearance rate per session. However, because it is an intermittent 
therapy that occurs only 3 times per week and 4 hours per session, its weekly 
clearance is similar to continuous therapy by peritoneal dialysis. The factors that 
influence hemodialysis solute clearance are listed in Table 1-5, and are grouped 
as dialysis-related, patient-related, and solute-related factors. Some of the key 
variables to consider when discussing hemodialysis clearance are blood flow 
rate, dialysate and its flow rate, dialyzer characteristics, ultrafiltration rate, and 
dialysis duration and frequency. Each of these key factors will be discussed in 
this section. Solute characteristics are key to its clearance rate, which is also 
influenced by its compartmental distribution. This will be discussed in the next 
section. 
 
Table 1-5. Factors Influencing Solute Concentrations in Dialysis Patients 
Dialysis-related Patient-related Solute-related 
Time Body weight and total body 
water 
Compartmental 
Distribution 
Frequency Solute 
intake/absorption/generation 
Protein Binding 
Blood flow Residual renal function 
 
Charge 
Dialysate flow Blood viscosity 
 
Molecular weight 
Dialyzer characteristics*  Steric configuration 
Membrane absorption  Intracellular 
Concentration 
Ultrafiltration   
* surface area, pore size, hydrophilic/hydrophobic 
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Figure 1-2. Diffusion of Molecules in Two Solutions Through a Semi-
permeable Membrane 
 
1.5.2. Chronic Hemodialysis Access and Blood Flow Rate 
To reach adequate weekly hemodialysis with conventional hemodialysis 
treatment, the blood flow rate needs to be 300-400 mL/min for patients with 
minimal renal function. They will need at least 3-4 hours of treatment per session. 
It is of paramount importance to have reliable vascular access. Because of the 
need for high blood-flow rate, chronic hemodialysis was not possible before the 
development of chronic vascular access techniques. Prior to the 1960’s, a 
surgical procedure to cut down the arterial and venous vessels was required prior 
to each hemodialysis treatment. Therefore, patients would eventually run out of 
vessels to allow vascular access. In the 1960’s, this issue was resolved by the 
development of Scribner’s shunt. Subsequently, the development of other 
vascular accesses, such as an arteriovenous fistula, an arteriovenous graft, and 
a central venous catheter, allowed chronic hemodialysis to be possible.   
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Connecting a vein to an artery creates an arteriovenous fistula. With the use of 
an artificial graft, an arteriovenous graft can be created. The advantage of an 
arteriovenous graft over a fistula is that it is available within a few weeks after its 
surgical creation. However, it has shorter access survival time as compared to 
fistula. There is also a higher risk of graft infection, thrombosis and stenosis. 
Therefore, the arteriovenous fistula is still the preferred chronic vascular access 
for hemodialysis patients over the arteriovenous graft. Another common vascular 
access in hemodialysis patients is the central venous catheter. It is most 
commonly placed through the internal jugular vein with cuffed tunneled catheters 
just under the skin. Other insertion sites such as subclavian and femoral veins 
have been used. Rarely, translumbar catheters to inferior vena cava have been 
used in patients with challenging vascular access. Each catheter has two 
lumens, one is the venous port and one is the arterial port. These two 
ports/lumens are within the venous system of the patient. Formation of a 
thrombus and/or a fibrin sheath at the tip of the catheter can cause delayed 
catheter dysfunction or a reduction in blood flow rate, and/or lead to recirculation. 
Sometimes, the blood flow rates are significantly affected and the arterial and 
venous lumens need to be reversed. This further increases the amount of access 
recirculation and reduces the solute clearance. Infection is another common 
complication when using the central venous catheter. Because the arteriovenous 
fistula method is consistently associated with the lowest risk of mortality versus 
arterio-venous grafts or catheters, therefore, the arteriovenous fistula is 
considered the preferred vascular access for hemodialysis patients. The 
discussion below will focus on the arteriovenous fistula.  
After the arteriovenous fistula creation surgery, there is an increase in shear 
stress in the vasculature because of the local substantial increase in blood flow. 
As a fistula matures, the diameter of the proximal part of the vein will grow. 
Experimental models showed that this is followed by compensatory changes, 
which are related to the release of nitro-oxide, prostacyclin and other mediators, 
as well as changes in endothelial cells and the remodeling of cellular and 
extracellular components of the wall. These adaptations may take 2-3 months to 
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develop.112-114 Surgical technique is quite critical to the success of fistula 
creation.115 A well-developed fistula can usually reach a flow rate of 645 ± 332 
mL/min in the forearm and 1336 ± 689 mL/min at the brachial or upper arm.116  
By contrast, some patients may develop a high blood flow rate in their fistula 
(>2,000 mL/min or access flow rate/cardiac output >30-35%). If the flow rate of 
the arteriovenous fistula is very high, patients can develop left ventricular 
hypertrophy and/or high output cardiac failure. A patient with total cardiac output 
of 7,400 mL/min and vascular access flow of 4,100 mL/min can reduce the 
systematically functional cardiac output. A group of high vascular access flow 
patients (3,135 ± 692 mL/min) demonstrated a significant reduction in functional 
cardiac output after access creation.117 Left ventricular mass regression, 
however, can be seen after ligation of the arteriovenous fistula.118 This can 
significantly compromise cardiac function. By contrast, a high output state does 
not seem to increase mortality. In fact, a study has shown that high access flow 
rate was associated with increased survival.119 
Blood flow rate at the needling sites of the fistula will depend on the arterial flow 
prior to entering the fistula (stenosis at the anastomosis site), collateral vascular 
system (taking away the blood flowing to the fistula), and the flow resistance 
within the fistula (stenosis of the fistula), and at the distal part of the venous 
system (central stenosis). One of the common issues with an arteriovenous 
fistula is reduction in access flow rate due to stenosis. As the stenosis gets more 
severe, the access flow rate can be reduced; in addition, the hemodialysis 
clearance will be reduced. Severe arteriovenous fistula stenosis is also a sign of 
a failing fistula. This can also increase clotting risk and/or lead to acute 
thrombosis of the fistula. If the stenosis is distal to the arterial needle during 
hemodialysis, recirculation can occur. When the arteriovenous fistula flow rate is 
less than the extracorporeal blood flow rate (<300-400 mL/min), recirculation will 
occur. 
Therefore, routine monitoring of the access function is recommended; 
measurement of the access blood flow rate is the preferred method. The gold 
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standard for measurement of the access blood flow (Qa; mL/min) is an indicator 
dilution technique.120 A dilutant, such as sodium, is injected into the venous line, 
and it can be detected in the dialyzer inlet immediately after. The indicator is the 
ultrasound velocity of the blood and the dilution is by saline solution. Another 
technique, such as thermodilution, has also been used: it is well validated and 
established and employs Krivitski’s theory:  
𝐐𝐚   =   𝐐𝐛  ×    𝟏!𝐑𝐑                                                                                         Equation 1-8 
where Qb is the blood flow (mL/min) through the dialyzer and R is the proportion 
of circulated blood through the access induced by reversing the arterial and the 
venous dialysis line. Other indicator dilution methods exist.121 Another 
phenomenon can be observed in an arteriovenous fistula: cardiopulmonary 
recirculation. This results when the ‘clean blood’ bypasses the systemic 
microcirculation from cardio and pulmonary vessels and returns to the extra-
corporeal circuit. Therefore, retrograded ‘clean blood’ will flow and mix with the 
blood that enters the hemodialysis machine. This can affect the clearance.  The 
amount of cardiopulmonary recirculation is proportional to the arteriovenous 
fistula flow rate and is inversely proportional to the cardiac output.   
Repeated needle entries into the fistula prior to each hemodialysis treatment 
allow access to high blood flow during hemodialysis. The viscosity of blood is 3 
times higher than that of water. This is because the hematocrit of the blood is ~ 
40% (the percentage of the blood that is cells). In addition, there are proteins in 
the plasma, although these effects on viscosity are much smaller. Unlike in 
simple fluids, blood viscosity varies by shear rates, and shear stress affects the 
particles and other contents of blood, such as hemoglobin. Therefore, the half-life 
of red blood cells is shorter in hemodialysis patients, because a small amount of 
hemolysis can occur with each hemodialysis treatment. Blood flow (Qb) through a 
vessel is dependent on the pressure difference (ΔP) between the two ends of the 
vessels and the vascular resistance (R). This follows Ohm’s Law:  
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  𝑸𝒃   =    ∆𝑷𝑹                                                       Equation 1-9 
Newtonian fluid (i.e. water) is a fluid in which the viscous stresses and the strain 
rate are related by a constant viscosity tensor. It does not relate to the flow rate. 
The Poiseuille’s law provides a helpful measure of the dependence of flow on 
viscosity and tube geometry.  The Poiseuille’s law is described as the following: 
𝑹   =    𝟖𝝁𝑳𝝅𝒓𝟒                                                                                                                            Equation 1-10 
where R is the resistance, µ is the blood viscosity, L is the access length, and r is 
the access radius.107 For example, with a reduction in r of 50%, R will increase by 
16 times. Although Poiseuille’s law is a widely used equation for fluid flow 
resistance measurements, it has certain restriction to Newtonian fluid with 
laminar flow in a straight tubes. Blood is a non-Newtonian fluid. This relationship 
will only serve as an estimate for the blood flow, especially in the dialysis tubing 
where the flow is laminar. In addition, the Reynolds number for straight, smooth, 
laminar flow of Newtonian fluid is usually ~ 2300. For blood, the Reynolds 
number is related to the blood flow, and tube diameter. In the extracorporeal 
circuit in dialysis patients where the tube diameter is 4.5 mm and the viscosity is 
3.5 mPa/S (with hematocrit of 0.38), the Reynolds number is below 500 for the 
blood flow < 600 mL/min (i.e. blood flow of 400 mL/min has Reynolds number 
~600).107 These are important factors to consider when assessing the blood flow 
rate of the fistula, as well as the extracorporeal blood flow rate within the 
connecting tubing and the dialyzer.  
In the extracorporeal circuit, there is generally laminar flow. However, the flows at 
the cannulation and connector sites are turbulent. The flow rate is proportional to 
the pressure differences between the inlet and the outlet of the circuit, and 
inversely proportional to the blood viscosity and the resistance of the circuit. 
Historically, the pressure differences between the artery and vein were used as 
the driving force in the extracorporeal circuit of a hemodialysis system. However, 
today’s hemodialysis machines use a pump-driven extracorporeal system. Most 
of these machines use rotary peristaltic pumps. A pump that allows flow reversal 
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has also been developed. This has been used in single-needle hemodialysis, 
especially in nocturnal hemodialysis patients and/or in patients with a new fistula.  
The stroke volume can be calculated based on the following equation122:  
𝑺𝒕𝒓𝒐𝒌𝒆  𝑽𝒐𝒍𝒖𝒎𝒆 = 𝑫  𝒅𝟐  𝝅𝟒                                                           Equation 1-11 
A typical pump has the diameter of its pump bed (D) of 8.8 cm and the tubing 
cross-section diameter (d) as 0.8 cm. The blood flow rate will be the product of 
the stroke volume per revolution and the rotation speed of the roller. Some 
hemodialysis machines, such as the Fresenius A2008C®, have a built in system 
to calculate the flow.  
Although the blood flow rate is typically set at 400 mL/min during a hemodialysis 
treatment, the actual blood flow rate is lower than 400 mL/min. Recently, in one 
of our published studies (see Chapter 5), we measured the true blood flow rate 
and compared this to the machine blood flow rate.123 This was measured by the 
Transonic HD01 monitor (Transonic Systems, Ithaca, NY). When the 
hemodialysis machine blood flow rates were set at 200 mL/min and 400 mL/min, 
the actual blood flow rates were 179 ± 2 and 331 ± 6 mL/min, respectively.  
1.5.3. Dialyzer  
Each dialyzer contains 7000-14000 hollow fibers. Resistance in the dialyzer can 
affect the blood flow rate. The smaller inner fiber diameter provides a shorter 
diffusive distance for the solute, but it has a higher shear rate as compared to the 
larger size fiber.120 The membrane of the hollow fibers consist of millions of pores 
that allow diffusion and ultrafiltration to occur. These pores allow the fluid and 
solutes to diffuse across the membrane through concentration gradients. The 
pore-related characteristics such as pore size and pore density influence the 
permeability of the solute. Water permeability is strongly related to the pore 
radius only. The larger the pores, the less transmembrane pressure is required 
for fluid transport. However, the larger the pores, the more the larger molecules, 
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such as protein (albumin), can diffuse through. This will have a significant clinical 
consequence.  
By contrast, one way to increase the diffusional clearance is to increase the 
surface area of the membrane. The synthetic hollow fibers have an inner 
diameter of approximately 180-220 µm, and a length of 20-24 cm. The surface 
area of a small fiber can be expressed as the following:  𝑺 = 𝟐𝝅𝒓𝑳                                                                       Equation 1-12 
The total surface area of the dialyzer (assuming 10000 fibers) is approximately 
1.51 m2. The surface area of an adult size dialyzer is generally in the range of 
1.6-2 m2.  As the dialyzer surface area increases, the diffusional clearance will 
also increase. This can be demonstrated in Figure 1-3. 
The absorption of the dialyzer is commonly ignored. However, this should be 
considered when assessing solute clearance. Generally, this will depend on the 
charge, size and other characteristics of the molecule. However, the 
characteristics and types of dialyzers can also influence the solute absorption.  
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Figure 1-3. The Relationship Between Small Solute Clearance and Total  
Surface Area of a Dialyzer.  
Larger surface area dialyzer (1.8 m2) and smaller surface area dialyzer 
(Reprinted with permission from reference by Ronco et al. 124) 
 
1.5.4. Dialysate and Its Flow Rate 
Dialysate is an important part of the hemodialysis treatment. In current use, 
dialysate water comes from purified water. A healthy person drinks ~1.5 – 2 L of 
water per day which is 10 -15 L per week, but a hemodialysis patient can be 
exposed to ~ 400 L of water per week. Dialysate water is exposed to blood 
directly; thus barriers such as intestinal protection are eliminated. Water 
contaminants, including particles (ion, sand, and clay), chemicals, and micro-
organisms/endotoxins (virus and fungi) need to be removed.    
For dialysate water, water purification is commonly done by using city water 
purified through distillation, reverse osmosis, ultrafiltration and/or deionizer 
systems. Because a distillation system is expensive and given the large amount 
of purified water required for hemodialysis units, ultrafiltration (using various 
sizes of filters), reverse osmosis and/or deionizer are more commonly used. In 
addition, softeners to remove calcium and magnesium, and activated carbon to 
removed organic contaminants, chlorine and chloramine, are common devices 
employed in the water purification systems.  
Reverse osmosis is an effective way of removing organic and inorganic solutes. 
As water flows through the system, it is pushed through a very tight membrane. 
Although the osmotic gradient at the ‘rejected’ side is much higher than the 
‘permeated’ side, the hydraulic pressure is high enough to push the fluid against 
the osmotic force.  These membranes are quite similar to dialyzers. By 
monitoring the conductivity of the ‘permeated’ water, as the conductivity 
increases, it provides an indication of the poor performance of the membrane.   
A deionizer system removes inorganic ions by an ionic exchange process. The 
water passes through a cationic resin, where the cation will exchange with H+. 
Then, the water passes through the anionic resin and the anion will exchange 
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with OH-. Again the resistivity of the water will be monitored. The resin will need 
to be changed if the resistivity of the water decreases. Instead of resin, an 
electric deionizer can also be used. A deionizer system will need to be followed 
by ultrafiltration system because it is not effective in removing organic or bacterial 
toxins.  
The quality of dialysate water is crucial. Aluminum toxicity has led to many 
deaths, and chloramine toxicity can lead to acute hemolysis, and microcystis 
aeroginosa overgrowth can also lead to inflammation and increase risk of 
infection. Currently, the recommended bacteria levels of dialysate water are < 
100 colony-forming units per milliliter of water. Endotoxin levels should be < 0.1 
EU/mL. The hardness of water should be < 1 ppm. The pressure between the 
pre- and post-water softener, carbon tank and deionizer should not drop more 
than 10 PSI. The resistivity of the reverse osmosis system and the deionizer 
system need to be monitored. An example of a reverse osmosis system is shown 
in Figure 1-4 and the constituents of dialysate are summarized in Table 1-6. 
 
 
Figure 1-4. An Schematic Diagram of a Water Purification System: the 
Reverse Osmosis System. 
 
 
 
Table 1-6. Constituents of Plasma and Dialysate. 3 
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 Plasma Dialysate 
Sodium (Na+; mEq/L) 142 140 
Potassium (K+; mEq/L) 5.0 1.0-4.0 
Calcium (Ca++; mEq/L) 3.0 2.5-3.5 
Magnesium (Mg++; mEq/L) 1.5 1.5 
Chloride (Cl-; mEq/L) 107 105 
Bicarbonate (HCO3-; mEq/L) 24.0 35.7 
Lactate-(mEq/L) 1.2 1.2 
Phosphate (HPO4=; mEq/L) 3 0 
Urea (mmol/L) 9 0 
Creatinine (µmol/L) 88 0 
Glucose (mmol/L) 5.5 7.0 
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In order to ensure the required concentration of the electrolytes in the dialysate 
solution, a monitoring system is required. Conductivity is the measured of 
electrical current conduction. Conductance is measured in S (Siemens) and 
resistance is measured in Ω (Ohm). Specific resistivity or conductivity is the 
resistance or the conductance of a cube of the substance in S/cm or Ω x cm 
units, respectively. Molar conductivity is the specific conductivity divided by the 
solute concentration. However, conductivity can also be used to measure 
concentration. At 25°C, the conductivity of sodium chloride of 103 mmol/L is 
equal to 10.68 mS/cm.125 Therefore, conductance was built into the hemodialysis 
machines. This allows measurements of electrolyte concentration (mainly sodium 
chloride), but has also been applied to measure single hemodialysis clearance 
(Kt/V) and vascular access flow.  One way to optimize solute clearance is to 
maintain the concentration between blood and dialysate by using the counter-
current dialysis method, see Figure 1-5. It has been shown that hemodialysis 
clearance can be increased either by increasing the dialysate or the blood flow 
rate.  
Generally, the blood and dialysate flow rates are set at 400 mL/min and 500-800 
mL/min, respectively.  However, in Figure 1-6, we can see that the clearance rate 
of small solutes does not increase linearly with the increased in blood flow rate. 
As the flow rate gets higher, the efficiency of clearance increases at a slower 
rate. Therefore, once the blood or dialysate flow rate reaches 400 mL/min or 800 
mL/min, respectively, the benefit of further increasing blood or dialysate flow 
rates is limited.  
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Figure 1-5. The Schematic Interpretation of Counter-Current and Parallel 
Flow Concentration Gradient 
 
 
 
 
 
 
 
 
 
 
Figure 1-6. Relationship Between Nominal Blood Flow Rate and Blood 
Water Urea at Dialysate Flow Rate of 500 mL/min  
(Reprint with Permission from Daugirdas126) 
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1.5.5. Hemodialysis Frequency and Duration 
The duration and frequency of hemodialysis treatments can also affect a patient’s 
total solute clearance.  Although conventional thrice-weekly, four-hours 
hemodialysis is the current standard of care, frequent and/or prolonged 
hemodialysis (quotidian) is being used more often clinically, especially in the 
home setting. Gotch127  has developed a method to estimate weekly urea 
clearance (weekly standard Kt/V of urea, weekly Std Kt/Vurea) in hemodialysis 
patients. This will be discussed in detail in a later section (Urea as a Marker for 
Dialysis Adequacy). Briefly, the initial intent of developing this method was to 
have a technique to compare small-solute clearance between conventional 
hemodialysis (intermittent) and peritoneal dialysis (continuous). However, the 
weekly Std Kt/Vurea has also been used to compare various hemodialysis 
modalities, especially in a research settings.128 The weekly Std Kt/Vurea of a 70 kg 
patient, who is on conventional hemodialysis (4 hours thrice weekly) with dry-
weight of 68 kg, and pre- and post-dialysis urea levels of 20 mmol/L and 6 
mmol/L, is 2.18. By increasing the frequency to 6 sessions per week, the Std 
Kt/Vurea will increase to 4.54.  
1.5.6. Convective Clearance 
Convective clearance is another major mechanism for solute or toxin clearance.  
Ultrafiltration is important for maintaining volume homeostasis, which affects 
blood pressure control. However, it is also important for middle molecular weight 
solute removal when using convectional clearance. In hemodialysis, the pressure 
gradient is generated by hydraulic pressure and in peritoneal dialysis, which is 
generated by osmotic pressure gradient. The membrane permeability to water is 
called the ultrafiltration coefficient (UFcoeff; mL/hr/mmHg),  
𝑼𝑭𝒄𝒐𝒆𝒇𝒇 = 𝑸𝒇𝑻𝑴𝑷                                                                                            Equation 1-13 
 
where Qf (mL/min) is the ultrafiltration rate, and TMP (mmHg) is the 
transmembrane pressure gradient. A dialyzer is considered to be low flux if its 
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UFcoeff is < 10 mL/hr/mmHg, it is considered high flux if ≥ 10 mL/hr/mmHg. This 
is different from a ‘high-performance’ dialyzer, where the UFcoeff is > 8-15 
mL/hr/mmHg in the US (and >10-20 mL/hr/mmHg in Europe), with a large 
surface area (≥ 2m2). During ultrafiltration, convectional clearance takes place. 
Generally, the amount of small solute is equal to the concentration of the solute 
in plasma and the amount of fluid that is removed. However, for larger molecules, 
if the sieving coefficient is < 1, the amount of solute removal will be less than the 
solute concentration times the amount of fluid removal. See Figure 1-7. Some 
observational studies have shown that the removal of middle molecules may be 
related to better survival rates.129 The benefit of a high-flux dialyzer is not as 
clear. The largest hemodialysis trial that compared high- and low-flux dialyzers 
did not show any survival benefit.130-135 We will now discuss some of the “uremic” 
solutes. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-7. The Relationship Between Diffusional Clearance and the Blood 
Flow for Various Molecular Weight Molecules Using High-Flux Dialyzers 
(Adapted from Advanced Renal Education Program136) 
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1.6. THE KINETICS OF SOLUTE CLEARANCE BY 
HEMODIALYSIS 
1.6.1. Body Compartments 
In an average adult patient, water is 60% of total body weight. For example, a 70-
kg man has about 42 L of total body water, where 28 L is in the intracellular 
compartment, 11 L in the interstitial space of extracellular compartment and 3 L 
in the intravascular space. Blood contains approximately 60% plasma, which is 
mostly water, 40% red blood cells, and <1% white blood cells and platelets; the 
average blood volume in a 70 kg man is about 5 L. However, this percentage 
may change associated with age and renal disease (Figure 1-8) The plasma and 
the interstitial compartments have similar ionic compositions (sodium, potassium, 
calcium, magnesium, chloride, phosphate, bicarbonate and others such as 
sulfates which are not routinely measured), but there are more proteins in the 
plasma. This leads to a higher concentration of cation than anion in the plasma, 
because proteins are negatively charged. Furthermore, the most abundant cation 
in interstitial fluid is potassium (K+) whereas sodium (Na+) is the most abundant 
cation in the intravascular space. Other nonelectrolyte solutes are phospholipids, 
cholesterol, glucose, urea, lactate, uric acid, creatinine, and bilirubin.1   
 
The tissue-blood interface, which is commonly ignored, is an important factor, 
which can affect the dialysis clearance of solutes.  There are inter-compartment 
solute mass transfers within the patient and the dialyzer clearance within the 
dialyzer when considering solute transport. Low inter-compartment solute mass 
transfer is responsible for solute disequilibrium during dialysis or solute rebound 
post-dialysis.126 However, when slow, prolonged hemodialysis or continuous 
dialysis (such as peritoneal dialysis) is used, these risks are minimized. Solute 
generation in patients also can also influence the dialysis clearance 
measurement.  
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Figure 1-8. Total Body Compartment 
 
1.6.2. Compartmental Modeling 
The concept of organ clearance, including the hepatics and pharmacokinetics of 
drug clearance, are based on an original concept describing urea clearance by 
the kidney.137-140 There are different techniques to model this clearance from 
organs. These include the compartmental and physiological models. These 
models include transport barriers, binding, and enzymatic activities.141 The 
physiological and compartmental models can both lead to similar inter-
compartmental elimination rate constants. Compartmental models have been 
used to develop renal and dialysis clearance models. Before discussing more 
details on urea kinetic modeling, the basic concepts of compartmental models 
will be discussed.  
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Two simple conventional models, the ‘well-stirred’ and the ‘parallel tube’ will be 
reviewed here (Figure 1-9). However, we will not be discussing other 
compartmental models, such as the series-compartment model and the 
distributed-model.142 The well-stirred model considers the organ (or device such 
as dialysis) as a well-stirred compartment. The concentration of the solute is in 
equilibrium with the blood.143,144 By contrast, the parallel tube model considers 
the compartment as a series of parallel tubes, where the concentration of solute 
declines along the tube.145 The well-stirred model considers 100% mixing in the 
compartment whereas the parallel tube model considers no mixing. A model that 
integrates intermediate mixing is the dispersion model.146   
We can consider dialysis as a simple single-compartmental model, such as the 
well-stirred model (a single compartment with the assumption that there is rapid 
equilibration, homogeneous throughout the whole tissue space and constant 
volume). The well-stirred model is simple and commonly used. Its clearance is 
based on the flow-limited approach; this equation is given by:  
𝒅𝒄𝒅𝒕   = 𝑸𝒃𝑽 (𝒄𝒊𝒏 − 𝒄𝝀𝑷𝟏:𝒑)                                                                    Equation 1-14 
where c is the concentration of the solute in the compartment, cin is the input 
concentration of the solute, t is the time (min), Qb is the blood flow (mL/min), V is 
the compartmental volume (mL), and λ partition coefficient of the solute.147 
In hemodialysis patients, the clearance occurs at the semi-permeable membrane 
of the dialyzer. It is only the intravascular compartment of the extracellular space 
that is directly accessible for dialysis. The blood concentration of a substance 
should be corrected for blood water concentration. Commonly, the hematocrit is 
usually lower than those of the general population (36% vs. 42%).148 This means 
that a blood flow rate of 200 mL/min will have a plasma flow rate of 140 mL/min 
and an erythrocyte flow rate of 60 mL/min. However, urea is dissolved in both 
plasma water and red blood cells. Approximately 93% of plasma is water and 
72% of an erythrocyte is water. However, urea also associates with the non-
water portion of erythrocytes. Therefore, it is considered dissolved in a volume ~ 
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80% of the erythrocytes.91 Without making this correction, urea removal will be 
overestimated by 10%. The common correction factor for clearance is 0.894.91 
Therefore, Qb should correct for blood water as Qp (plasma water flow rate). For 
simplicity, we will leave it as Qb to illustrate the concept of solute clearance and 
compartmental modeling. Finally, solute generation will need to be considered. 
The mass balance equation can be expressed as: 
𝑴𝒊 = 𝑸𝒃 𝑪𝒃𝒊 − 𝑪𝒃𝒇 = 𝑸𝑫 𝑪𝒅𝒇 − 𝑪𝒅𝒊                                                           Equation 1-15 
where Qd and Qb are the volume flow rates of the dialysate and blood (mL/min), 𝐶!!  and 𝐶!!  are the initial solute concentrations of dialysate and blood (mmol/L), 
and 𝐶!! and 𝐶!! are the final solute concentrations of the dialysate and blood 
(mmol/L).  This equation can also be expressed as the following:  
𝑴𝒊 = 𝑲𝒐𝑨   𝑪𝒅𝒇!𝑪𝒅𝒊 ! 𝑪𝒃𝒊 !𝑪𝒅𝒇   𝒍𝒏   𝑪𝒃𝒇!𝑪𝒅𝒊 𝑪𝒃𝒊 !𝑪𝒅𝒇                                                                                               Equation 1-16 
where KoA is the mass area transfer coefficient of the dialyzer (mL/min). It is also 
the property of the membrane. The solute can be considered to have the 
maximum clearance possible at infinite blood and dialysate flow rate.  
 
However, the single compartmental model can over-estimate the solute removal 
in hemodialysis clearance (Figure 1-10). It assumes the body acts as a single 
compartment with well stirred distributing among all body compartments and 
rapidly distributed among all compartments. When the inter-compartment solute 
exchange rate is slower, the one compartmental model cannot fully represent the 
solute clearance. To consider the whole body, the model will need to take into 
account the volume distribution of the solute in the other compartments of the 
body, and not just the blood-water component. For example, urea is also 
dissolved in the extra-cellular and intra-cellular spaces. The inter-compartmental 
solute movement can also affect the solute concentration in the blood-water. 
Unless the solute equilibration rate between the compartments is rapid and 
100%, there will be an overestimation of total solute clearance if the inter-
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compartmental clearance is not considered. This can be observed with a post-
dialysis solute concentration rebound. There are other components of the solute 
that need to be considered. These include its distribution at other compartments 
and inter-compartmental clearance, solute generation, and renal clearance.  
 
The multi-compartmental model describes the body as composed of multiple 
compartments in which solute distributes with a mass transfer governed by the 
inter-compartmental clearance constants (Figure 1-11). Solute generation 
provides input into the compartments while elimination occurs through the 
vascular compartment by renal, non-renal pathways as well as through dialysis. 
Volume of distribution at steady-state (VSS) was calculated from the following 
relationship:  𝑽𝑺𝑺 =   𝑽𝑰 𝟏+ 𝑲𝒌𝑰𝑬𝒌𝑬𝑰                                                                                                 Equation 1-17 
VI is the solute concentration in intravascular space. KIE is the solute inter-
compartmental transfer clearance from intravascular space to extravascular 
space. KEI is the solute inter-compartmental transfer clearance from 
extravascular space to intravascular space. K is a constant. The rate of change 
of solute mass in the multi compartmental model can be written as a differential 
equation: 149 𝒅𝑴𝒊𝒅𝒕 = 𝑮−   𝑲𝑫 𝑪𝒊𝒔   −   𝑪𝑫   −   𝑲𝒓 𝑪𝒊𝒔                          Equation1-18 
where KD is dialysis clearance, and Kr is the renal clearance (mL/min). CIS and CD 
are solute concentrations (mmol/L) in the intravascular space and dialysate.   
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Well-Stirred Model Parallel Tube Model 
 
 
  
 
Figure 1-9. The Well Stirred and the Parallel Tube Models 
 
 
 
 
 
  
  
 
Co
nc
en
tr
at
io
n 
Co
nc
en
tr
at
io
n  
 46 
 
Figure 1-10. The Single Compartmental Model of Hemodialysis Clearance 
C1 and V1 are the solute concentration and volume in plasma space.  C2 and V2 
are the solute concentration and the volume of dialysate space.  Cin and Cout are 
the solute concentrations of plasma prior entering and after leaving dialyzer. By 
contrast, Cdin and Cdout are the solute concentrations prior entering and after 
leaving the dialyzer. Qpin and Qdin are the plasma and dialysate flow rates, 
respectively. Quf is the ultrafiltration rate. AQu is the amount of solute removal by 
ultrafiltration. (C: mmol/L, V: L)   
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Figure 1-11. Multi Compartmental Model of a Solute Disposition in the Body 
VI is the solute concentration in intravascular space and VE is the solute 
concentration in extravascular space. KD is the dialyzer solute clearance 
(mL/min), KIE is the solute inter-compartmental transfer clearance from 
intravascular space to extravascular space, KEI is the solute inter-compartmental 
transfer clearance from extravascular space to intravascular space, and G is the 
solute generation rate. KE and KN are non-renal and renal clearance of a solute.  
 
1.6.3. Uremic Toxins 
The word ‘uremia’ is created from the Greek words, ouron (urine) and haima 
(blood). Uremia is the toxicity related to the retention of organic waste solutes; it 
was fatal before dialysis became available.150,151 It results in physiological and 
biological deterioration.  Uremic compounds can lead to common symptoms such 
as fatigue, anorexia, nausea, neuropathy, sleep disturbance, amenorrhea, sexual 
dysfunction, increased protein catabolism, pruritus, and platelet dysfunction. 
There have been ~130 to 300 uremic compounds identified. There is great 
interest in finding these ‘uremic toxins’, and the list continues to expand.152,153 
However, with current dialysis therapies, not only the ‘bad’ solutes are removed, 
but ‘good’ solutes can also be removed. To compensate for the latter, as an 
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example, it is recommended that hemodialysis patients receive a multi-vitamin 
daily, as especially the water-soluble vitamins are removed by hemodialysis. The 
dosage of multi-vitamin is usually doubled for nocturnal hemodialysis patients.  
Because urea is a small molecule, it is easily removed by dialysis and it can be 
used to measure renal function; it has been used as a dialysis clearance marker, 
especially since the National Corporative Dialysis Study, despite urea per se 
being not very toxic.  In a normal kidney, the glomerulus filters molecules up to a 
molecular weight of 58 kDalton.154 While the dialysis membrane can clear some 
larger molecules, it is not up to the ability of inherited renal function. Generally, 
low molecular weight molecules (aka small molecular solutes) are characterized 
by molecular weights up to 300 Dalton, whereas middle molecular solutes range 
from 300 to 15 kDalton.  For small molecular solutes (e.g. urea and creatinine), 
the hemodialysis clearance occurs mainly by diffusion.  The surface area of the 
dialyzer is an important factor for diffusional clearance. For middle molecular 
solutes (e.g. cystatin C, B2-microglobulin and beta trace protein), a larger 
proportion of the clearance occurs by convective clearance (Figure 1-12). 
In addition to urea and creatinine, β2-Microglobulin (β2-M) has gained some 
interest as a dialysis clearance marker.  It is part of the major histocompatibility 
antigen, and one of the most studied middle size uremic molecules. A high-flux 
dialyzer removes it. Because of the β2-M distribution among several body 
compartments, there is a concentration rebound after a hemodialysis 
treatment.155 β2-M accumulation in dialysis patients can lead to dialysis-related 
amyloidosis, but other biological impacts are minimal.154 Although prior research 
has studied using β2-M as a clearance molecule, urea remains the primary 
clearance marker for the dialysis population.   
Other examples of middle molecules have been studied extensively, including 
advanced glycation end-products (AGE). AGE (2-6 kDalton) is the product of 
reduced sugars that reacted with free amino acids.156  It is absorbed through the 
gastrointestinal tract; its level is affected by diabetes and age, in addition to renal 
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function. Increased oxidative stress and impaired renal function can lead to an 
accumulation of AGEs. AGE is mainly dialyzed by a high-flux dialyzer.157 
Elevated AGE levels can lead to inflammatory responses and the release of 
cytokines.158 Some solutes such as albumins are usually not removed by 
hemodialysis. Therefore, the clearance of these protein-bound compounds 
(mainly albumin-bound) depends on the fraction of “unbounded” compounds and 
the rate at which the compounds dissociate from the proteins.  
 
Figure 1-12. The Relationship Between Diffusional and/or Convective 
Clearance Rate and Molecular Weight of the Solute 
 
1.6.4. Urea Clearance and Kinetic Modeling 
Dialysis clearance is defined as the hypothetical amount of blood that is totally 
cleared of a particular substance in one minute. The total clearance includes 
solute removal by both diffusional and convectional clearance. Again, diffusion 
and convection clearance are the main methods for hemodialysis solute removal. 
Although diffusion occurs at two sites, one at the dialyzer interface between 
dialysate and blood and the other at the capillary space between blood and 
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extravascular compartments, diffusion at the dialyzer level follows the first order 
phenomenon. Fick’s law of diffusion states that:159  
𝑱𝒔 = 𝑫𝒇∆𝑿   𝑨   ∙ ∆𝑪                                                                                          Equation 1-19 
where Js is the rate of diffusion (mol/s), A is the surface area where diffusion 
occurs (m2), ∆C is the change in concentration (mol/m3), ΔX change in positions 
(m) and Df is the diffusion coefficient (m2/s). For a dialyzer with fixed surface 
area, the term K0A is used to describe the mass transfer area coefficient, with 
units in mL/min; it can also be interpreted as the solute clearance at maximum 
blood flow rate.  
In the early days of hemodialysis, various molecules were proposed as uremic 
toxins.160 The middle molecule hypothesis had been competing with the method 
of using solely small molecules for dialysis dose determination. The theory came 
from the observation that peritoneal dialysis patients showed higher urea but less 
neuropathy. A prolongation of hemodialysis time arrests the peripheral 
neuropathy. However, the debate between using small molecules or middle 
molecules for assessing dialysis clearance was settled after the results of the 
National Co-operative Dialysis Study (NCDS).161 The NCDS included 165 
patients in a 2 x 2 factorial randomized controlled study design. The patients 
were randomized to high or low time-average blood urea nitrogen concentration 
level groups (50 vs. 100 mg/dL) and longer or shorter treatment time groups (2.5-
3.5 vs. 4.5-5 hours) thrice weekly. Treatment parameters, such as blood flow 
rate, were adjusted to match the target-time average blood urea nitrogen levels 
based on the following concept:162 
𝑪𝒑𝒐𝒔𝒕 =   𝑪𝒑𝒓𝒆  ×  𝒆!𝑲𝒕𝑽                                                                             Equation 1-20 
where Cpre and Cpost were the solute concentrations pre- and post-hemodialysis. 
In this study, the solute of interest is urea. Once again, K is the urea clearance, t 
is the time on dialysis and V is the volume of distribution of urea. The patients 
were randomized into one of the four groups. The study was designed to assess 
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the rate of hospitalization by comparing urea clearance and by comparing high 
and low-flux dialyzers, respectively.  
The results of the NCDS showed that the hospitalization and mortality rates were 
higher in patients who had higher time-averaged concentrations of urea. This 
was not evident when comparing hospitalization rates between the groups who 
received different durations of dialysis treatment. One of the criticisms of the 
study is that the time-averaged concentrations were too high in the high-urea 
group and that was not the standard of care. Furthermore, the sample size was 
too small to detect any significant outcome difference between the groups 
undergoing different treatment durations (p=0.06). Despite these criticisms, urea 
has become the most commonly used solute for the measurement of dialysis 
efficiency.161 The use of middle molecules in dialysis clearance assessment has 
been reduced significantly. 
Table 1-7.The Time-Averaged Concentrations of Urea (mmol/l) and Dialysis 
Durations (minutes) for the Four Groups in the National Co-operative 
Dialysis Study. 161 
Groups Time-Average Urea (mmol/l) Dialysis Duration (Minutes) 
 Target Achieved Target Achieved 
1 18 18 240-270 271 
2 36 31 240-270 268 
3 18 19 180-210 200 
4 36 33 180-210 190 
 
Urea Reduction Ratio 
After the results of NCDS were published, urea has become the main state of 
‘dialysis adequacy’ measurement. However, the term ‘dialysis adequacy’ refers 
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to the achievement of treatment objectives that fulfill the definitions of adequacy 
and the overall health of dialysis patients is improved by dialysis. Frequent 
assessments and consultations by physicians, nurses, dieticians and 
physiotherapists, and regular blood works are suggested.120,163 Because some of 
these assessments do not have objective standards, physicians and health care 
providers have relied on ‘dialysis adequacy’, based solely on dialysis solute 
clearance, specifically urea. Here, the common methods of measuring dialysis 
clearance, mainly urea, will be discussed. 
Urea Reduction Ratio 
The simplest way to estimate dialysis urea clearance is to measure its 
concentration change before and after a hemodialysis treatment. The term ‘urea 
reduction ratio’ (URR) is used to describe this change in urea concentrations. A 
URR greater than 65% per treatment is considered the standard of care for 
conventional hemodialysis.163 The URR, however, does not take into account 
convectional clearance, urea generation, and urea equilibration from other 
compartments. Although the URR has its weaknesses, the URR method is easy 
to use and has been shown to be as meaningful as Kt/Vurea, which will be 
discussed next.164 
𝑼𝑹𝑹 =   𝑷𝒓𝒆𝒅𝒊𝒂𝒍𝒚𝒔𝒊𝒔  𝒖𝒓𝒆𝒂  𝒄𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏!𝑷𝒐𝒔𝒕𝒅𝒊𝒂𝒍𝒚𝒔𝒊𝒔  𝒖𝒓𝒆𝒂  𝒄𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏𝑷𝒓𝒆𝒅𝒊𝒂𝒍𝒚𝒔𝒊𝒔  𝒖𝒓𝒆𝒂  𝒄𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏                           Equation 1-21 
Single-Pool Kt/V of urea by various equations 
The initial NCDS used time-average concentration of urea as a measure of 
dialysis adequacy. However, the levels were strongly influence by dietary protein 
intake.161 Gotch et al.162 reanalyzed the NCDS data and derived another dialysis 
clearance measurement tool called Kt/V of urea (Kt/Vurea). Single pool Kt/Vurea is 
now the most popular method of assessing a single hemodialysis clearance.161 
Kt/V is a dimensionless parameter (where K = clearance in mL/min, t = time in 
minutes and V = volume of distribution in mL).165 The clearance K of a solute is 
influenced by the blood flow rate, the dialysate flow rate, the dialyzer membrane 
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resistance and the surface area of the dialyzer. By contrast, total removal of a 
solute is influenced by the product of K and total time on dialysis (Kt). This 
product is further adjusted by the volume of the distribution of the solute, which in 
the NCDS is urea.  The volume of distribution of urea is equal to total body water. 
The single pool Kt/V, without considering solute generation and ultrafiltration, can 
be written as: 
𝑪𝒑𝒐𝒔𝒕 = 𝑪𝒑𝒓𝒆𝒆!𝑺𝒑  𝑲𝒕/𝑽                               Equation 1-22 
Therefore, this can also be related to the urea reduction ratio (URR): 𝑺𝒑  𝑲𝒕/𝑽𝒖𝒓𝒆𝒂 = −𝒍𝒏 𝟏− 𝑼𝑹𝑹                                                               Equation 1-23 
However, solute generation, convective clearance, and volume of distribution for 
urea need to be considered. Daugirdas126 developed several methods to 
estimate Sp Kt/Vurea, using the pre-dialysis and post-dialysis urea ratios. Again, 
the relationship between the URR and Sp Kt/Vurea is non-linear. The first and 
second-generation equations Daugirdas developed are described below: 
𝑺𝒑  𝑲𝒕/𝑽𝒖𝒓𝒆𝒂   = −𝑰𝒏 𝟏− 𝑼𝑹𝑹 − 𝟎.𝟎𝟎𝟖𝒕−   𝒇 𝑼𝑭𝑾                             Equation 1-24 𝑺𝒑  𝑲𝒕/𝑽𝒖𝒓𝒆𝒂   = −𝑰𝒏 𝟏 − 𝑼𝑹𝑹 − 𝟎.𝟎𝟎𝟖𝒕 +    𝟒 − 𝟑.𝟓 𝟏 − 𝑼𝑹𝑹   ×    𝟎.𝟓𝟓 𝑼𝑭𝑽     
Equation 1-25 
where UF is ultrafiltration in liters, V is volume of distribution of urea in liters, t is 
duration on dialysis in hours, f is 0.7, 1, and 1.25 when Kt/V is >1.3, between 0.7 
and 1.3 and <0.7 respectively, W is the post-dialysis weight (kg).    Equation 1-25 
has been also validated in children.166 In both equations, convective clearance is 
included.  
Furthermore, Daugirdas126 has also developed other formulae that incorporate 
the total protein equivalent of total nitrogen appearance and residual renal 
function. The post-dialysis urea measurement is usually taken at 15-30 seconds 
after hemodialysis, although some recommend taking it 2 minutes post 
termination. As the immediate postdialysis urea samples do not reflect the 
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“equilibrated urea” levels, the urea concentration measured immediately post-
dialysis is lower than the equilibrated sample. The urea has not equilibrated from 
other compartments, such as the muscle to blood (double pool), thus Sp Kt/Vurea 
overestimates the urea clearance.  
In the equilibrated method blood urea samples are usually taken 30 minutes 
post-dialysis. This considers the potential urea disequilibrium problem and 
rebound of urea into vascular compartments, whereas the Sp Kt/Vurea method 
does not. This “double-pool” Kt/Vurea is also called equilibrated Kt/Vurea (e 
Kt/Vurea), which is usually 0.21 lower than the Sp Kt/Vurea.135 This difference 
diminishes as the dialysis duration increases. For example, continuous 
hemodialysis or peritoneal dialysis treatments are in an equilibrated condition. 
Daugirdas has also developed other formulae, depending on the sampling time 
and the types of accesses (arteriovenous or venovenous) that were shown to 
correlate well with the measured eKt/Vurea.167,168 Although it is important to 
understand the equilibrated and double-pool effects of urea, many hemodialysis 
studies, especially studies that looked at survival outcomes, such as the HEMO 
study (see below), were done using Sp Kt/Vurea.135 Therefore, the Sp Kt/Vurea 
method is still more commonly used than the eKt/Vurea.  𝒆𝑲𝒕/𝑽𝒖𝒓𝒆𝒂   = 𝑺𝒑  𝑲𝒕/𝑽𝒖𝒓𝒆𝒂   − 𝟎.𝟒𝟕  ×   𝑲 𝑽 +   𝟎.𝟎𝟏𝟕            Equation 1-26  
Since the NCDS study showed that there was a significant benefit of reducing 
hospitalization rates in patients who had Sp Kt/Vurea values above 0.9-0.95, the 
next question was raised, ‘is there a benefit of a further increase in Kt/Vurea?’ This 
question was answered by the HEMO study.135 It was a multi-center, 2x2 factorial 
designed study that involved 1846 patients. The patients were randomized to 
target standard and high-dose Sp Kt/Vurea, and to use high- and low-flux 
dialyzers. The results showed that the high-flux dialyzer does not improve 
survival rates and that targeting Sp Kt/Vurea of 1.25 is as good as 1.65. Despite 
other observational studies that have shown a survival benefit in targeting higher 
Sp Kt/Vurea, the HEMO study did not shown any reduced mortality from 
increasing Sp Kt/ Vurea >1.25.169,170 Therefore, the KDOQI recommends targeting 
 55 
intermittent hemodialysis clearance with a minimum Sp Kt/Vurea of 1.2 or URR of 
65%. 171,172 
Clinical information is required to measure and calculate Sp Kt/Vurea, including 
pre-dialysis and post-dialysis weight and urea levels, ultrafiltration volume, intra-
dialysis and inter-dialytic time, and hematocrit. Only in the case of patients who 
are not in a steady-state (urea generation equal to urea clearance), a pre-dialysis 
urea sample is required prior to the next dialysis session. Otherwise, the 
computer model can estimate the third pre-dialysis urea level. The residual renal 
function and the protein equivalent of total nitrogen appearance is measured and 
calculated from the inter-dialytic urine collection. Urea kinetic modeling involves 
advanced mathematical calculation and, therefore, a computer-modeling 
program is usually required.  
Urea kinetic modeling will calculate dialysis and renal clearance, and urea 
generation. The following are the steps involved in urea kinetic modeling: first, 
the program calculates the Kt/Vurea of the hemodialysis treatment. This takes into 
consideration renal clearance and urea generation, in addition to dialytic urea 
removal by diffusion and convection.  Second, an expected value can be 
calculated based on a validated nomogram. Finally, the expected Kt of urea is 
compared with the calculated Kt/Vurea. V is then back-calculated. The predicted V 
value based on anthropometrical calculation and the calculated V value are 
compared.  If there is a discrepancy between these two V values, it can be due to 
access recirculation when the calculated V over-estimated the athropometric V, 
or malnutrition, where the calculated V under-estimated the athropometric V.165 
Ionic dialysance  
Another measurement technique for hemodialysis clearance has been developed 
using the Effective Ionic Dialysance (EID) method. EID  was first proposed by 
Petitclerc et al.173   Studies have demonstrated that EID provides a reliable 
surrogate for measuring either blood side or dialysate side urea clearance during 
the dialysis procedure.174 It corrects for access and cardiopulmonary 
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recirculation. Furthermore, it can be done on-line during the dialysis procedure; 
this requires the incorporation of two conductivity measurement cells within the 
dialysis circuit. Each cell will measure the conductivity of the dialysate solution in 
mS/cm. On-line dialysance requires the measurement of the conductivity of 
mobile electrolytes through the dialysis membrane, at the inlet and the outlet, at 
two different set points. The dialysate conductivity at the inlet at the prescribed 
value of dialysate sodium (the main determinate of conductivity) is X1, the 
corresponding value at dialysate outlet is measured: this is Y1. The dialysate 
conductivity is, then, increased to X2 at the inlet by a step up in dialysate sodium 
concentration by 10 mmol/l (1 mS/cm approximately in conductivity units). The 
dialysate conductivity at the outlet is measured again after a 6-minute stable 
period; this corresponds to the value Y2. Finally, the inlet conductivity is returned 
to X1, and outlet conductivity is measured again to confirm (Y1) after another 6-
minute stable period. The EID measurement is completed and computed based 
on  
𝑬𝑰𝑫 = 𝑸𝒅+ 𝑸𝒖𝒇 𝟏− 𝒀𝟏!  𝒀𝟐𝑿𝟏!𝑿𝟐                                                                       Equation 1-27 
where Qd and Quf are the dialysate and ultrafiltration flow rates, respectively.  
Weekly Standardized Kt/Vurea  
Using Sp Kt/Vurea > 1.2 to target hemodialysis clearance is only applied to thrice 
weekly hemodialysis, and cannot apply to frequent hemodialysis and/or 
peritoneal dialysis. Therefore, a method to compare various dialysis therapies 
was developed by Gotch127 and Leypoldt et al.175 This dimensionless index was 
named the weekly “standardized” Kt/Vurea (Std Kt/Vurea).  
The concept of Std Kt/Vurea was based on two principal hypotheses. The peak 
concentration hypothesis was postulated by Keshaviah:176 that uremic toxicity 
correlate with the amount of time the patient spends with a urea concentration 
above a threshold level, rather than the time-average urea concentration. Urea 
concentrations in patients on intermittent hemodialysis change constantly, with 
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peak levels prior to hemodialysis and trough levels post-hemodialysis. By 
contrast, urea concentrations in patients on peritoneal dialysis are relatively 
stable. Therefore, when the peak urea concentrations are the same on 
intermittent thrice-weekly hemodialysis as on peritoneal dialysis, the time-
averaged urea concentrations are lower for the thrice-weekly hemodialysis 
patients. However, Depner177,178 questioned the peak concentration hypothesis 
and stated that time-average urea concentrations are also important. It is the 
inefficiency of intermittent hemodialysis that explains the difference between 
continuous therapies and the intermittent thrice-weekly hemodialysis therapies. 
Firstly, the later part of a hemodialysis treatment would have less urea removal 
than the first part of the treatment. Therefore, the amount of urea removal has 
lessened as the therapy continues. Secondly, the urea disequilibrium during 
intermittent hemodialysis, which results in post-hemodialysis rebound, also 
provides evidence of the inefficiency of intermittent hemodialysis. Likely, both the 
Depner and Keshaviah theories are at least partially true.  
Based on the peak concentration hypothesis, and the assumption that 
intermittent thrice-weekly hemodialysis and peritoneal dialysis are equal, Gotch 
developed the Std Kt/Vurea equation, and Leypold et al.175 further derived an 
estimated equation that correlated with Gotch’s127 original equation. Std Kt/Vurea 
is expressed as the relationship between urea generation (normalized protein 
catabolic rate, nPCR) and the peak urea concentration (Cpeak urea):127 
𝑺𝒕𝒅  𝑲𝒕 𝑽𝒖𝒓𝒆𝒂   =    𝟎.𝟏𝟖𝟒 𝒏𝑷𝑪𝑹!𝟎.𝟏𝟕 𝑽  ×  𝟎.𝟎𝟎𝟏𝑪𝒑𝒆𝒂𝒌  𝒖𝒓𝒆𝒂   ×   𝟕  ×  𝟏𝟒𝟒𝟎        𝑽                           Equation 1-28 
where the term 0.184 𝑛𝑃𝐶𝑅 − 0.17 𝑉  ×  0.001  is equal to the urea generation rate 
in mg/min and V is the total body water. The Cpeak urea takes into account the 
frequency, and the duration, of the dialysis treatments. As a result, a series of 
curves were generated based on this formula and a Std Kt/Vurea of 2 attained by 
peritoneal dialysis is equivalent to a Sp Kt/Vurea of 1.2 achieved by thrice-weekly 
hemodialysis. It is more effective to increase Std Kt/Vurea by increasing the 
frequency of hemodialysis than to increase the Sp Kt/Vurea per session. Despite 
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Depner’s argument, Std Kt/Vurea is the only tool available at this point to compare 
dialysis clearance between hemodialysis and peritoneal dialysis, and between 
various forms of frequent hemodialysis. However, it has to be kept in mind that 
this model has only been validated against clinical outcomes until the recent 
Frequent Hemodialysis Network (FHN) trials.128 
1.6.5. Urea as a Marker for Dialysis Adequacy 
Currently, “hemodialysis adequacy” is monitored based on blood urea levels and 
symptoms of uremia and volume overload. Although the concept of the “middle 
molecule hypothesis” (or square meter hour hypothesis) was emerging, the 
NCDS shifted the focus to small molecular weight solute removal, mainly urea, 
as a dialysis adequacy marker. Again, the NCDS confirmed that urea reduction, 
which translated into single-pool Kt/Vurea (Sp Kt/Vurea) > 0.9, significantly reduced 
hospitalization rates.161 Therefore, conventional thrice weekly treatments 
targeting a Sp Kt/Vurea ≥ 1.2 became the standard of care for the management of 
patients who are on hemodialysis. Subsequently, the HEMO study did not show 
any additional mortality benefit with targeting a Sp Kt/Vurea > 1.6 as compared to 
1.2.135 These studies have confirmed that three times per week of a four-hour 
hemodialysis regime is ‘adequate’, based on small urea clearance. Because of 
these results, and for health-economic reasons, shorter and less frequent (4 
hours thrice weekly) hemodialysis focusing on urea clearance, which had started 
in the United States, was then adopted by the rest of the world.  
Current hemodialysis clearance measurements are based on urea; however, 
urea is not an ideal marker. Urea is used as a surrogate marker for the clearance 
of other uremic toxins. The clearance of other uremic solutes may be related to 
convectional clearance, with different production and extracellular distribution. 
Some of the larger molecules are protein-bound and are therefore less likely to 
clear by dialysis, especially by peritoneal dialysis therapy.179,180 Urea 
measurements are influenced by urea generation, urea rebound and 
recirculation. Several mathematical techniques and models have been developed 
to correct these errors.92  
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Because of shorter and only thrice weekly treatments, the fluid and electrolyte 
management of hemodialysis have become difficult, with significant 
hemodynamic effects during and post-hemodialysis.181 In the HEMO study, the 5-
year mortality rates in patients who were on hemodialysis were 60%.135,182 The 
leading cause of death in dialysis patients is cardiovascular disease, and 
cardiovascular morbidity in this population is very high; heart failure developed in 
up to 50% of the dialysis patients.183 A contributing factor may be that the 
prevalence of existing cardiovascular disease on the initiation of dialysis 
treatment is high.184 However, the chance of developing cardiovascular disease 
is also very high after the initiation of dialysis. Certainly, hypertension and chronic 
volume overload are common in dialysis patients.185 Ninety percent of 
hypertension responds to volume control.186,187 Volume overload leads to left 
ventricular hypertrophy, heart failure/dilation, and it is associated with other 
cardiovascular risk factors.188 The management of volume overload in dialysis 
patients is one of the major challenges for nephrologists.  
Hemodialysis itself is also an independent risk factor for the development of de 
novo and recurrent heart failure. A phenomenon called myocardial stunning 
occurs in hemodialysis patients and can leads to transient left-ventricular 
dysfunction.189 McIntyre et al.190 showed that dialysis-induced cardiac 
dysfunction is associated with a reduction in global and segmental myocardial 
blood flow. In patients with no cardiac stunning, the survival rate after 1 year was 
100%. By contrast, in patients with cardiac stunning, the 1-year mortality rate 
was 28%.191  
Clearly, there are a lot of limitations with current hemodialysis treatment. Before 
we can develop new techniques and devices to improve hemodialysis outcomes 
and therapies, we need to have some methods to compare various hemodialysis 
treatments. Using urea as the sole marker to assess ‘dialysis adequacy’ is not 
adequate. The Std Kt/Vurea measurement has not yet been validated in large 
prospective or randomized controlled trials, and its use in comparing various 
dialysis modalities remains more theoretical than with clinically proven. 
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Therefore, an ideal dialysis adequacy marker for current hemodialysis therapies 
should be simple, cleared by kidney and dialysis, and associated with: 
1. Mortality outcome,  
2. Cardiovascular morbidities and mortalities,  
3. Volume status of the patient, and  
4. The amount of dialysis (time, frequency and duration) 
We propose that we should examine middle molecules, in particular, cystatin C.   
1.6.6. Cystatin C as a Marker for Renal Clearance  
Cystatin C is known as a γ trace protein and a base protein inhibitor with a 
molecular weight of 13359 Dalton.54 It is produced at a constant rate by all 
nucleated cells and appears in human plasma and serum. It is freely filtered by 
the glomerulus and not secreted by the tubule. It may be influenced by high cell 
turn-over rate such as in hyperthyroidism and inflammation. However, unlike 
creatinine, it is not influenced by muscle mass, food intake or body surface area. 
It consists of one polypeptide chain with 120 amino acids (SSPGK PPRLV 
GGPMD ASVEE EGVRR ALDFA VGEYN KASND MYHSR ALQVV RARKQ 
IVAGV NYFLD VELGR TTCTK TQPNL DNCPF HDQPH LKRKA FCSFQ 
IYAVP WQGTM TLSKS TCQDA). It does not have any glycosylation. It has an 
isoelectric point of 9.3. It has disulphide bonds between residues 73 and 83, and 
97 and 117. Its gene is located on chromosome 20 at p.11.2. Its plasma half-life 
is 20 minutes under normal renal function (blood concentration of 0.96 mg/L with 
range between 0.57-1.79 mg/L). Cystatin C measurement is based on enhanced 
immnonephelometric assay using antibodies from a rabbit. It is calibrated using 
purified cystatin from human urine against recombinant rabbit; the measurement 
ranges from 0.3 to 10 mg/L.  
Cystatin C has been shown to be superior to creatinine as a marker for kidney 
function assessment in patients with chronic kidney disease.66,78 In addition, 
cystatin C has been studied in the context of cardiovascular outcomes. One 
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study has shown that serum cystatin C is associated with cardiovascular survival 
in patients with chronic kidney disease stages 3 and 4.192 Other studies have 
shown that cystatin C levels are associated with vasospastic angina and 
cardiovascular outcomes independent of renal function, and a level >1.3 mg/L is 
a risk factor for the occurrence of fatal and non-fatal cardiovascular events.193-195 
Xie et al. found that oxidants induce cystatin C elevation, which affects cardiac 
extracellular remodeling by regulating Cathepsin B activity.196 Furthermore, 
studies have found an association between cystatin C and monocyte levels, 
which can lead to atherosclerosis.197 The above studies have shown that cystatin 
C can be a marker for both kidney function and cardiovascular outcomes.  
Unlike with its use in measuring residual renal function, there are few studies on 
the use of cystatin C in dialysis patients. Both Delaney and Hoek suggested that 
cystatin C levels mainly relate to residual renal function, rather than dialysis 
clearance, whereas Thysell, Lindström and Park demonstrated the kinetics of 
cystatin C in a single hemodialysis treatment.198-202 Thysell et al.198  showed that 
with low-flux hemodialysis, cystatin C concentrations rose after a single treatment 
by 4 ± 6.3%. Lindström et al.199 demonstrated cystatin C levels were reduced 
with one dialysis session, with the highest clearance occurring with 
hemofiltration, compared to hemodiafiltration and low flux hemodialysis. Park et 
al.200 recently also demonstrated more effective cystatin C clearance by high-flux 
hemodialysis when compared to low-flux hemodialysis. Thus it is safe to say that 
cystatin C, a middle molecule, is cleared by dialysis, but there is little information 
on the factors that influence this clearance. None of these studies demonstrated 
any association between cystatin C and dialysis dose; we are the first to do this.  
Al-Malki published a cross-sectional pilot study of cystatin C in 35 functionally 
anephric patients receiving various forms of dialytic therapies (peritoneal dialysis, 
conventional thrice weekly hemodialysis, and frequent short daily and nocturnal 
hemodialysis).203 All patients underwent urea kinetic studies and had values 
calculated for Sp Kt/Vurea and weekly Std Kt/Vurea. The study showed that 
there was no correlation between pre-dialysis cystatin C levels and Sp Kt/Vurea 
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values, but there was a significant inverse linear correlation with weekly Std 
Kt/Vurea values (r =-0.49; p = 0.003). In other words, cystatin C was influenced 
by the weekly total dose of dialysis received, and lower pre-dialysis cystatin C 
levels are found with patients undergoing more intensive dialysis (e.g. nocturnal). 
In our current study we have demonstrated that cystatin C is cleared by the 
kidney. As discussed above, previous studies have shown that it correlated with 
cardiovascular morbidity and mortality. However, there are very few studies, 
which have looked at its removal by hemodialysis. 
1.7. Cystatin C as a New Marker for Dialysis Adequacy 
We have proposed that cystatin C is a useful marker to gauge dialysis adequacy. 
To evaluate this, we would first need to assess the pathophysiological changes in 
its clearance as kidney function declines, and its ability to predict residual renal 
function in end-stage renal disease. Furthermore, we need to understand its 
removal during a single hemodialysis treatment. Finally, once we have confirmed 
that it is removed by hemodialysis, we would assess its kinetics, volume of 
distribution, rebound, and conventional and diffusion clearance during a single 
hemodialysis treatment therapy. We have performed the following 4 studies.  
To better understand the removal of cystatin C in a single hemodialysis 
treatment, we conducted the study (Chapter 2): Cystatin C reduction ratio 
depends on normalized blood liters processed and fluid removal during 
hemodialysis.204 The aim of the study was to assess cystatin C kinetics in a 
single hemodialysis treatment. We measured cystatin C levels at pre-, mid- and 
post-hemodialysis treatment on three consecutive treatments in 15 hemodialysis 
patients with no residual renal function. We hypothesized that there is significant 
reduction in cystatin C level by high-flux hemodialysis treatment, and this 
reduction is significantly associated with the number of liters processed and the 
ultrafiltration volume.  
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To better assess the effects of hyperfiltration on cystatin C renal clearance, we 
conducted the study (Chapter 3): Hyperfiltration affects accuracy of creatinine 
eGFR measurement.205 In this post-hoc analysis study, 127 pediatric patients 
with chronic kidney disease not yet on dialysis were observed. The goal of the 
study was to see whether hyperfiltration affects the renal biomarkers, creatinine, 
cystatin C and beta trace protein. We hypothesized that the accuracy of small-
molecules-based eGFR (creatinine) is significantly affected by hyperfiltration, 
whereas the middle-molecules-based eGFR (cystatin C and beta-trace protein) 
are not.  
Currently the gold standard method of measuring residual renal function is using 
24-hour urine mean urea and creatinine clearances. However, it is inconvenient 
for the patients. To determine if cystatin C levels can be used to measure both 
dialysis efficacy and residual renal function in dialysis patients, we conducted the 
study (Chapter 4): Residual renal function calculated from serum cystatin C 
measurements and a knowledge of the weekly standardized Kt/Vurea.206 We 
recruited 15 patients and developed a cystatin C-based estimated residual renal 
function equation. The study aimed to assess whether cystatin C levels can be 
used to determine both dialysis efficacy and residual renal function in dialysis 
patients. We hypothesized that the difference between the measured cystatin C 
level and that estimated from the Al-Malki study, the Δcystatin C, would 
significantly correlate with residual renal function as measured by the average of 
urinary creatinine and urea clearances. 203 We further hypothesized that this 
correlation would be significantly stronger than the association between the 
measured residual renal function and the residual renal function using the Hoek 
equation.201 
Finally, to better examine the kinetics of cystatin C removal over the course of 
single hemodialysis treatments, we conducted the study (Chapter 5): The kinetics 
of cystatin C removal by hemodialysis.123 The aim of the study was to calculate 
the diffusional and convectional clearances of cystatin C by hemodialysis, and to 
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estimate its volume of distribution and intra-compartmental equilibration rate 
constants.  
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2. Chapter 2. Cystatin C Reduction Ratio Depends on 
Normalized Blood Liters Processed and Fluid 
Removal 
To better understand the removal of cystatin C in a single hemodialysis 
treatment, here, we measured cystatin C levels at pre-, mid- and post-
hemodialysis treatment on three consecutive treatments in 15 hemodialysis 
patients with no residual renal function. We found that the amount of cystatin C 
reduction was influenced positively by dialysis blood flow rate and treatment time, 
and negatively by ultrafiltration rate. From this we hypothesized that cystatin C 
behaves as a middle molecule with distribution likely in the extracellular 
compartment with a slow equilibration rate between interstitial space and 
intravascular space. This Chapter is similar to work already published in the 
Clinical Journal of the American Society of Nephrology in 2011. 1 
2.1. INTRODUCTION 
Serum creatinine and urea are small molecules that are commonly measured to 
monitor renal function in patients with chronic kidney disease (CKD). Serum 
creatinine (SCr) is the most commonly used surrogate marker for assessing 
kidney function in patients with CKD stage I-IV. It has molecular weight of 113 
Daltons and is a metabolic product of creatine and phosphocreatine.1 The use of 
serum urea (SUr) is recommended by the Kidney Disease Outcomes Quality 
Improvement (KDOQI) clinical practice guideline to assess dialysis clearance. 2 It 
has molecular weight of 60 Daltons.3 
The preferred assessment of hemodialysis (“dose”) efficiency is by urea kinetic 
modeling (UKM) calculating the dimensionless parameter Kt/V (urea) (where K = 
clearance in mL/min, t = time in minutes and V = volume of distribution in mL). 
Kt/V values may be given for single pool (Sp Kt/V) or double pool (equilibrated or 
                                            
1	  Huang SH, Filler G, Yasin A, Lindsay RM. Cystatin C Reduction Ratio Depends on Normalized 
Blood Liters Processed and Fluid Removal During Hemodialysis. Clin J Am Soc Nephrol. 2011 
Feb;6(2):319-25. PMID: 21115625.	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eKt/V) volumes of distribution; they depend upon the urea reduction ratio (URR) 
over a single hemodialysis treatment.4 To assess dialysis efficiency over a period 
of one week, Gotch5,6  derived a new dialysis assessment index named the 
weekly “standardized” Kt/V (Std Kt/V). Std Kt/V allows comparison of different 
dialysis modalities (e.g. peritoneal versus hemodialysis) and weekly treatment 
frequencies.    
Cystatin C (CysC) is a low molecular weight protein (13 kDalton, 121 amino-acid 
residues) that is produced by all nucleated cells.7 It is positively charged with an 
iso-electric point of 9.3. CysC has attractive characteristics as a marker for 
assessing native kidney or dialysis clearance. Its plasma level is not influenced 
by age, gender and body mass index.8 CysC is distributed mainly extracellularly.9 
Its production is relatively constant and it is freely circulating.10 However, it may 
be affected by conditions that alter cell turn-over rate, such as inflammation or 
thyroid dysfunction.11,12 It remains controversial whether glucocorticoid 
medications may change the serum CysC level.9,13 Estimated glomerular filtration 
rate (eGFR) by CysC has shown to be superior to eGFR by SCr for patients with 
chronic kidney disease.14-16 
There have been few studies of CysC in dialysis.  In peritoneal dialysis patients, 
the study by Delaney et al.17 showed that CysC levels are mainly related to the 
residual renal function, rather than the dialysis clearance. Furthermore, the study 
by Hoek et al.18 demonstrated a good correlation between 1/CysC and residual 
renal function. To obviate the effect of residual renal function we examined pre-
dialysis or steady state serum CysC levels and found these to be influenced by 
the dialytic treatment modality and the Std Kt/V and hence were lowest in 
patients receiving 5-7 nights per week of hemodialysis as compared with 
conventional hemodialysis and peritoneal dialysis.19 There are a few studies 
using CysC reduction ratio (CCRR) to assess CysC hemodialysis clearance. 
Thysell et al.20 demonstrated that with low-flux hemodialysis, CysC 
concentrations rose after dialysis by 4 ± 6.3%. Furthermore, Lindström et al.21 
compared CCRR after hemodiafiltration, hemofiltration and low-flux 
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hemodialysis. The post-treatment CysC concentrations were lowest after 
hemofiltration, and highest after low-flux hemodialysis. A recent study by Park et 
al.10 showed a more effective CysC clearance by high-flux hemodialysis 
compared to low-flux hemodialysis. Although these studies have demonstrated 
the potential value of CysC as an indicator of middle molecule clearance, the 
variables affecting CCRR were not identified. 
In this study, we aimed at assessing the CysC hemodialysis clearance and 
handling compared to the two small molecules urea and creatinine. Given a 
largely extracellular distribution of CysC and a presumed slow equilibration 
between the intravascular and the extravascular volume because of its size, we 
hypothesized that there is significant reduction in CysC level by high-flux 
hemodialysis treatment, and this reduction is significantly associated with the 
number of liters processed and the ultrafiltration volume. 
2.2. MATERIAL AND METHODS 
Participants 
In this cross-sectional, single center, open study of patients with end stage renal 
disease receiving hemodialysis therapy, a total of 15 patients were recruited. All 
patients provided written informed consent. All patients were on thrice weekly 
high-flux high-efficiency hemodialysis therapies. Only functionally anephric 
patients, defined as urine output < 250 mL per day, were included in the study. 
Patients were excluded if they did not consent to the study, or if during the 
previous three months hospitalization or dialysis prescription changes occurred. 
The study was approved by the Ethic Review Board at the University of Western 
Ontario (HSREB#16599E).  
Experimental Procedure 
All patients were dialyzed using high-flux high-efficiency polysulphone membrane 
dialyzers (Optiflux F160NR or F200NR Fresenius Inc., Toronto, Canada). Either 
central venous catheters or fistulas served as dialysis access. The blood flow 
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was between 300-400 mL/min and the dialysate flow was at 500 mL/min. The 
blood samples were taken through the patients’ dialysis access at the beginning, 
at the middle and at the end of their dialysis sessions. The blood samples were 
taken at all three hemodialysis sessions over a one-week period. In addition to 
CysC, SCr, and SUr, the pre-dialysis blood samples prior the first hemodialysis 
session included thyroid function (TSH) and C reactive protein (CRP) 
measurements. Blood samples were taken at mid-dialysis for CysC 
measurements. Finally, additional blood samples for CysC, SCr, and SUr were 
taken post-dialysis. The post-dialysis blood samples utilized the 15-second slow 
flow methodology to obviate urea dilution by recirculation.4 For the analyses, the 
averages of all three pre-, mid- and post-dialysis measurements were used.  
CysC was measured by immune nephelometry using an N-latex cystatin C kit 
(Dade Behring, Mississauga, Canada) on a Behring BN ProSpec analyzer (Dade 
Behring Marburg, Germany) at the reference laboratory at the Children’s Hospital 
of Eastern Ontario in Ottawa.  The co-efficient of variation (CV) of the CysC 
measurements has been previously established at 3.1% at 1.06 mg/L; 3.5% at 
2.04 mg/L and 6.7% at 5.26 mg/L. 22 CysC was reported as an absolute level in 
mg/L, rather than as eGFR. SCr was measured by modified Jaffe’s reaction, 
using the Synchron System Kits on a Beckman Coulter LX20 Pro (Beckman 
Coulter Inc, Brea, CA) with a normal adult reference interval of 55-120 µmol/L. 
CRP was measured by immunonephelometry (Dade Behring BN Prospec, 
Mississauga, Canada) with CV of 4.02% at the level of 12.79 mg/L and 4.48% at 
50.87 mg/L.  TSH was measured by direct chemiluminescence assay (Bayer 
Centaur Instrument, Germany).   
The single hemodialysis treatment efficacy was taken as the Sp Kt/V calculated 
by UKM. It was carried out during the second hemodialysis session of the week. 
The Std Kt/V also calculated from UKM based on Gotch’s initial paper.6 
Reduction ratios for CysC (CCRR), urea (URR) and creatinine (CRR) were 
calculated by taking the difference between pre- and post- levels, and divided by 
pre-levels. We assumed that the volume of distribution of CysC is different from 
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that of urea and creatinine yet still related to body weight.  We also assumed the 
dialyzer clearance of CysC is mainly related to the dialysis circuit blood flow and 
total amount removed by time (surface area being similar for all). We, thus, 
hypothesized that CCRR will be related to the liters of blood processed (LP; L) 
during dialysis normalized by the target post-dialysis weight (LP/kg).  LP (L) = 
dialyzer blood flow (Qb) (mL/min) x time (min).  LP values were obtained at the 
end of each dialysis directly from the dialysis machine.  The amount of 
ultrafiltration (L) during dialysis was recorded as it was also felt to influence 
CCRR by a) convective removal versus b) hemoconcentration of CysC.   
Statistical Analysis 
Statistical analysis was performed using the GraphPad Prism software version 
4.03 for Windows (GraphPad Software, San Diego, CA, U.S.A.). For the multiple 
stepwise regression analysis, Medcalc version 11.2.1.0 (Medcalc Software bvba, 
Mariakerke, Belgium) was used. Contiguous data were analyzed for normal 
distribution with the Shapiro-Wilk normality test. Mean and standard deviation 
were reported for normally distributed data; otherwise, median, 25th, and 75th 
percentiles (inter quartile range) were given. The paired t-test for normally 
distributed variables and the Mann-Whitney test for non-normally distributed 
variables were used to compare between the pre- and post-dialysis CysC, SCr 
and SUr levels. We also compared pre-dialysis levels from the three dialysis 
sessions to assess the intra-patient variability. Depending on whether or not data 
were normally distributed, Pearson’s correlation or the non-parametric 
(Spearman’s rank) correlation analysis was used to assess the strength of 
relationship between CCRR, and URR, CRR, Sp Kt/V, Std Kt/V, TSH and CRP 
as well as LP/kg and UF. Pearson correlation coefficients were expressed as r-
values and the significance level of the p-value was also recorded. A p value of 
<0.05 was considered significant. For the multiple regression analysis, we 
calculated the correlation coefficients r2: this is the proportion of the variation in 
the dependent variable explained by the regression model. It can range from 0 to 
1 and is a measure of the goodness of fit of the model. 
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2.3. RESULTS 
A total of 15 patients were enrolled into the study, all functionally anephric with 
urine output <250 mL per day. All patients met the inclusion criteria without 
violating exclusion criteria with unchanged conventional thrice weekly in center 
high-efficiency and high-flux hemodialysis prescription and without 
hospitalizations over the last 3 months. The mean age ± standard deviation (SD) 
was 67.3 ± 11.2 years. The most common cause of end-stage renal disease was 
diabetes mellitus (53.3%). The median dialysis time was 3.75 (3, 4) hours per 
session. The mean pre- and post-dialysis CysC concentrations were 5.96 ± 0.94 
mg/L and 4.66 ± 1.09 mg/L, respectively (Figure 2-1). All of the patients had 9 
CysC values over the one-week interval except one patient who had a single 
missing post-dialysis CysC value. The mean Sp Kt/V was 1.51 ± 0.24, while the 
median Std Kt/V was 2.63 (2.15, 2.71). The median TSH (normal range 0.27 to 
4.20 mIU/L) was 1.62 (1.31, 3.16) mIU/L. The mean CRP concentration (normal 
range ≤5.0 mg/L) was 20.51 ± 15.13 mg/L. The mean LP/kg and UF were 0.89 ± 
0.21 L/kg and 2.84 ± 1.06 L. Clinical results are summarized in Table 2-1. The 
URR, the CRR and the CCRR were 70.2 ± 9.0 %, 64.5 ± 8.2 % and 26.1 ± 11.8% 
(p≤0.002), respectively (Figure 2-2).   
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Table 2-1. Baseline Characteristics 
Baseline Characteristics Mean*/ 
MedianΔ/ 
Total® 
SD Inter Quartile 
Range 
(25% minimum, 
75% maximum) 
Age (years) 67.33 11.20  
Dialysis time (hr) 3.75  3.00, 400 
Sp Kt/V 1.51 0.24  
Std Kt/V 2.63  2.15, 2.71 
Pre-dialysis cystatin C (mg/L) 5.95 0.94  
Post-dialysis cystatin C (mg/L) 4.66 1.09  
TSH (mIU/L) 1.62  1.31, 3.16 
CRP (mf/L) 20.51 15.13  
LP/kg (L/kg) 0.89 0.21  
UF (L) 2.84 1.06  
Cause of renal failure: N (%)    
Diabetes 8 (53.3)   
Hypertension 1 (6.6)   
Renal Cancer 1 (6.6)   
Glomerularnephritis 2 (13.3)   
Acute renal failure 1 (6.6)   
Polycystic kidney disease 1 (6.6)   
Reflux nephropathy 1 (6.6)   
*Expressed as mean if the variable is normally distributed by Shapiro-Wilk 
normality test ΔExpressed as median if the variable is not normally distributed by 
Shapiro-Wilk normality test ®Expressed in total number and percentage; Sp Kt/V 
= Single pool Kt/V, Std Kt/V = Standardized Kt/V or weekly Kt/V, TSH = Thyroid 
stimulating hormone, CRP = C reactive protein, UF = Ultrafiltration volume, LP/kg 
= Normalized liter processed  
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Figure 2-1. Mean Cystatin C Levels During Hemodialysis Sessions.  
This figure shows for each of the 15 patients the cystatin C levels at the start, the 
middle, and the end of dialysis. Each value represents the average of three 
dialysis treatments.  
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Figure 2-2. Cystatin C, Urea, and Creatinine Reduction Ratios (CCRR, URR 
and CRR, Respectively).  
The reduction ratio for each of the biomarkers is shown. The values for URR, 
CRR, and CCRR were 70.2% ± 9.0%, 64.5% ± 8.2%, and 26.1% ± 11.8%, 
respectively. By Paired t test, each post-dialysis biomarker concentration was 
significantly lower than the pre-dialysis value (P < 0.002). 
 
There were no statistically significant correlations between the CCRR and Sp 
Kt/V, URR and CRR (p>0.151). The correlation coefficient was significant 
between CCRR and LP/kg (r=0.678, p=0.006). There also was a significant but 
negative correlation between CCRR and UF (r=-0.724, p=0.002). Multiple 
regression analysis with these two parameters provided a model that explained 
81% of the variance (r2=0.811, p<0.001), CCRR = 0.127 + 0.331 LP/kg - 0.072 x 
UF (Figure 2-3). There was no correlation between pre-dialysis CysC, and Std 
Kt/V, TSH, CRP (p>0.166). As expected, there were strong correlations between 
Sp Kt/V, and URR (r=0.770, p<0.001) and CRR (r=0.727, p=0.002). URR and 
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CRR correlated weakly with LP/kg but not with UF. The results of correlation 
analyses are summarized in Table 2-2. 
There were no significant differences between the three pre-dialysis CysC levels 
(Paired t-test, p>0.115) of the three dialysis sessions in the one week. For the 
pre-dialysis SUr, however, there was a significant difference between Session 1 
and 3 (Mann-Whitney test, p=0.029). For the pre-dialysis SCr, there were 
significant differences between Session 2 and 3 (Paired t-test, p<0.001), and 
Session 1 and 3 (Paired t-test, p=0.005).  
Table 2-2. The Correlation Analysis and the Multivariable Analysis between 
CCRR, URR and CRR, and Other Variables. 
Variable 1 Variable 2 Variable 3 Pearson Correlation 
Coefficients (r) 
P value 
CCRR Sp Kt/V  0.212 0.447 
CCRR URR  0.390 0.151 
CCRR CRR  0.363 0.184 
CCRR LP/kg  0.678 0.006 
CCRR UF  -0.724 0.002 
UUR Sp Kt/V  0.770 <0.001 
URR LP/kg  0.650 0.009 
URR UF  0.029 0.920 
CRR Sp Kt/V  0.727 0.002 
CRR LP/kg  0.641 0.010 
CRR UF  -0.024 0.933 
Pre-CysC Std Kt/V  -0.377 0.166 
Pre-CysC TSH  -0.196 0.485 
Pre-CysC CRP  0.339 0.216 
Variable 1 Variable 2 Variable 3 Correlation 
Coefficients (r2) 
P value 
CCRR UF LP/kg 0.811 <0.001 
URR UF LP/kg 0.359 0.072 
CRR UF LP/kg 0.327 0.067 
CCRR = Cystatin C reduction ratio, URR = Urea reduction ratio, CRR = 
Creatinine reduction ratio, Sp Kt/V = Single pool Kt/V, Std Kt/V = Standardized 
Kt/V or weekly Kt/V, Pre-CysC = Pre-dialysis Cystatin C level, TSH = Thyroid 
stimulating hormone, CRP = C reactive protein, UF = Ultrafiltration, LP/kg = 
normalized liter processed 
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Figure 2-3. Correlation Between the Calculated and the Measured Cystatin 
C Reduction Rate (CCRR) Based on a Model Using the Ultrafiltration 
Volume (UF [L]) and the Normalized Liters Processed (LP/kg)  
The model explained 81% of the variance. This figure shows a highly significant 
linear correlation between the predicted CCRR and the measured CCRR 
(r2=0.811, p<0.001). Note. The three patients with low CCRR have 4-5 L of fluid 
removal during hemodialysis treatments.  
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2.4. DISCUSSION 
The purpose of this study was to evaluate the dialysis clearance and handling of 
CysC and the variables that affect its clearance in a single high-flux high-
efficiency hemodialysis session. It is a continuation of the study by Al-Malki et 
al.19 There was significant CysC reduction through a single high-flux high-
efficiency hemodialysis session. The CCRR was 26.1 ± 11.8%. This is lower than 
the small solutes clearance, with URR and CRR being 70.2 ± 9.0 % and 64.5 ± 
8.2 %, respectively. There was no significant correlation between CCRR, and the 
small solute clearance (Sp Kt/V, URR and CRR). Multiple regression analysis 
with the LP/kg and UF provided a model that explained 81% of the variance 
(r2=0.811, p<0.001), CCRR = 0.127 + 0.331 x LP/kg - 0.072 x UF. To the best of 
our knowledge, this is the first description of the parameters that influence 
CCRR. 
Thysell et al.20 showed a paradoxical increase in post-dialysis CysC level in low-
efficiency hemodialysis. This was likely due to hemoconcentration and slow 
equilibration of CysC between intravascular and extravascular spaces. A 
previous study demonstrated that CysC elimination was more efficient by 
hemodiafiltration compared to low-flux hemodialysis.21 Park et al.10  showed a 
significant difference between low- and high-flux dialyzers in CysC clearance. 
CCRR results were 11.5 ± 16.2% with low-flux dialyzers and 42.4 ± 6.3% with 
high-flux dialyzers, respectively, with a significant difference in CCRR between 
dialyzers (p<0.0001). The lower CCRR of 26% in our study despite very high 
blood flows may be explained by differences in UF rates, although no details 
were provided in the Park manuscript. Park et al.10 also revealed a weak 
correlation between CCRR, and URR and eKt/V. By contrast, there was a strong 
correlation with CCRR and ß2-microglobulin clearance. These studies have 
demonstrated a significant reduction of CysC through hemodialysis but the 
variables that affect the CysC clearance were not assessed.  
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The results of our study suggest a very different handling of CysC compared to 
the clearances of the small solutes urea and creatinine, in a single high-flux high-
efficiency hemodialysis treatment. All patients were functionally anephric, which 
eliminates the effects of residual renal function on CysC clearance. Three factors 
should affect CysC clearance: diffusive clearance – albeit small, convective 
clearance and the ultrafiltration volume. So what do we know about Cystatin C 
clearance to explain our findings? CysC is a middle molecule that distributed 
mainly extracellularly.9 It is also minimally protein bound with presumed slow 
redistribution between intravascular space and extravascular space because of 
its size. Unfortunately, little is known about the equilibration of CysC between the 
intra- and extravascular space; however, in view of what is known about other 
middle molecule redistribution, we can assume a slow equilibration.20 Zingraff et 
al.23 compared the clearance of radioiodinated serum amyloid P component 
(125I-SAP), a constituent for systemic amyloidosis deposits, in healthy subjects 
and chronic hemodialysis patients. In the hemodialysis patients, the decline was 
in a biexponential mode, rather than a single-exponential slope. There was also 
evidence of “tissue retention” of 125I-SAP in the extravascular space. This was 
enhanced in patients with symptomatic dialysis–related amyloidosis. By contrast, 
SUr and SCr are distributed both in extracellular (both intra- and extravascular) 
and intracellular spaces, with presumed rapid equilibration between all three 
compartments during hemodialysis.24 It is presumed that small molecules are 
mostly affected by diffusive clearance and relatively unaltered by UF because of 
rapid equilibration. By contrast, CCRR is affected by a combination of diffusive 
and convective clearance. The data of Park et al.10 data suggest that convective 
clearance is much more important for CysC. Removal of some cystatin C by 
membrane adbsorbtion as does occur with B2- microglobulin must also be 
considered.25 There is, as yet, no published information on this. This possibility 
needs to be explored. 
Given these facts and after establishing the inverse correlation between UF and 
CCRR, we hypothesized that CysC, SCr, and SUr have different volumes of 
distribution within different fluid body compartments and had different inter-
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compartmental rates of equilibration. We hypothesize that SUr and even more so 
SCr equilibrate quickly between the intra- and extravascular space, thereby 
remaining unaffected by UF. By contrast, CysC is only altered in the intravascular 
space by the dialysis, equilibrates slowly, and is largely affected by the 
sometimes substantial UF observed in our patients (max 5L) in this study. Figure 
2-4 presents a hypothetical model for the different handling of the two molecule 
classes. This model is well supported by the fact that we can explain 81% of the 
variance by UF and liters processed.  
 
Figure 2-4. Kinetic Model of Creatinine, Urea and Cystatin C during 
Hemodialysis.  
Cystatin C is a middle molecule that is distributed mainly extracellular and 
minimally protein bound. It was presumed to have slow redistribution between 
intravascular space and extravascular space because of its size. By contrast, 
urea and creatinine are distributed both in extracellular (both intra- and 
extravascular) and intracellular spaces, with presumed rapid equilibration 
between all three compartments during hemodialysis. As a result, it is presumed 
that small molecules are mostly affected by diffusive clearance and relatively 
unaltered by UF because of rapid equilibration. By contrast, CCRR is affected by 
a combination of diffusive and convective clearance and by ultrafiltration, which 
may concentrate the intravascular content of Cystatin C. 
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Our study had a few limitations. It was a small pilot study of only 15 patients. All 
of the patients used high-flux dialyzers. The study results are not applicable to 
low-flux hemodialysis treatments. The previous study by Al-Malki et al.19 
demonstrated a significant negative correlation between Std Kt/V and pre-dialysis 
CysC in functionally anephric patients. We did not find such a correlation and did 
not expect to due to the small samples size and the narrow range of Std Kt/V 
values obtained from patients on identical dialysis modalities.  We did not assess 
CysC rebound post-hemodialysis. This was previously demonstrated in the study 
by Lindström et al.;21 there was a rise in CysC level by 12% in the 
hemodiafiltration group.  
Why is CysC an attractive dialysis adequacy marker? By increasing small 
molecule clearance, the HEMO and the ADEMEX studies have failed to show 
any mortality benefit.  By contrast, there is evidence that CysC levels associate 
with clinical outcome.26,27 CysC levels have been shown to correlate with cardiac 
mortality in patients with coronary heart disease.28 In patients with Stage III or IV 
chronic kidney disease, the CysC level is associated with all cause and 
cardiovascular disease mortality.29 If CysC level correlates with clinical outcome 
in the dialysis population regardless of the residual renal function, it may become 
an important dialysis adequacy parameter. As a result, further studies remain to 
assess this association and the target of a satisfactory CysC level.   
In conclusion, this study is the first to define the parameters that determine 
CCRR. The total dialysis dose measured as normalized liters processed plus the 
ultrafiltration rate are the most important determinants for CCRR. This is novel. 
Based on molecular characteristics, we hypothesize on the differences that 
explain the different handling of SCr and SUr on the one hand and CysC on the 
other. The current study provides a first model for the kinetics of Cystatin C 
removal by dialysis.    Further studies are indicated.  
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3. Chapter 3. Hyperfiltration Affects Accuracy of 
Creatinine eGFR Measurement 
To better assess the effects of hyperfiltration on cystatin C renal clearance, here, 
127 pediatric patients with chronic kidney disease not yet on dialysis were 
observed. We demonstrated that there is a significant negative correlation 
between the errors for the Schwartz estimated glomerular filtration rate and the 
filtration fraction (the ratio of GFR and renal plasma flow). Both cystatin C and 
beta-trace protein were not affected by differences in filtration fraction. Therefore, 
cystatin C might be a useful marker for the assessment of kidney function in 
advanced kidney disease. This Chapter is similar to work already published in 
the Clinical Journal of the American Society of Nephrology in 2011.2 
3.1. INTRODUCTION 
Renal function measurement is often focused on the glomerular filtration rate 
(GFR) and, to a lesser extent, on the renal blood flow.1 The gold-standard for 
measuring the GFR is inulin clearance.2 However, nuclear medicine studies have 
replaced inulin clearance owing to convenience and absence of urine collection. 
In Europe, 51Cr-ethylenediamine tetra-acetic acid (EDTA) is the most widely used 
method for the determination of GFR, whereas in North America, the 99Tc 
Diethylenetriamine penta-acetic acid (DTPA) renal scan enjoys the most 
widespread utilization.3-5 While less demanding than inulin clearance studies, 
nuclear GFR studies are still cumbersome, invasive and involve the handling of 
radiopharmaceutical substances. Endogenous markers for estimated GFR, such 
as serum creatinine and more recently Cystatin C, are hampered by diagnostic 
imprecision.6 Recently Beta trace protein (BTP) has been introduced as a 
surrogate marker for GFR measurement.7 
Creatinine (113 Dalton, neutrally charged) is the metabolic product of creatine 
and phosphocreatine found in muscle, and therefore reflects muscle mass.8,9 
                                            
2	  Huang SH, Sharma AP, Lindsay RM, Clark WF, and Filler G. Hyperfiltration Affects Accuracy of 
Creatinine but not Cystatin C or Beta Trace Protein eGFR Measurement. Clin J Am Soc Nephrol. 
2011 Feb;6(2):274-80. PMID: 20966120.	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Given the large variability of muscle mass, there is substantial inter-patient 
variability of serum creatinine concentration due to its high water solubility.10,11 
Serum cystatin C has been shown to be an excellent marker for GFR.12,13 It is a 
small molecular weight protein (13 kDalton, positive charge with isoelectric point 
of 9.3) that was initially known as γ–trace protein and its amino acid sequence 
was determined in 1981.14,15 This protein is produced at a very constant rate and 
is affected by only a few conditions, such as uncontrolled hyperthyroidism.16 BTP 
(23-29 kDalton, mildly negatively charged with isoelectric point of 5.8-6.7, also 
known as prostaglandin D synthase), has been traditionally used as a marker of 
cerebrospinal fluid leakage.17,18 It is expressed in all tissues except the ovaries.19 
Preliminary studies have confirmed a good correlation between serum BTP 
levels and GFR measurement by inulin clearance and nuclear medicine 
techniques.5,20 
Hyperfiltration is considered an abnormal increase in the glomerular filtration 
rate.21,22 However, this definition ignores the fact that hyperfiltration can take 
place in a single nephron even with globally decreased GFR.  Other sources 
have defined hyperfiltration as the result of an increase in the glomerular capillary 
pressure.23,24 The filtration fraction (FF) is the ratio of GFR and effective renal 
plasma flow (ERPF). A normal filtration fraction is 18.7±3.2 percent in healthy 
young adults, between the ages of 20-30 years.25 Hyperfiltration should be 
considered if the filtration fraction is above the reference interval.  
We were interested in whether hyperfiltration affects the diagnostic accuracy of 
commonly used eGFR measurements using creatinine, cystatin C and BTP in a 
pediatric population. The precision between the surrogate markers and the eGFR 
is reduced at higher GFR. One possible explanation for this phenomenon may be 
that some patients have hyperfiltering and others do not. 
3.2. MATERIALS AND METHODS 
(1) Participants 
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The study received approval of the local ethics boards and was in accordance 
with the ethical standards of the Helsinki declaration of 1975 (revised in 1983).5 
Written consent was obtained in each case from the parents and in case of a 
consenting minor, from the patients as well. One hundred and twenty-seven of 
the patients had a 51Cr EDTA renal scan with concomitant determination of the 
131I Hippurate clearance (ERPF), thus allowing for the calculation of the FF. 
Hyperfiltration should be considered if the filtration fraction is above 18.7±3.2. 
Venous blood samples were obtained from 127 children with various renal 
pathologies, referred for determination of nuclear medicine GFR study. Patients 
were recruited consecutively and their ages ranged from 1.0 to 18.0 years with a 
mean of 11.5 ± 4.2 years. Thirty-five percent of patients were females. Mean 
height was 136.7 ± 28.4 cm (range 62.3 - 189.1 cm), mean weight was 
40.2 ± 20.0 kg (range 6.5 – 104.0 kg) and mean body surface area was 
1.22 ± 0.42 m2 (range 0.33 - 2.20 m2). The main indications for GFR 
measurements were: various forms of glomerulonephritis (44.7%), obstructive 
uropathy (19.9%), reflux nephropathy (13.6%), post renal transplantation (5.4%), 
and others (16.4%, including post hemolytic uremic syndrome, steroid sensitive 
nephrotic syndrome, cystinosis, orthostatic proteinuria, etc.). 
(2) Experimental Procedure 
The methods for the simultaneous measurement of both GFR and ERPF using 
51Cr EDTA renal scan with concomitant determination of the 131I Hippurate 
clearance have been described elsewhere.25 GFR and ERPF were corrected to a 
standard body surface area of mL/min/1.73 m2. For consistency, we mean by 
GFR and ERPF the corrected values per 1.73 m2 body surface area throughout 
the manuscript. Filtration fraction was calculated as the ratio between 51Cr EDTA 
GFR and 131I Hippurate ERPF and was expressed in percent. Serum creatinine 
was measured with an enzymatic assay (Ortho Clinical Diagnostics). As 
enzymatic assays measure approximately 20% lower than the Jaffé method that 
was used in the original formula by George Schwartz, we used 20% higher 
constants (38 for children above 1 year of age, 48 for adolescent males) to 
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calculate the eGFR estimate according to Schwartz.26 We validated these 
revised constants for the Schwartz formula in our patient cohort. For adolescent 
males, the estimated constant was 49.4 ± 10.5, not significantly different from 48 
(p=0.3271, one-sample t-test). For the non-adolescent male patients, the 
constant was 40.3 ± 7.7, again not significantly different from 38. We therefore 
used the constants 38 and 48. The formula reads: 
            Equation 3-1 
The methods for the determination of Cystatin C (Siemens Diagnostics GmbH) 
and BTP (Siemens Diagnostics) were described in the previous study.5 Cystatin 
C eGFR was calculated using the Filler formula.27 For the BTP eGFR, we used a 
recently published and validated formula by Benlamri et al.28  
We calculated the error between the measured GFR and the estimated GFR for 
creatinine using Schwartz, cystatin C and BTP using (estimated GFRParameter-
measured GFR)/measured GFR. 
(3) Statistical Analysis 
 
All statistical analyses were performed using GraphPad Prism Software for 
Science Version 4.0c, San Diego, CA, USA. Standard regression and correlation 
analysis were applied. Normal distribution was assessed using the Shapiro Wilks 
test.  
Agreement between methods was tested using the Bland and Altman plot 
method.29 The Bland and Altman plot is a statistical method used to compare two 
measurement techniques. In this graphical method the differences (or 
alternatively the ratios) between the two techniques are plotted against the 
averages of the two techniques. Horizontal lines are drawn at the mean 
difference, and at the mean difference plus and minus 1.96 times the standard 
deviation of the differences. If the differences within mean ± 1.96 SD are not 
GFR estimate =
Height [cm] x constant
serum creatinine [µmol/L]
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clinically important, the two methods may be used interchangeably. Standard 
deviation (SD) of the differences between the two assay methods is used to 
calculate the limits of agreement, computed as the mean bias plus or minus 1.96 
times its SD. The bias is computed as the value determined by one method 
minus the value determined by the other method. If one method is sometimes 
higher, and sometimes the other method is higher, the average of the differences 
will be close to zero. If it is not close to zero, this indicates that the two assay 
methods are producing different results. Correlation analysis was performed 
using appropriate parametric (in case of normal distribution) or non-parametric 
tests (Spearman rank). In case of non-normal distribution, data are given as a 
median (25th percentile, 75th percentile). The percentiles in brackets are also 
known as inter-quartile range (IQR). A p-values <0.05 was considered 
statistically significant. 
3.3. RESULTS 
The 127 children had a median age of 11.9 (IQR 8.5, 14.9) years, weighed 39.9 
(28.8, 54.3) kg, and had a height of 146.0 (131.0, 163.8) cm. Mean body surface 
area was 1.30±0.39 m2. The mean measured 51Cr EDTA GFR was 100.6 ± 32.1 
mL/min/1.73 m2. The median 131I hippurate clearance (ERPF) was 588 (398, 
739) mL/min/1.73 m2. The mean filtration fraction was 17.7± 4.5% and 
hyperfiltration is considered if the filtration fraction is above 18.7±3.2. Median 
serum creatinine 56 (52, 74) µmol/L, whereas median cystatin C was 0.98 (0.83, 
1.21) mg/L and median BTP was 0.76 (0.62, 0.98) mg/L.  The results of the most 
important parameters are summarized in Table 3-1.  
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Table 3-1. Statistics of the Most Important Measured and Calculated  
 
Hipp.=Hippurate, FF=Filtration fraction, Creat.=Creatinine, eGFR=estimated 
glomerular filtration rate, CysC=Cystatin C, BTP=beta trace protein, W=Wilk 
constant. Num = number of patients, 25% = 25th percentile, 75% = 75th 
percentile, and Std. Dev. = standard deviation. *unit for GFR =  mL/min/1.73 m2 
 
 
 
  
  
51Cr 
EDTA* 
 
123I-
Hipp. * 
 
FF [%] 
 
Creat. 
[µmol/L] 
 
Schwartz 
eGFR*  
  
Cys C 
[mg/L] 
 
CysC 
eGFR 
*  
BTP 
mg/L 
 
BTP 
eGFR  
* 
Num. 127 127 127 127 127 127 127 127 127 
25%  77 398 14.6 41.55 84.5 0.83 73.97 0.62 81.67 
Median 97 588 17.4 55.69 108.7 0.98 93.72 0.76 103.4 
75%  121 739 20.3 74.26 134.6 1.21 113 0.98 126 
Mean 100.6 614 17.7 58.76 112.4 1.105 91.27 0.8935 102.4 
Std. 
Dev. 32.08 296.5 4.5 23.26 37.86 0.376 27.8 0.4774 31.35 
Shapiro-Wilk normality test 
W 0.98 0.91 0.99 0.96 0.95 0.86 0.98 0.67 0.99 
P value 0.15 P<0.01 0.20 P<0.01 P<0.01 P<0.01 0.06 P<0.01 0.332 
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Bland and Altman analysis revealed a bias of 10.8±21.2%, with a 95% limit of 
agreement from -0.8 to 52.4% between the Schwartz formula eGFR and the 
measured GFR. For cystatin C, the bias was -9.6±21.6% with a 95% limit of 
agreement from -52.0 to 32.7%, and for BTP, the bias was 1.4±28.3 with a 95% 
limit of agreement from -54.0 to 56.8% (Table 3-2).  
The median (IQR) relative error ((eGFR-GFR)/GFR) for the Schwartz formula 
was +12 (IQR -4, +24)%, whereas the median error for Cystatin C eGFR was -9 
(IQR -21, +6)%, and for BTP eGFR was +5 (IQR -16, +25)% (Table 3-3).  
There was no significant correlation between the FF and the error for Cystatin C 
eGFR and BTP eGFR, whereas there was a significant negative correlation 
between the error for the Schwartz eGFR and the FF (Figure 3-1). Further, a 
significant negative correlation existed between FF and GFR, Schwartz GFR, 
Cystatin C eGFR and BTP eGFR. Clinically, this suggests that most patients with 
a lower GFR have hyperfilteration, whereas only some hyperfilter with normal 
GFR. Table 3-2 summarizes the correlation analysis (Spearman rank). There 
was no significant correlation between the error for the Cystatin C eGFR and 
BTP eGFR and the FF. On the other hand, a significant negative correlation 
existed between FF and GFR, Schwartz GFR, Cystatin C eGFR and BTP eGFR.   
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Table 3-2. Bland & Altman Results Summarized for Agreement of Various 
eGFR Formulae with the Measure Isotope GFR. 
Formula Schwartz eGFR Cystatin C eGFR BTP eGFR 
Bias 10.8 9.6 1.4 
SD % 21.2 21.6 28.3 
95% limit of 
agreement 
-0.80 to 52.4 -52.0 to 32.7 -54.0 to 56.8 
 
Table 3-3. Error by Level of eGFR (eGFR-GFR/GFR) for Various eGFR 
Formulae. 
Formula Schwartz eGFR Cystatin C eGFR BTP eGFR 
Median error +12.0 -9.0 +5 
25th 
percentile 
error 
-4.0 -21.0 -16.0 
75th 
percentile 
error 
+24.0 +6.0 +25.0 
 
Table 3-4. Spearman Rank Correlations between the Error of the GFR 
Estimate Models (BTP, Cystatin C, Schwartz) with FF (filtration fraction) 
Parameter Schwartz %error CysC %error BTP  %error   
Number of XY 
Pairs 
127 127 127 
Spearman r -0.2365 -0.08541 -0.1089 
95% 
confidence 
interval 
-0.3988 to -0.05968 -0.2607 to 0.09535 -0.2826 to 
0.07185 
P value (two-
tailed) 
0.0074 0.3397 0.2232 
P value 
summary 
** Ns Ns 
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Figure 3-1. The Relationship Between the Percentage Error of the Schwartz, 
Filler and Benlamri eGFR and the Measured GFR, Plotted Against the 
Filtration Fraction (FF). 
There was a significant negative correlation (Spearman r=-0.2365, p=0.0074). 
For the non-linear regression model, we used a one-phase exponential decay 
model with the constants SPAN=2295, K=0.0001440, PLATEAU=-2295, 
HalfLife=4815.   
 
 
3.4. DISCUSSION 
The main finding of the study was that creatinine-based eGFR was influenced by 
the FF, whereas the accuracy of the eGFR from the Filler’s equation using serum 
cystatin C and the Benlamri’s equation using serum BTP was unaffected. In fact, 
there was a significant negative correlation between error of eGFR calculated 
from the Schwartz’s formula and the measured GFR and the FF. To the best of 
our knowledge, this is the first study that demonstrates that the error between 
Schwartz formula eGFR and measured GFR is altered by hyperfiltration. By 
contrast, eGFR based on low molecular weight proteins was not altered by 
hyperfiltration.  
This finding is novel and has significant implications. Previous studies have 
focused on the errors in eGFR from various surrogate markers and their 
respective formulas, to the nuclear GFR studies.30,31 Consistently, better 
agreement was found in the low GFR range, whereas the precision between 
Schwartz Filler Benlamri 
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measured GFR and surrogate marker eGFR worsened with normal and high 
GFR values.24,32 It was therefore logical to assess the effect of hyperfiltration on 
the diagnostic performance of surrogate eGFR markers. Previous studies did not 
include the ERPF or the FF.  
What does this mean? It appears that a small molecular weight soluble 
substance can be affected by hyperfiltration that weakens its diagnostic 
performance as a GFR marker, whereas low molecular weight proteins are 
unaffected. This would render serum creatinine a less accurate marker for eGFR 
in the presence of hyperfiltration. As GFR may remain constant in the early 
stages of CKD while the nephron endowment deteriorates secondary to a renal 
disease, patients with a normal GFR may or may not be hyperfiltrating. In 
advanced CKD, all remaining nephrons hyperfilter.33 It is therefore conceivable 
that the degree of hyperfiltration may serve as the main explanation for the 
reduced precision of any surrogate GFR marker in the normal and high GFR 
range. Admittedly, the correlation was only 0.24, which was significant, but not 
very impressive. The study was not designed to discover a strong correlation 
between the error of a creatinine-based eGFR formula and the filtration fraction. 
Rather, it was designed to test the hypothesis whether some of variance of the 
scatter can be explained by the degree of hyperfiltration. The clinical significance 
of our findings lies in the fact that indeed some of the imprecision of creatinine-
based eGFR can be explained by hyperfiltration, and especially patients early in 
the course of diabetic nephropathy and IgA nephropathy may have significant 
hyperfiltration. In the low GFR range, the phenomenon becomes less important, 
but our data suggest that creatinine handling may be altered by the filtration 
fraction to a degree that it renders the marker less favorable when compared to 
the low molecular weight eGFR markers. 
Of course, the question arises as to why the small molecule creatinine is handled 
differently than the small molecular weight proteins cystatin C and BTP. All 
surrogate eGFR markers have different charges and isoelectric points. As 
cystatin C and BTP are handled identically, electric charge is unlikely to explain 
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the negative correlation between the error in eGFR for creatinine in the 
measurement of the FF. One possible explanation for this increase in error in 
creatinine based eGFR using the Schwartz’s formula is that creatinine is also 
secreted by the renal tubule along with the excretion from glomerular filtration 
while there is minimal or no tubular reabsorption of creatinine.34 Cystatin C and 
BTP are exclusively eliminated through glomerular filtration. Therefore, with low 
filtration fraction, there is more blood flow in the efferent arteriole and 
subsequently more creatinine available in the peritubular capillaries for tubular 
secretion. This may lead to an increase of tubular secretion at lower FF, thereby 
creating an overestimation in the eGFR.  It should be noted that the difference 
between the 25th and 75th percentile (i.e. IQR, a measure of precision) was 
inferior for BTP, suggesting that of the two low molecular weight proteins, 
Cystatin C should be preferred.  
When the filtration fraction is increased, there is a decrease in efferent blood flow 
with a subsequent decrease of creatinine available for tubular secretion. 
Therefore, the eGFR from the creatinine based formula correlates better with 
measured GFR at higher filtration fraction. The proposed differential handling of 
creatinine with lower and higher filtration fraction is demonstrated in Figure 3-2. 
As tubular secretion does not modify cystatin C and BTP concentrations, the FF 
is unaffected by the error between the eGFR errors for both cystatin C and the 
beta trace protein based formulae.  
Our study has limitations.  The first limitation is related to the nuclear medicine 
methods chosen to determine GFR and ERPF. No separate gold standard such 
as inulin clearance and para-aminohippuric acid (PAH) clearance were used to 
evaluate the accuracy of the nuclear medicine methods.  Nuclear medicine 
methods are known to be imperfect measures of GFR and ERPF. Inulin and PAH 
clearance studies are no longer performed in most tertiary centers. However, the 
methods were validated and performed as described in as the standard of care.25 
While earlier studies comparing inulin clearance and 51Cr EDTA clearance mostly 
reported correlations upon introduction of the nuclear medicine methods, a 
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recent study from Medeiros et al.35 used appropriate testing for agreement with 
Bland and Altman analysis for an identical method to ours and revealed narrow 
limits of agreement and a difference (bias) of 2.8 and 2.7 mL/min, respectively.  
They concluded that 51Cr-EDTA-Clearance was a reliable method to measure 
GFR compared with Inulin clearance. The authors are unaware of any modern 
studies employing Bland and Altman analysis to study agreement between 131I 
Hippurate clearance with PAH clearance, however, a study from 1980 
demonstrated identical results with PAH clearance and slightly better 
performance of 131I Hippurate clearance that we used in our study when 
compared to123I Hippurate clearance.36 Furthermore, this study was conducted in 
a pediatric population and it is unclear whether these findings can be generalized 
to all ages. In children, eGFR is calculated using the Schwartz’s formula that is 
based on creatinine and patient height. Adult eGFR calculations based on serum 
creatinine such as the Modification of Diet in Renal Disease study (MDRD) 
equation and the Cockcroft-Gault equation. In children, these formulae cannot be 
used before the findings of this study can be generalized. 37 
The eGFR errors using the Schwartz’s formula change with the state of FF. It is 
impractical to measure FF in every patient. FF can only be measured if GFR and 
ERPF are determined simultaneously. In Canada, 131I or 121I paraaminohippuric 
acid are not commercially available. Furthermore, for a simultaneous nuclear 
medicine method, two different isotopes with gamma and beta radiation are 
required, which is impractical in North America because 51Cr EDTA is not 
commercially available.38 While we have a general rule of thumb that the tubular   
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Figure 3-2. Schematic Interpretation of Relationship Between the Filtration 
Fraction and Efferent Blood Flow.  
When the filtration fraction decreases, there is an increase in efferent blood flow 
and creatinine availability. This will lead to increase in tubular secretion. 
 
 
secretion for creatinine is approximately 10% of the total excretion, this may not 
be applicable for different states of hyperfiltration.34 The creatinine based eGFR 
formulas may be unpredictable in terms of the eGFR errors. Other limitations 
include a relatively low sample size of 127 patients and with a small proportion of 
patients with low GFR. Our study casts significant doubts on the accuracy of 
serum creatinine in patients with a variable degree of hyperfiltration. Early in the 
course of disease, hyperfiltration may or may not be operant.  In case of a GFR > 
150 mL/min/1.73 m2, hyperfiltration can be assumed, but in case of normal GFR, 
hyperfiltration may or may not occur. Our study suggests that a surrogate marker 
for eGFR should be based on a low molecular weight protein rather than serum 
creatinine. 
The question of the clinical applicability of these findings remains to be 
established. Short of performing a proper inulin and para-aminohippuric acid 
clearance study, filtration fraction is not easily measurable.  Clinically, we 
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assume hyperfiltration whenever the GFR is high. Our study suggests that also 
all patients with a low GFR hyperfilter. The importance of this study lies less in 
the clinical applicability of the effect of hyperfiltration on creatinine excretion, but 
rather points to an important factor that explains some of the scatter when using 
surrogate markers for the estimation of eGFR. The study also suggests that 
CysC is less affected by hyperfiltration than creatinine. 
In conclusion, this study showed that creatinine based Schwartz’s formula is 
influenced by filtration fraction. The errors of eGFR negatively correlate with 
filtration fraction. Only the eGFRs based on low molecular weight proteins 
(Filler’s equation using the cystatin C and the Belami’s equation using the beta 
trace protein) are unaffected at different levels of FF. Further studies are required 
to test the result in adult populations with other creatinine based formulae.  
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4. Chapter 4. Short Communication: Residual Renal 
Function Calculated from Serum Cystatin C 
Measurements and A Knowledge of The Standard 
Weekly Kt/V (Urea) 
Currently the gold standard method of measuring residual renal function is using 
24-hour urine mean urea and creatinine clearances. However, it is inconvenient 
for the patients. To determine if cystatin C levels can be used to measure both 
dialysis efficacy and residual renal function in dialysis patients, we recruited 15 
patients and developed a cystatin C-based estimated residual renal function 
equation. This equation was a better estimate of residual renal function than 
previously published equations with r2=0.81 (p< 0.0001). For our equation, we 
found that the cystatin C residual renal function estimating equation performed 
better when we incorporated the weekly dialysis clearance. This Chapter is 
similar to work already published in the Peritoneal Dialysis International, 2011.3 
4.1. INTRODUCTION 
 
The residual renal clearance was found to be a predictor of survival in dialysis 
patients.1,2 It is important to monitor and to preserve residual renal function (RRF; 
mL/min/1.73m2) in dialysis patients.3,4 Cystatin C (CysC) is a low molecular 
weight protein. The studies by Delaney et al.5 and Hoek et al.6 showed strong 
correlations between serum CysC levels and residual renal functions (RRF) in 
dialysis patients. In the Hoek study, an estimating equation was developed: 
estimated RRF (mL/min)  = 22/CysC – 0.70. A recent study by Al Malki et al. 
showed a significant inverse relationship between serum CysC levels and 
‘Weekly Standardized’ Kt/V (Std Kt/V) values in functionally anephric patients: 
Std Kt/V = 7.254 - 0.703 CysC.7  
                                            
3	  Huang SH, Filler G, Lindsay RM. Residual Renal Function Calculated from Serum Cystatin C 
Measurements and a Knowledge of the Standard Weekly Kt/V (Urea). Perit Dial Int. 2012 Jan-
Feb;32(1):102-4. PMID: 22302925	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In this study, we aimed to assess the role of serum CysC levels and dialytic 
clearance in measuring RRF. We hypothesized this difference between the 
measured CysC and that estimated from the Al Malki equation would significantly 
correlate with RRF as measured by the average of urinary creatinine and urea 
clearance. We also postulated that this correlation might be stronger than Hoek’s 
RRF, which uses 1/CysC values alone. 
4.2. MATERIAL AND METHODS 
This is a cross-sectional, single center pilot study of patients with end stage renal 
disease receiving peritoneal dialysis and conventional thrice weekly high-flux 
hemodialysis therapy. Blood and urine samples were collected prospectively. All 
patients provided written informed consent. Patients with recent changes in 
dialysis prescription within the last 3 months were excluded. The study was 
approved by the Ethic Review Board at the University of Western Ontario 
(HSREB#16598E).  
Seven of the 15 patients were on peritoneal dialysis. Eight of 15 patients were on 
conventional high-flux hemodialysis therapies (3-4 hours thrice weekly). The 
serum CysC, urea and creatinine levels were measured. For the hemodialysis 
patients, the pre-dialysis blood samples were used to measure serum CysC on 
the mid-week hemodialysis session, although our recent study demonstrated that 
pre-dialysis CysC values do not vary between hemodialysis sessions. 8Serum 
CysC levels were measured by immune nephelometry using an N-latex cystatin 
C kit (Siemens Healthcare Diagnostics Ltd.) on a Behring BN ProSpec analyzer 
(Dade Behring Marburg, Germany) at the reference laboratory at the Children’s 
Hospital of Eastern Ontario in Ottawa, with established co-efficient of variation.  
We obtained 24-45 hours of urinary output collection. The RRF were measured 
by average urinary creatinine and urea clearance, which were further adjusted for 
body surface area (BSA) using the DuBois’ formula (mRRF; mL/min/1.73m2). 9 
For the peritoneal dialysis patients, a 24 hours collection of peritoneal effluent 
was obtained and the total urea loss was measured. From these, the daily urea 
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clearance was calculated and the Std Kt/V values were derived (7 times daily K, 
L) employing the Watson equation for V.3,10 For the hemodialysis patients, the 
single hemodialysis treatment efficacy was taken as the single pool Kt/V (Sp 
Kt/V) calculated by Urea Kinetic Modeling and the Std Kt/V was derived.4,11,12  
All 15 patients had their RRF estimated using the Hoek equation.6 By rearranging 
the Al Malki equation, we can use the Std Kt/V to predict the pre-dialysis cystatin 
C levels (expected pre-dialysis cystatin C). The expected CysC levels did not 
incorporate RRF.7 The differences between the expected CysC levels and the 
measured CysC levels were defined as ΔCysC values. The ΔCysC estimated 
RRF equation was derived using ΔCysC value.  
Statistical analysis was performed using the GraphPad Prism software version 
4.03 for Windows (GraphPad Software, San Diego, CA, U.S.A.). Mean and 
standard deviation (SD) were reported for normally distributed data; otherwise, 
median, 25th, and 75th percentiles (inter quartile range) were given. A linear 
regression equation was derived from ΔCysC values.  Pearson’s correlation 
analysis was used to assess the strength of the relationship between measured 
RRF and ΔCysC values, and the measured RRF and estimated RRF, using both 
the Hoek equation and the ΔCysC equation. The Bland-Altman test was used to 
calculate the bias and the standard deviation of the bias between the estimated 
RRF and measured RRF. A p value of <0.05 was considered significant. 
4.3. RESULTS 
A total of 15 patients had completed measurements. The mean age ± standard 
deviation was 63 ± 15 years. The three most common causes of end-stage renal 
disease were hypertensive nephropathy (33%), diabetic nephropathy (27%) and 
glomerulonephritis (14%). The mean measured pre-dialysis CysC concentration 
was 4.57 ± 1.02 mg/L. The mean Std Kt/V values, with and without the 
consideration of RRF, were 2.61 ± 0.67 and 1.65 ± 0.59, respectively. The mean 
measured RRF was 1.73 ± 0.67 mL/min/1.73m2.  
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There was a statistically significant correlations between measured RRF and 
ΔCysC values as r2=0.81 (p< 0.0001). The association between measured RRF 
and ΔCysC values was: measured RRF (mL/min/1.73m2) = 0.3601 ΔCysC + 
0.5034. The ΔCysC estimated RRF values were plotted against measured RRF 
and data are shown in Figure 4-1. The bias was 0.001 ± 0.290 mL/min/1.73m2. 
The correlation coefficient between Hoek RRF and measured RRF was r2 = 0.69 
(p < 0.0001), see Figure 1, with a bias of 2.70 ± 0.847 mL/min/1.73m2.  
 
 
Figure 4-1. Correlation Analysis of the Hoek Residual Renal Function (RRF) 
and the Measured RRF, and ΔCysC RRF and Measured RRF (r2 = 0.69, and 
0.81, respectively; p ≤ 0.0001). 
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4.4. DISCUSSION 
Hoek et al.6 derived an equation to obtain RRF using serum 1/CysC values in 
both hemodialysis and peritoneal dialysis patients. However, they ignored the 
dialytic clearance of CysC. In our study, we showed strong correlation between 
measured RRF (mL/min/1.73m2) and ΔCysC levels (r2=0.81, p< 0.0001), which 
considered only the dialytic clearance. The linear relationship between the two 
parameters was expressed as measured RRF = 0.3601 ΔCysC + 0.5034. The 
bias was 0.001 ± 0.290 mL/min/1.73m2 (p=0.40). Figure 4-1 showed that the 
regression lines for ΔCysC estimated RRF, which was closer to the line of 
identity compared to the Hoek’s.  
Why does the Hoek RRF overestimate measured RRF? This is likely due to the 
difference in Std Kt/V values in our study population and the Hoek study 
population. There was a significantly higher mean pre-dialysis CysC level in the 
Hoek study (5.8-6.1 mg/L) as compared to ours (4.6 ± 1.20 mg/L), even though 
the measured RRF in our study was lower than Hoek’s (1.73 ± 0.67 
mL/min/1.73m2 vs. 2.7-3.3 ± 1.3-1.5 mL/min/1.73m2, respectively). This indicated 
that the mean Std Kt/V, without consideration of renal clearance, in the Hoek 
study, was lower than our study. Therefore, it is not surprising that the Hoek RRF 
systemically over-estimated the residual renal function in our study population. 
Incorporating Std Kt/V can eliminate this systematic error.  
The accuracy is limited regarding the nuclear medicine isotopic glomerular 
filtration rate method when it is below 30 mL/min/1.73m2.13 Therefore, we used 
average urinary creatinine and urea clearance as our reference RRF. We did not 
find a correlation between Std Kt/V and CysC, and did not expect to because of 
the small sample size and the narrow range of Std Kt/V values obtained from 
patients on identical dialysis modalities. Although Sjostrom et al. suggested that 
renal clearance of CysC is in a form of hyperbolic function (1/X), we were unable 
to incorporate the Std Kt/V to derive RRF without using the Al Malki equation. 
The major limitation of the study is its small size. Furthermore, both the Al Malki 
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equation, which was used to derive the ΔCysC, and the estimated RRF equation 
in this study need further validation. Another limitation of the study is the small 
and narrow range of the RRF values. However, this study was designed to 
support our operational hypothesis. We found the importance of incorporating 
Std Kt/V into the estimated RRF equation, as this can result in systematic bias 
when the study population has different Std Kt/V values. We plan to conduct a 
larger study with wide ranges of Std Kt/V values to validate the ΔCysC equation. 
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5. CHAPTER 5. THE KINETICS OF CYSTATIN C 
REMOVAL BY HEMODIALYSIS 
There have been only a limited number of published studies to examine the 
kinetics of cystatin C removal over the course of single hemodialysis treatments. 
We hypothesized that the primary method of cystatin C clearance would be 
convective clearance and that its volume of distribution would be similar to the 
extracellular volume. We analyzed 10 hemodialysis sessions with high-flux 
dialyzers from 9 patients, finding that indeed cystatin C is cleared during dialysis 
by both diffusion and convection. It is distributed mainly in the extracellular space 
but equilibrates slowly between the extravascular and intravascular spaces. This 
Chapter is similar to work already published in the American Journal of Kidney 
Disease in 2015.4  
5.1. INTRODUCTION 
The mainstay for calculating dialysis dose, and determining its adequacy as 
delivered, is by clearance measurement of solutes that accumulate in uremic 
patients. Urea (Ur) kinetic modeling is the most commonly described method. 1 
Nevertheless, there are pitfalls in using Ur clearance to assess hemodialysis 
dose: (1) studies have not shown any benefits of further increasing Ur clearance 
once a threshold level has been reached (single pool Kt/Vurea of 1.2), and (2) 
estimations of dialysis dose using Ur clearance with hemodialysis of variable 
duration and frequency (standardized weekly Kt/Vurea) have not been validated.2,3 
Therefore, there is an interest in assessing alternative quantitative methods and 
biomarker solutes in the optimization of dialysis dose.  
Cystatin C (CysC), a middle molecular protein (13.4 kDalton), is dialyzable when 
a high-flux dialyzer is used. It is cleared from the blood though diffusion and 
convection processes.4-6 Al-Malki et al.5 showed that pre-dialysis CysC levels in 
anuric dialysis patients depended on the intensity of treatment; patients treated 
                                            
4	  Huang SH, Tirona RG, Reid-Wilkinson F, Thomson BKA, Filler G, Stodilka R, Lindsay RM. The 
Kinetics of Cystatin C Removal by Hemodialysis. Am J Kidney Dis. 2015 Jan;65(1):174-5. PMID: 
25282341	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using nocturnal hemodialysis had lower levels than those who underwent 
conventional thrice-weekly treated patients. Although there was a significant 
inverse correlation between the pre-dialysis blood CysC levels and the standard 
weekly Kt/Vurea yet there is no relationship between this parameter and any per-
treatment urea kinetic parameter. This suggests that the pre-dialysis blood CysC 
level depends on whether the treatment is chronic, rather than on a single 
treatment.  
In a previous study, we showed that the CysC reduction ratio ((predialysis CysC 
minus postdialysis CysC)/predialysis CysC) over the course of a single dialysis 
treatment (84%), mainly depended on the normalized liters of blood processed 
(L/kg), and was inversely related to by the ultrafiltration volume (L). 4 We 
proposed that CysC has a volume of distribution equal to the extracellular fluid 
compartment volume and shows time-limited equilibration between the interstitial 
space and blood water.4 
As a result, we hypothesized that CysC levels may thus provide an additional 
index for assessing dialysis treatment adequacy. This is analogous to the use of 
hemoglobin A1C (CysC levels) and fasting glucose (single-pool Kt/Vurea) in 
diabetic monitoring.7 We hypothesized that CysC would be mostly cleared by 
convective clearance, unlike Ur. We, therefore, conducted this CysC kinetic study 
to calculate the diffusional and convectional clearances of CysC by hemodialysis, 
and to estimate its volume of distribution and intra-compartmental equilibration 
rate constants. 
5.2. METHODS 
(1) Setting & Participants  
This study included a total of 9 patients from the home hemodialysis program at 
London Health Sciences Centre (London, Ontario, Canada). This study was 
approved by Western University’s Health Sciences Research Ethics Board 
(HSREB #: 16599E) and all patients gave signed informed consent prior to study 
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commencement. The patients were included if they had been on a stable 
hemodialysis regime for at least 3 months (30 patients eligible). The patients 
were excluded if they had known access recirculation or poor access flow 
(access blood flow < 400 mL/min) (0 patients), or they had recent hospital 
admissions (0 patients) or transportation issue/conflict with their schedule (6 
patients). The remaining patients were contacted.   
(2) Outcome and Measurements 
We analyzed hemodialysis sessions from 9 patients. Each patient had at least 3-
hours of hemodialysis using a high-efficiency high-flux polysulphone dialyzer 
(Optiflux® 160, Fresenius Medical Care North America, USA), one patient had 
two such sessions and one patient underwent a 4-hour session of hemodialysis. 
Each hemodialysis session consisted of 3 periods: one-hour was ultrafiltration 
alone (TU), one-hour was dialysis only (TD), and the last hour was combined 
ultrafiltration and dialysis (TUD). The first two periods were in random order. One 
patient who had 4 hours of hemodialysis received 2 hours of TUD. We divided a 
hemodialysis session into 3 different periods to minimize alteration of patients’ 
baseline dialysis treatment prescription.   
For the TD period, the blood flow rate on the hemodialysis machine (Qb) was 
varied. Patients received dialysis at Qb 200 mL/min (Qb200) for ten minutes and at 
Qb 400 mL/min (Qb400) for 50 minutes in random order. The ultrafiltration volume 
for the individual patient was assessed by clinical examination (blood pressure 
and edema) and by the pre-hemodialysis weight. For each patient, half of the 
ultrafiltration volume was removed during the TU and the other half was removed 
during the TUD. No fluid was removed during the TD. 
Samples from the arterial lines were taken to measure the blood concentrations 
of CysC, creatinine (Cr) and Ur prior to and 30 minutes after each session. 
Additional blood samples were taken from both the arterial and the venous lines 
at the end of the treatment modalities (TU, TD and TUD). During the TD, the arterial 
and the venous samples were taken at Qb200 and Qb400. These samples were 
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sent immediately to the London Laboratory for measurements. With the pre-
hemodialysis blood samples, we also measured C-reactive protein (CRP) and 
thyroid-stimulating hormone (TSH) levels.  
Serum CysC levels were measured by immune nephelometry using an N-latex 
cystatin C kit (Siemens Healthcare Diagnostics Ltd., Mississauga, ON) on a 
Behring BN ProSpec analyzer (Dade Behring Marburg, Germany) at the 
reference laboratory at the Children’s Hospital of Eastern Ontario in Ottawa.  The 
coefficient of variation (CV) of the CysC measurements has been previously 
established at 3.1% at 1.06 mg/L; 3.5% at 2.04 mg/L and 6.7% at 5.26 mg/L.8 
CRP was measured by immunonephelometry (Dade Behring BN Prospec, 
Mississauga, Canada) with CV of 4.02% at the level of 12.79 mg/L and 4.48% at 
50.87 mg/L.  TSH was measured by direct chemiluminescence assay (Bayer 
Centaur Instrument, Germany). Ur and Cr were measured by enzymatic 
photometric and enzymatic colorimetric methods, respectively, with reference 
range <8.3-11.9 mmol/L and 55-120 µmol/L. 
Although the machine blood pump Qb was set at either 200 or 400 mL/min during 
TD, the actual Qb may be lower especially at higher pump speeds. Furthermore, 
the actual Qb was converted to a plasma flow rate (includes fluids inside the red 
blood cells and plasma, Qp) and a plasma water flow rate (includes only plasma, 
Qpw) in the calculation of dialysis clearances; to do so, we used the generic 
correction factors of 0.85 for Qp and 0.59 for QPW, which is justified in this 
population.9,10 These generic factors were based on our previous study that the 
mean hematocrit (Hct) ± standard deviation (SD) and blood total protein (Tp) 
value ± SD were 0.36 ± 0.02 u and 66.5 ± 4.01 g/L.  
Qp = Qb (0.72 Hct + [1 – Hct] [1-0.00107 Tp])       Equation 5-1 
Qpw = Qb ([1 – Hct] [1-0.00107 Tp])         Equation 5-2 
To prevent access recirculation, all patients who had arterial venous fistulae or 
graft had access flow measured to ensure the blood flow rates were greater than 
the dialysis blood flow rates and the arterial and venous needles were at least 2 
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inches apart. Although there were two patients who used central venous 
catheters, we ensured these patients had good catheter blood flow to minimize 
recirculation. In four of our patients, we also measured the true blood Qb to 
compare this with the dialyzer blood flow rate as assessed by the blood pump. 
Both Qa and Qb were measured by the Transonic HD01 monitor (Transonic 
Systems, Ithaca, NY). At machine Qb of 200 mL/min and 400 mL/min (Qb200 and 
Qb400) the actual blood flow rates were 179 ± 2 and 331 ± 6 mL/min, respectively. 
However, for consistency and clarity, the use of the parameters, “Qb, Qb200 and 
Qb400”, will be continued throughout the chapter. These values were further 
corrected for Qp and Qpw. The Qp values (152 mL/min and 281 mL/min for Qb200 
and Qb400, respectively) were used for the Ur and Cr clearance calculation 
because Ur and Cr are distributed in plasma and intracellular space. The Qpw 
values (106 mL/min and 195 mL/min for Qb200 and Qb400, respectively) were used 
for CysC clearance calculation because CysC is likely distributed exclusively in 
the extracellular space.  
Dialyzer Clearance  
At the end of each dialysis period, dialyzer clearance (K) of CysC was calculated 
as follows: 
𝑲   = 𝑸𝒑𝒘   𝑪𝒊𝒏!𝑪𝒐𝒖𝒕𝑪𝒊𝒏                                                                               Equation 5-3 
where Qpw is the plasma water flow rate at the dialyzer inlet, and Cin and Cout are 
the concentrations of the solute at the inlet and outlet of the dialyzer. For Ur and 
Cr, we used Qp rather than Qpw to calculate the K values.  
In addition, the sieving coefficient (S) and mass transfer area coefficient (K0A) of 
CysC were calculated as follows:11   
𝑺   =     𝑲𝒖𝒇𝑸𝒖𝒇                                                                                                                      Equation 5-4 
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𝑲𝟎𝑨   =      𝑸𝒑𝒘𝑸𝒅𝑸𝒑𝒘!𝑸𝒅     𝒍𝒏   𝟏!𝑲𝒅 𝑸𝒑𝒘    𝟏!  𝑲𝒅 𝑸𝒅                                                                                         Equation 5-5  
where Qpw and Qd are the plasma flow rate and the dialysate flow rate. Quf is the 
ultrafiltration rate. Kuf is the convective clearance for the solute (i.e. CysC). Kd is 
the dialysate clearance.   
Multi-compartmental Model: Kinetics of CysC Distribution and Estimation of 
Volume of Distribution 
The CysC inter-compartmental (intravascular to and from extravascular space) 
clearance constants and CysC volume of distribution were estimated from blood 
CysC time course data using a compartmental model. Briefly, the model 
describes the body as two pools (two compartments defined as vascular and 
extravascular spaces) to which CysC distributes with mass transfer governed by 
inter-compartmental transfer constants. CysC generation provides input into the 
extravascular compartment while CysC elimination occurs through the vascular 
compartment by renal, non-renal pathways as well as through dialysis. While 
applying this model to characterize CysC kinetics, we made several 
assumptions. First, we set the CysC generation rate (117ug/min/1.73m2) based 
on data from the literature.12 From our previous study, we had shown that CysC 
pre-hemodialysis levels were not significantly different hemodialysis sessions.4 
Therefore, we made the assumption that CysC level would reach the same pre-
hemodialysis CysC level by the next hemodialysis session. We included the 
measured residual renal clearance in the model. The calculated amount of CysC 
removed from subject for each dialysis period was input into the model. Volume 
of the intravascular compartment (VI) was assumed to be 40 mL/kg (plasma 
water volume). For each patient, the dialysis input plasma CysC concentrations, 
which reflect vascular compartment concentrations, prior to and throughout the 
dialysis periods, were used for least-squares fitting to the Model (Scientist, 
MicroMath Scientific Software, St. Louis, MO). Data fitting furnished estimates for 
three parameters: two CysC inter-compartment transfer constants (from 
intravascular space to extravascular space and from extravascular space to 
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intravascular space, kIE and kEI), and the non-renal non-dialyzer CysC clearance. 
Inter-compartmental clearance (KC) was calculated as the product of VI and kIE. 
Volume of distribution at steady-state (VSS) was calculated from the following 
relationship:  
𝑽𝑺𝑺 =   𝑽𝑰(𝟏+ 𝒌𝑰𝑬𝒌𝑬𝑰 )                                                   Equation 5-6 
Measuring Cystatin C Rebound 30 Minutes Post-hemodialysis 
Finally, we measured CysC concentrations at the end of the hemodialysis 
treatment (0 minutes) and at 30-minutes post-hemodialysis session. We 
calculated the CysC rebound ratio at 30-minutes post-hemodialysis by:  
𝑹𝒆𝒃𝒐𝒖𝒏𝒅  𝒓𝒂𝒕𝒊𝒐 =    𝑪𝒚𝒔𝑪  𝒂𝒕  𝟑𝟎  𝒎𝒊𝒏  !𝑪𝒚𝒔𝑪  𝒂𝒕  𝟎  𝒎𝒊𝒏𝑪𝒚𝒔𝑪  𝒂𝒕  𝟎  𝒎𝒊𝒏                                                                   Equation 5-7 
 (3) Statistical analysis  
The statistical analysis was performed using SPSS V21.0. (IBM, SPSS Inc, 
www.spss.com) and GraphPad Prism software version 5 (GraphPad Software, 
San Diego, CA, U.S.A.). This study was designed as a pilot study with limited 
sample size (n=9). Baseline characteristics were described as mean (standard 
deviation (SD)) and median with interquartile range (IQR, 25th percentile, and 
75th percentile). We have reported mean and SD of dialyzer clearance, and 
CysC mass transfer area coefficient, the sieving coefficient, distribution volume, 
whole body kinetics, and 30-minutes post-hemodialysis rebound ratio. However, 
the median and IQR can be found in tables. We compared the CysC, Ur, and Cr 
clearance values and 30-minutes post-hemodialysis rebound ratio using the 
Paired t-test. A p value of <0.05 was considered significant.     
5.3. RESULTS 
We studied hemodialysis sessions in 9 patients (5 were female).  The mean age 
± SD of the patients was 57 ± 9.8 years. The mean dry-weight (kg) and 
 140 
ultrafiltration volume per session (mL) were 80.8 ± 27.82 kg and 2.0 ± 1.06 L. 
Refer to Table 5-1 for patient data.  
 
Table 5-1. Patients’ Baseline Characteristics (N=9) 
 Mean or 
Percentage 
Standard 
Deviation 
Median  
(Interquartile Range) 
Age (Years) 57 9.8 57 (51.3, 61.0) 
Gender (%; Male) 56   
Dry-weight (kg) 80.8 27.82 83.5 (58.88, 86.50) 
Total ultrafiltration volume (L) 2.0 1.06 2 (1.37, 2.40) 
Systolic blood pressure (mmHg) 142 25.3 151 (126.0, 158.0) 
Diastolic blood pressure (mmHg) 82 18.9 81 (63.8, 98.0) 
Thyroid-stimulating hormone (mIU/L) 2.5 0.82 2.4 (2.11, 2.63) 
C-reactive protein (mg/L) 6.0 5.5 7.4 (0.6, 11.45) 
Pre-hemodialysis cystatin C (mg/L) 5.4 1.57 5.2 (4.99, 6.23)  
Pre-hemodialysis creatinine (umol/L) 699 247.2 699 (638.0, 747.0) 
Pre-hemodialysis urea (mmol/L) 19 6.7 19 (17.6, 21.8) 
Hemodialysis Access (%)    
Arterio-venous fistula 67   
Arterio-venous graft 22   
Central Venous Catheter 22   
 
1) Dialyzer Clearance of CysC under Conditions of Convection and/or 
Diffusion  
The mean CysC dialyzer clearances were 12 ± 7.1 mL/min, 19 ± 5.9 mL/min, 20 
± 8.0 mL/min and 26 ± 8.6 mL/min by ultrafiltration, dialysis at Qb200, dialysis at 
Qb400 and combination treatments, respectively. These clearance values were 
significantly lower than Cr and Ur clearance values (p<0.05) (Table 5-2). 
(2) Mass Transfer Area Coefficient and the Sieving Coefficient   
During ultrafiltration, the clearances of Ur and Cr closely followed ultrafiltration 
rates (Table 5-2). However, clearance of CysC was less than ultrafiltration rate 
indicating lower efficiency of CysC removal with convection. Indeed, the sieving 
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coefficient of CysC was 0.80 ± 0.266. The KoA of CysC was 22 ± 9.5 mL/min at 
Qb400 (Qpw = 195 mL/min) indicating relatively poor dialyzer membrane 
permeability of this middle molecule.  
(3) CysC Distribution Volume and Whole Body Kinetics 
 
Good fits to the two-pool Model were obtained with CysC concentrations over 
time for patients undergoing dialysis treatment periods in differing order. The 
CysC volume of distribution was estimated to be 204 ± 92.4 mL/kg. The CysC 
inter-compartmental clearance (KC) was 2.3 ± 1.27 mL/min/kg. The CysC non-
renal non-dialysis clearance was 25 ± 8.2 mL/min.  Lastly, the CysC, Ur and Cr 
30-minutes post-hemodialysis rebound ratio were 0.09 ± 0.059, 0.31 ± 0.250 and 
0.31± 0.191. The CysC 30-minutes post hemodialysis rebound ratio was 
significant lower compared to Ur (-0.223, p=0.02) and Cr (-0.217, p<0.01). 
However, there was no significant difference between Ur and Cr (p>0.05). All the 
CysC values are summarized in Table 5-3.  
 
Table 5-2. The Mean and Median Dialyzer Clearance (K, mL/min) for 
Cystatin C (CysC), Urea (Ur) and Creatinine (Cr).  
Variables Cystatin C Urea Cr 
Mean 
(SD) 
Median 
(IQR) 
Mean 
(SD) 
Median (IQR) Mean 
(SD) 
Median (IQR) 
K (mL/min): 
ultrafiltration 
only 
12 
(7.1) 
10  
(6.9, 19.4) 
19 
(8.7) 
20  
(11.4, 25.0) 
19 
(10.1) 
18  
(9.8, 26.1) 
K (mL/min): 
dialysis only at 
Qb200 
19 
(5.9) 
20  
(16.0, 22.8) 
141 
(7.3) 
144  
(140.4, 145.1) 
117 
(8.3) 
116  
(110.0, 122.8) 
K (mL/min): 
dialysis only at 
Qb400 
20 
(8.0) 
19  
(15.1, 24.5) 
225 
(13.2) 
225  
(212.1, 231.0) 
185 
(18.8) 
184  
(166.2, 200.2) 
K (mL/min): 
combined 
ultrafiltration 
and dialysis at 
Qb400 
26 
(8.6) 
23  
(18.7, 34.9) 
212 
(35.0) 
227  
(214.1, 236.3) 
185 
(12.3) 
187  
(171.8, 196.9) 
IQR: interquartile range; K: solute dialyzer clearance; Qb 200: Blood flow rate set 
at 200 mL/min on the hemodialysis machine; Qb400: Blood flow rate set at 400 
mL/min on the hemodialysis machine; SD: standard deviation  
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Table 5-3. Assigned and Estimated Parameters for the Two-Pool Model of 
Cystatin C kinetics.  
Variables Mean SD Median  
(Interquartile Range) 
CysC production rate (µg/min) 138 47.6 142 (96.0, 162.5) 
Volume of the intravascular space 
(VI, mL) 
3300 1140 3400 (2300, 3890) 
Volume of distribution at steady 
state, VSS  (mL/kg) 
204 92.4 206 (98.5, 292.5) 
Inter-compartmental clearance 
constant, KC (mL/min/kg) 
2.3 1.27 2.1 (1.59, 3.00) 
Residual renal clearance (mL/min) 0.7 1.42 0 (0, 1.13) 
Non-renal non-dialysis clearance 
(mL/min) 
25 8.2 22 (20.4, 28.7) 
30-minutes post-hemodialysis 
rebound 
   
Cystatin C 0.09 0.059 0.10 (0.061, 0.120) 
Urea 0.31 0.250 0.24 (0.163, 0.416) 
Creatinine 0.31 0.191 0.22 (0.183, 0.402) 
 
5.4. DISCUSSION 
The study has two major findings: (i) that CysC is dialyzable and cleared by both 
convection and diffusion. Given its size, a significant proportion of the 
hemodialysis clearance should be through convection, which is compatible with 
our data; (ii) that the volume of distribution is approximately 200 mL/kg, which 
reflects the extracellular volume. There have been limited studies to assess 
volume of distribution of CysC.  
There have been numerous studies assessing CysC as a marker for estimating 
GFR.13-20 By contrast, there are limited studies assessing the hemodialysis 
clearance of CysC and the potential use of this middle molecule for determining 
the adequacy of hemodialysis. 4,5,21-23 Delaney et al.23 and Hoek et al.22 
suggested that cystatin C levels mainly relate to the residual renal function, 
rather than peritoneal dialysis clearance. In this study, we demonstrate that CysC 
is cleared by hemodialysis, and by both diffusion and convection. This may 
explain the inaccuracy of the CysC residual renal function equations when 
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applied to other populations, as these equations do not take into account 
peritoneal dialysis clearance.24 The K by diffusion alone was higher than by 
convection; however, this of course would depend on the ultrafiltration rate. The 
mean ultrafiltration volume was 2.0 ± 1.06 L per session. The K by convection 
can also be expressed as 13 ± 4.4 mL/min per L of ultrafiltration.    
During convectional treatment, the sieving coefficient of CysC was 0.80 ± 0.266. 
This is much lower than the sieving coefficients of small solutes, such as Ur and 
Cr, which are close to 1.25 The sieving coefficient of beta-2 microglobulin is close 
to 0.60.25  Furthermore, during diffusional dialysis, the K0A of CysC was 
estimated as 22 ± 9.5 mL/min.  Small solutes, such as Ur and Cr have much 
higher K0A values (>700 mL/min) than CysC and reported with the same 
dialyzer.26 In comparison, lysozyme, a middle molecule with molecular weight of 
14.8 KDalton, has a K0A of 70 mL/min under normal clinical conditions. 
Differences between CysC and lysosome K0A values may relate to differential 
protein interactions with the dialyzer membrane. It is also possible that there 
might be CysC dialyzer adsorption. This needs to be confirmed by staining the 
dialyzer and was not done in our study. 
Although Thysell et al.27 showed that with low-flux hemodialysis, blood CysC 
concentrations rose after a single treatment, Lindström et al.6 demonstrated 
CysC levels were reduced with a dialysis session, and high-flux hemodiafiltration 
provided higher CysC clearances than did low flux hemodialysis. The study by Al 
Malki et al.5  demonstrated that pre-hemodialysis CysC levels correlated 
inversely with the standardized weekly Kt/Vurea, indicating that patients receiving 
more intensive dialysis have lower blood levels. We previously showed that the 
CysC reduction ratio over hemodialysis was 26% as compared to 70% and 65% 
reduction of Ur and Cr. We proposed that CysC had a slow inter-compartmental 
equilibration rate but was likely distributed throughout the extracellular space 
only.4 In this study, we confirmed that the inter-compartmental equilibration rates 
were slow, either from intravascular space to extravascular space or from 
extravascular space to intravascular space. This explained the observed CysC 
 144 
rebound 30-minutes post-hemodialysis of 8.5%. These rebound values (%) were 
lower than for Ur and Cr.  Furthermore, the average KC of CysC was 2.3 
mL/min/kg; a value considerably lower than that estimated for Ur of ~8 
mL/min/kg.28 We did not perform serial CysC measurements post hemodialysis. 
Therefore, CysC rebound would likely be higher than 9%. Interestingly, we also 
observed that with all patients who received TD followed by TU, the CysC 
concentration increased in the blood during TU. This is likely due to the solute 
concentration effects of ultrafiltration together with relatively slow rebound. 
Indeed, dialyzer output CysC blood concentrations were greater than input blood 
concentrations (4.8 mg/L vs. 5.0 mg/L, respectively, p=0.03) during TU. Modeling 
of the blood CysC concentration time-course provided estimates for volume of 
distribution for CysC of 204 ± 92.4 mL/kg. This is approximately 1/3 of total body 
water and the volume of the extracellular space. Studies have also shown that 
CysC level is an independent predictor of cardiovascular outcomes, independent 
of residual renal function.29 Shlipak et al.30  demonstrated that CysC eGFR is a 
better predictor of overall mortality and cardiovascular mortality in patients with 
and without chronic kidney disease than Cr eGFR, and while Cr eGFR and CysC 
eGFR were no different in predicting end-stage renal disease. Perhaps, CysC 
could be a marker for extracellular volume and may be an attractive biomarker 
for dialysis adequacy and for volume assessment.7 Further understanding of 
CysC, its relationship to outcomes and how it may be removed by dialytic 
methods is warranted.  
This study has some shortcomings including its small sample size. The study, 
however, was designed to be a pilot study of the kinetics of CysC removal during 
hemodialysis. In the estimation of total body CysC kinetics, we made several 
assumptions, including the CysC generation rate which we did not attempt to 
measure, but used values from the work of Sjostrom et al.12 Consequently, we 
estimate significant non-renal, non-dialytic clearance of CysC (25 ± 8.2 mL/min) 
in this subject cohort. Moreover, the modeling results appear to correspond to 
what we and others have observed, especially with regard to the volume of 
distribution and inter-compartmental equilibration of CysC. Of relevance, beta-2 
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microglobulin, a commonly used middle molecule for assessing dialysis 
adequacy also has a volume of distribution approximately 1/3 of the urea 
distribution volume (total body water). 31,32 Finally, we had demonstrated that 
there was significant CysC rebound post-hemodialysis. However, we only had 
one sample 30-minutes post-hemodialysis. Further studies are needed to better 
assess the duration and the extent of CysC rebound after 30 minutes of 
hemodialysis.  
5.5. CONCLUSIONS 
This study demonstrated that CysC is cleared by hemodialysis, both through 
convective and diffusive clearance. Its volume of distribution is 204 ± 92.4 kg/mL, 
a value indicating a distribution limited to the extracellular space. CysC has a 
slow equilibration rate with rebound of ~9 % at 30 minutes post-hemodialysis.  
These findings are important for understanding CysC kinetics during 
hemodialysis. The use of CysC as a dialysis adequacy marker deserves to be 
further assessed. 
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6. CHAPTER 6. LIMITATIONS, FUTURE WORK AND 
SIGNIFICANCE 
6.1. OVERVIEW AND SUMMARY 
From our four studies, we have shown that cystatin C could be a marker for both 
dialysis and renal clearance, individually and/or combined.1-4 It is easy to 
measure and is stable between dialysis treatments, rather than being influenced 
by a single dialysis treatment. The cystatin C reduction ratio study showed that 
during a single hemodialysis treatment, the URR, the CRR and the CCRR were 
70.2±9.0 %, 64.5±8.2 % and 26.1±11.8 % (p≤0.002). There was no correlation 
between the CCRR and the small molecule clearance, while the CCRR 
correlated positively with liters processed (normalized by weight), and negatively 
with ultrafiltration volume. Multiple regression analysis with these two parameters 
provided a model that explained 81% of the variance (r2=0.811, p<0.001). The 
amount of cystatin C reduction was influenced positively by dialysis blood flow 
rate and treatment time, and negatively by ultrafiltration rate. Cystatin C reduction 
did not correlate with any urea removal parameters such as Sp K/Vurea, URR and 
CRR. From this we hypothesized that cystatin C behaves as a middle molecule 
with its distribution in the extracellular compartment, with a slow equilibration rate 
between the interstitial and intravascular spaces. 
Cystatin C level can also be used to predict residual renal function. As kidney 
function declined, there was a significant negative correlation between the error 
for the creatinine-based eGFR and the filtration fraction. Both cystatin C and 
beta-trace protein are not affected by differences in FF. This may be due to the 
changes in tubular creatinine secretion when the filtration fraction is altered. 
Previously, Hoek et al.5  developed an equation to estimate residual renal 
function in patients already on dialysis: RRF = 22/Cystatin C - 0.70. However, 
this equation does not take into account the dialysis clearance, which must have 
some influence on cystatin C concentration. Assuming a dialysis patient has no 
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kidney function remaining, the expected cystatin C level is based on the weekly 
Std Kt/Vurea equation derived from the Al-Malki study.6 The difference between 
the measured and estimated cystatin C levels had a significant correlation with 
the measured residual renal function, r2=0.81 (p< 0.0001). The equation we have 
developed had less bias when compared to Hoek’s. We found that the pre-
dialysis cystatin C levels incorporate both the Std Kt/Vurea and the RRF values.  
Finally, we have estimated that the mean cystatin C dialyzer clearances were 12 
± 7.1 mL/min, 19 ± 5.9 mL/min, 20 ± 8.0 mL/min and 26 ± 8.6 mL/min by 
ultrafiltration, dialysis at Qb200, dialysis at Qb400 and combination treatments, 
respectively. The sieving coefficient of cystatin C was 0.80 ± 0.266. The KoA of 
cystatin C was 22 ± 9.5 mL/min at Qb400 and its volume of distribution was 
estimated to be 204 ± 92.4 mL/kg, with the cystatin C inter-compartmental 
clearance (KC) of 2.3 ± 1.27 mL/min/kg. The cystatin C non-renal non-dialysis 
clearance was 25 ± 8.2 mL/min.  The cystatin C rebound was 9 ± 59%. These 
results indicated that cystatin C is cleared by hemodialysis at a much slower rate 
than small solutes such as creatinine and urea. Cystatin C is dialyzable and 
cleared by both convection and diffusion. A significant clearance is through 
convection. The estimate of the cystatin C volume of distribution of 204 mL/kg, is 
approximately 1/3 of total body water and the volume of the extracellular space. 
The cystatin C inter-compartmental equilibration rates were slow. This explained 
the observed CysC rebound 30-minutes post-hemodialysis of only 9%.  
Cystatin C levels are stable prior to hemodialysis sessions, and simple to 
measure. In the Al-Malki study, researchers have shown that cystatin C levels 
closely relate to dialysis intensity.6 Because cystatin C is distributed in 
extracellular space, it is also closely related to extracellular volume status. 
Therefore, indirectly, it is also a marker for monitoring volume status in clinical 
settings. In dialysis patients, most of the excessive volume is distributed in 
extracellular space.  We have shown that cystatin C can also be a marker for 
residual renal function. Previous studies have shown that residual renal function 
is an important prognostic marker for dialysis patients.7,8 This is likely related to 
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both fluid removal and uremic toxin clearance. Intra-dialytic hypotension and 
episodes of dehydration are associated with a more rapid decline in residual 
renal function. 9 Preserving residual renal function is an important goal. 
6.2. LIMITATIONS OF CURRENT WORK 
A number of limitations currently affect the potential clinical application of cystatin 
C in dialysis population. Firstly, our studies were relatively small in size. 
However, these were studies with the aims to understand the clearance and 
kinetics of cystatin C during dialysis treatments. As a result, sample size of the 
four studies was between 10-130 depending on the objectives of the studies.  
 
Another limitation is that we have developed a residual renal function equation 
and have applied the Al-Malki equation to our studies. Both of these equations 
were only internally validated. We still need to validate both equations externally 
in a larger study with a different dialysis population. The applications of these two 
equations to general dialysis population need to be further assessed.  
Although we have confirmed that cystatin C is removed by dialysis and its 
distribution in likely in extracellular space, we have not yet assessed its 
association with clinical outcome, such as cardiovascular mortality and/or fluid 
overload. By contrast, the NCDS showed that lower urea clearance is associated 
with higher hospitalization rate in hemodialysis patients.  
The most common cause of death in hemodialysis patients is cardiovascular 
disease and the mortality rate of dialysis patients remains high at 5 years of 
dialysis treatment.10,11 The pathophysiology of cardiovascular disease in the 
dialysis population cannot be solely explained by traditional atherosclerosis 
coronary artery disease. In fact, improving traditional risk factors for 
cardiovascular disease have not resulted in a significant improvement in 
cardiovascular morbidity and mortality. The development of cardiovascular 
disease is multi-factorial (see Figure 6-1). relating to uremia, volume overload, 
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recurrent myocardial stunning and other factors resulting from ischemic perfusion 
injury.12,13  
Volume overload is common in dialysis patients and is a risk factor for increasing 
cardiovascular morbidity and mortality. Expanded ECV becomes the main driver 
for elevated blood pressure in dialysis patients. Volume overload is associated 
with left ventricular hypertrophy and poor cardiovascular survival rates.14,15 Left 
ventricular hypertrophy is associated with increased sudden cardiac death and 
cardiovascular mortality.16,17 Improving volume control can lead to the benefit of 
left ventricular mass regression.18 If a patient’s diet contains more sodium than is 
recommended, this will expand the extra-cellular space. Salt restriction resulted 
in better volume control and a reduction in left ventricular mass.19 By contrast, 
aggressive fluid removal and targeting euvolemia can have negative 
consequences.  It can lead to intradialytic hypotension, and a decline in residual 
renal function.9 It can also lead to myocardial stunning involving muscle fiber 
survival but with poor contractile function. Therefore, accurate assessment of 
volume status is important. Unfortunately, despite advances in technology, there 
is currently no gold standard measurement for dry weight.  
Because cystatin C is mainly distributed in extracellular space, and its level is 
influenced by extracellular volume, there is a need to assess the relationship 
between cystatin C levels and volume status, and cardiovascular outcome in 
dialysis population.  
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Figure 6-1.  The Pathophysiology of Cardiovascular Morbidity and Mortality 
in Dialysis Patients.  
 
6.3. FUTURE WORK 
At this point, the development of cystatin C as a dialysis adequacy biomarker 
(here, not a disease biomarker) would approximate stage two of the 
recommended guidelines (Table 6-1). We have been comparing results using 
this biomarker with the conventionally accepted measurements of dialysis 
adequacy using urea.  In Chapter 1, we have briefly discussed the 5 
recommended stages for developing and implementing biomarkers. In Stage 
three, retrospective studies establish whether the biomarker detects disease 
before a clinical diagnosis becomes evident. In stage four, the biomarker 
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undergoes prospective evaluation to determine performance characteristics of 
the test in a setting in which it will be clinically applied. Finally, in stage five, the 
focus is on the use of biomarkers to change the natural course of illness. When 
biomarkers are used for screening, it should be shown in randomized controlled 
trials that the application of interventions earlier in the process is indeed 
beneficial.  
Table 6-1. Recommended Stages for Biomarker Development and Testing 
Preclinical Exploratory Stage one Promising marker identified 
Clinical Assay and 
Validation 
Stage two Clinical assay detects established 
disease 
Retrospective Studies Stage three Biomarker can detect disease 
early before it becomes clinical. 
Prospective Studies Stage four Extent and characteristics of 
disease detected by the test. 
Disease Control Stage five Impact of screening on reducing 
the burden of disease is quantified 
 
In our proposed future studies, we wish to confirm our findings, in a randomized 
prospective trial setting. At the same time, we wish to see whether a reduced 
cystatin C level is associated with improved clinical outcomes that reflect “renal 
health” and, eventually, survival. We plan to use the repository blood samples 
and data from the Frequent Hemodialysis Network (FHN) trials.20,21 The FHN 
trials are two multi-center North American sponsored randomized controlled trials 
designed to test the influence of increased frequency and/or time of dialysis 
treatment upon outcomes. The Daily Study compared six times per week 
treatments with the conventional three times, in an in-center situation. The 
Nocturnal Study compared six nights per week with three conventional 
treatments with the patients treated at home. There were 245 patients 
randomized in the Daily Study, 120 to three times per week and 125 to six times. 
On the other hand, only 87 patients were randomized in the Nocturnal Study, 42 
to three times per week and 45 to six nights. Dialysis times (hours per week; all 
mean values ± standard deviation (SD)) for the treatment modalities were 10.4 ± 
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1.6 (Daily Study, 3x/week), 12.7 ± 2.2 (Daily Study, 6x/week), 12.5 ± 2.0 
(Nocturnal Study, 3x/week), and 28.2 ± 11.4 (Nocturnal Study, 6x/week) hours. 
These treatments delivered weekly Std Kt/Vurea of 2.47 ± 0.27, 3.49 ± 0.63, 2.61 
± 0.44, and 4.47 ± 1.60, respectively. There were two co-primary composite 
outcomes for both trials: death or change in left ventricular mass in survivors 
(from baseline to 12 months), as assessed by cardiac magnetic resonance 
imaging, and death or change in the physical-health composite score of the 
RAND 36-item health survey. Enrolment for both studies started in 2006. Once 
randomized, the patients were followed for one year and the studies ended in 
2010. The Daily Study showed that frequent hemodialysis, as compared with 
conventional hemodialysis, was associated with more favorable results with 
respect to the composite outcomes of death or change in left ventricular mass 
and death or change in physical-health composite score. The study details and 
results are now published in the New England Journal of Medicine.21 The 
Nocturnal Study did not show a significant benefit for either of the two co-primary 
outcomes. Possible explanations for the death or left ventricular mass results 
(with a Hazard Ratio of 0.68) include limited sample size and patient 
characteristics. The study details and results have been published.20 
In both studies, urea kinetic and residual renal function information were 
collected at baseline, and at four and twelve months for all trial participants. From 
these data 2 separate values for weekly Std Kt/Vurea have been calculated: a 
dialysis weekly Std Kt/Vurea and a total weekly Std Kt/Vurea which is adjusted 
for residual renal function clearance. Most trial participants also agreed to have 
blood collected at these times; these samples have been stored in a central 
biorepository. Our proposed research will be a supplementary study to these 
FHN trials. We have received approval from the FHN Executive committee and 
will have access to all trial demographic and baseline data, as well as the urea 
kinetic and residual renal function information. We will have access to the 
biorepository blood samples, and thus we can make use of repeated 
measurements of cystatin C (baseline, 4 months, and 12 months). Most 
importantly, the blindly collected trial primary outcomes will be available to us.  
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6.4. SIGNIFICANCE 
Urea clearance and kinetic modeling cannot be used as a sole method of 
assessing dialysis adequacy. The pre-dialysis urea level bears no constant 
relationship to adequacy outcomes; in fact a low urea gives a greater prediction 
of a poor, rather than good, outcome because of its relationship to protein 
malnutrition. While the correlation between cystatin C level and cardiovascular 
outcome may be speculative, it is nevertheless plausible, as previously 
discussed in Chapter 1.  
The results of our studies are important and of clinical relevance in addressing 
the adequacy of cystatin C as a biomarker. Cystatin C may give a more stable 
indication of overall hemodialysis treatment efficacy, and it may be analogous to 
hemoglobin A1C in diabetic management.22 Furthermore, a single pre-dialysis 
cystatin C level will allow for an assessment of both residual renal function and 
dialytic clearance, without the inconvenience of urine collections, multiple blood 
samples and complicated mathematical computation. It is not affected by one 
poor dialysis run, as are urea kinetics.  
The long-term goal will be to define the cystatin C threshold level that influences 
“hard outcomes” such as morbidity and mortality and to allow better dialysis 
prescriptions for patients with varying (and changing) residual renal function. The 
outcomes addressed by the FHN studies were surrogates for mortality in the 
dialysis population. If the FHN supplementary study demonstrates a significant 
positive correlation with FHN Trials outcomes, cystatin C will be the new 
standard for dialysis adequacy monitoring. Should cystatin C level correlate with 
FHN study outcomes, an important step in determining its value in dialysis care 
will have occurred. There is the potential for the first major advancement in 
assessing dialysis adequacy in thirty years. The simplicity of a single pre-dialysis, 
stable blood test as such an assessment will be appealing.  
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